P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
2.904e-15 | -33.47 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 34 | 16828 | 48 |
SLC1A3,PHYHIPL,HS6ST3,SASH1,PDZRN4,CTNND2,GABBR2,DMD,LSAMP,SMOC1,DPP6,PTPRT,CTNNA3,QKI,PPP2R2B,GPM6A,SLC1A2,SOX6,GABRB1,DCLK1,PRKG1,PCDH9,ZBTB20,NPAS3,SPON1,LIFR,GRID2,PTPRZ1,NRG3,TNIK,GRIK1,CPE,GRIA4,LAMA2 |
3.000e-15 | -33.44 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 38 | 16828 | 48 |
PPP2R2B,CTNNA3,QKI,PTPRT,GPM6A,DPP6,CLU,LSAMP,MYO16,SMOC1,GABBR2,DMD,CTNND2,PDZRN4,AQP4,ATP1A2,NTRK2,SASH1,SPARCL1,HS6ST3,PHYHIPL,SLC1A3,GRIA4,LAMA2,TNIK,NRG3,CPE,GRIA1,GRID2,SPON1,LIFR,DGKG,PCDH9,PRKG1,SLC1A2,DTNA,GABRB1,SOX6 |
6.851e-15 | -32.61 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 29 | 16828 | 48 |
GRIA1,CPE,NRG3,LAMA2,GRIA4,NPAS3,SPON1,GRID2,PCDH9,DGKG,SOX6,GABRB1,SLC1A2,PRKG1,DPP6,GPM6A,PTPRT,CTNNA3,PPP2R2B,GABBR2,SMOC1,MYO16,LSAMP,SASH1,NTRK2,CTNND2,SLC1A3,PHYHIPL,HS6ST3 |
6.851e-15 | -32.61 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 29 | 16828 | 48 |
DPP6,PTPRT,CTNNA3,PPP2R2B,GPM6A,GABBR2,LSAMP,SMOC1,MYO16,NTRK2,SASH1,CTNND2,SLC1A3,PHYHIPL,HS6ST3,NRG3,GRIA1,CPE,LAMA2,GRIA4,NPAS3,SPON1,GRID2,DGKG,PCDH9,SLC1A2,SOX6,GABRB1,PRKG1 |
3.274e-14 | -31.05 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 35 | 16828 | 48 |
HS6ST3,PHYHIPL,AQP4,PDZRN4,CTNND2,SASH1,SPARCL1,ATP1A2,SMOC1,MYO16,LSAMP,DMD,GABBR2,GPM6A,PTPRT,PPP2R2B,QKI,CTNNA3,CLU,DPP6,PRKG1,SOX6,GABRB1,SLC1A2,PCDH9,DGKG,GRID2,LIFR,SPON1,GRIA4,LAMA2,GRIA1,CPE,NRG3,TNIK |
8.002e-14 | -30.16 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 30 | 16828 | 48 |
PTPRZ1,GRID2,LIFR,SPON1,GRIA4,LAMA2,CPE,TNIK,GRIK1,NRG3,PRKG1,DCLK1,SOX6,GABRB1,ZBTB20,PCDH9,SMOC1,LSAMP,GABBR2,GPM6A,QKI,PPP2R2B,CTNNA3,PTPRT,DPP6,HS6ST3,PHYHIPL,SLC1A3,CTNND2,SASH1 |
1.662e-13 | -29.43 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 28 | 16828 | 48 |
GPM6A,PPP2R2B,CTNNA3,PTPRT,DPP6,MYO16,SMOC1,LSAMP,DMD,GABBR2,CTNND2,SASH1,NTRK2,HS6ST3,PHYHIPL,SLC1A3,GRIA4,LAMA2,GRIA1,NRG3,PTPRZ1,GRID2,SPON1,PCDH9,PRKG1,SOX6,GABRB1,SLC1A2 |
1.662e-13 | -29.43 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 28 | 16828 | 48 |
GPM6A,CTNNA3,PPP2R2B,PTPRT,DPP6,MYO16,SMOC1,LSAMP,DMD,GABBR2,CTNND2,SASH1,NTRK2,HS6ST3,PHYHIPL,SLC1A3,GRIA4,LAMA2,GRIA1,NRG3,PTPRZ1,GRID2,SPON1,PCDH9,PRKG1,GABRB1,SOX6,SLC1A2 |
1.758e-13 | -29.37 | synapse | cellular component | GO:0045202 | 1473 | 23 | 19108 | 49 |
SLC1A3,DTNA,CLU,SPARCL1,CTNND2,DMD,LAMA2,GABBR2,TNIK,NRG3,GRIK1,GRIA1,QKI,GRIA4,PTPRT,GPM6A,ATP1A2,SLC1A2,GABRB1,GRID2,DCLK1,PTPRZ1,NTRK2 |
2.068e-13 | -29.21 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 28 | 16828 | 48 |
MYO16,SMOC1,LSAMP,DMD,GABBR2,GPM6A,CTNNA3,PPP2R2B,PTPRT,DPP6,HS6ST3,PHYHIPL,SLC1A3,CTNND2,SASH1,NTRK2,PTPRZ1,GRID2,SPON1,GRIA4,LAMA2,GRIA1,NRG3,PRKG1,SOX6,GABRB1,SLC1A2,PCDH9 |
2.090e-13 | -29.20 | nervous system development | biological process | GO:0007399 | 2185 | 27 | 18204 | 48 |
PCDH9,MYO16,QKI,CTNND2,LSAMP,GRIA1,PTPRZ1,GRID2,GPM6A,NTM,GABRB1,SLC1A2,NRG3,CLU,LAMA2,DGKG,SOX6,ATP1A2,GFAP,TNIK,PRKG1,GRIK1,NTRK2,DCLK1,SLC1A3,DMD,GPM6B |
5.477e-12 | -25.93 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 29 | 16828 | 48 |
LSAMP,SMOC1,MYO16,GABBR2,PTPRT,CTNNA3,PPP2R2B,GPM6A,DPP6,HS6ST3,SLC1A3,PHYHIPL,PDZRN4,CTNND2,NTRK2,SASH1,GRID2,SPON1,LIFR,LAMA2,GRIA4,NRG3,GRIA1,CPE,PRKG1,SLC1A2,GABRB1,SOX6,PCDH9 |
1.496e-11 | -24.93 | cell junction | cellular component | GO:0030054 | 2224 | 25 | 19108 | 49 |
GABBR2,PCDH9,LAMA2,CTNNA3,GRIA1,NRG3,GRIK1,TNIK,SLC1A3,DTNA,CLU,DMD,CTNND2,SPARCL1,DCLK1,PTPRZ1,NTRK2,SLC1A2,GPM6A,ATP1A2,GRIA4,QKI,PTPRT,GRID2,GABRB1 |
1.525e-11 | -24.91 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 29 | 16828 | 48 |
GABBR2,MYO16,SMOC1,LSAMP,DPP6,GPM6A,PPP2R2B,CTNNA3,PTPRT,PHYHIPL,SLC1A3,HS6ST3,SASH1,NTRK2,CTNND2,PDZRN4,LIFR,SPON1,GRID2,CPE,GRIA1,NRG3,GRIA4,LAMA2,SOX6,GABRB1,SLC1A2,PRKG1,PCDH9 |
2.504e-11 | -24.41 | central nervous system development | biological process | GO:0007417 | 995 | 18 | 18204 | 48 |
PRKG1,GRID2,PTPRZ1,GRIA1,GFAP,QKI,ATP1A2,SOX6,MYO16,PCDH9,GPM6B,CLU,NTRK2,DCLK1,GRIK1,GABRB1,SLC1A2,NRG3 |
2.761e-11 | -24.31 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 20 | 16828 | 48 |
AQP4,CTNND2,SASH1,PCDH9,PRKG1,HS6ST3,GABRB1,SOX6,LAMA2,GRIA4,PTPRT,CTNNA3,GRIA1,NRG3,TNIK,SMOC1,MYO16,LSAMP,GRID2,SPON1 |
3.473e-11 | -24.08 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 14 | 16828 | 48 |
NRG3,GRIA4,GPM6A,CTNNA3,PTPRT,GABBR2,LSAMP,GRID2,PCDH9,CTNND2,GABRB1,SOX6,PHYHIPL,PRKG1 |
3.980e-11 | -23.95 | postsynapse | cellular component | GO:0098794 | 646 | 15 | 19108 | 49 |
ATP1A2,GPM6A,PTPRT,GRIA4,DMD,CTNND2,GRID2,GABRB1,GABBR2,DCLK1,LAMA2,GRIA1,GRIK1,NTRK2,TNIK |
3.983e-11 | -23.95 | neurogenesis | biological process | GO:0022008 | 1334 | 20 | 18204 | 48 |
CTNND2,QKI,SOX6,MYO16,GPM6A,TNIK,PRKG1,NTM,GFAP,GRID2,PTPRZ1,NTRK2,DCLK1,CLU,SLC1A3,GABRB1,DGKG,LAMA2,GPM6B,DMD |
7.067e-11 | -23.37 | system development | biological process | GO:0048731 | 3533 | 30 | 18204 | 48 |
DGKG,LAMA2,CLU,SLC1A2,NRG3,GABRB1,NTM,GPM6A,GRIA1,PTPRZ1,GRID2,LSAMP,CSMD1,QKI,CTNND2,SMOC1,MYO16,PCDH9,DMD,GPM6B,SLC1A3,DCLK1,NTRK2,GRIK1,PRKG1,TNIK,GFAP,ATP1A2,CPE,SOX6 |
1.037e-10 | -22.99 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 32 | 16828 | 48 |
CTNND2,SASH1,NTRK2,HS6ST3,SLC1A3,GPM6A,PTPRT,PPP2R2B,CTNNA3,DPP6,NTM,SMOC1,MYO16,LSAMP,GABBR2,ZBTB20,PCDH9,PRKG1,SOX6,GABRB1,SLC1A2,LAMA2,GRIA4,GLIS3,GRIA1,CPE,NRG3,TNIK,GRID2,PTPRZ1,LIFR,SPON1 |
1.037e-10 | -22.99 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 32 | 16828 | 48 |
HS6ST3,SLC1A3,CTNND2,SASH1,NTRK2,MYO16,SMOC1,LSAMP,GABBR2,GPM6A,PPP2R2B,CTNNA3,PTPRT,NTM,DPP6,PRKG1,GABRB1,SOX6,SLC1A2,ZBTB20,PCDH9,PTPRZ1,GRID2,LIFR,SPON1,LAMA2,GRIA4,CPE,GLIS3,GRIA1,TNIK,NRG3 |
1.586e-10 | -22.56 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 14 | 16828 | 48 |
GRID2,LSAMP,PTPRT,PPP2R2B,CTNNA3,GPM6A,GRIA4,LAMA2,NRG3,HS6ST3,PRKG1,GABRB1,CTNND2,PCDH9 |
1.773e-10 | -22.45 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 16 | 16828 | 48 |
PCDH9,NTRK2,CTNND2,GABRB1,PRKG1,CPE,GRIA1,DPP6,NRG3,GRIA4,CTNNA3,QKI,DMD,NPAS3,PTPRZ1,GRID2 |
1.932e-10 | -22.37 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 15 | 16828 | 48 |
GABRB1,PRKG1,NTRK2,PCDH9,CTNND2,NPAS3,DMD,PTPRZ1,GRID2,NRG3,CPE,DPP6,GRIA1,CTNNA3,GRIA4 |
1.973e-10 | -22.35 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 15 | 16828 | 48 |
NPAS3,DMD,PTPRZ1,GRID2,NRG3,CPE,DPP6,GRIA1,CTNNA3,GRIA4,GABRB1,PRKG1,NTRK2,PCDH9,CTNND2 |
2.318e-10 | -22.19 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 22 | 16828 | 48 |
DTNA,GABRB1,SOX6,PHYHIPL,SLC1A3,PRKG1,DCLK1,PCDH9,NTRK2,CTNND2,LIFR,DMD,GABBR2,SMOC1,LSAMP,GRID2,TNIK,NRG3,GRIA4,GPM6A,CTNNA3,PTPRT |
2.867e-10 | -21.97 | neuron development | biological process | GO:0048666 | 859 | 16 | 18204 | 48 |
DGKG,GPM6B,LAMA2,DMD,SLC1A3,DCLK1,NTRK2,GABRB1,NTM,PRKG1,TNIK,GPM6A,PTPRZ1,GFAP,CTNND2,MYO16 |
2.992e-10 | -21.93 | cell periphery | cellular component | GO:0071944 | 6020 | 37 | 19108 | 49 |
AQP4,CPE,GRIA4,PRKG1,PTPRT,GPM6A,SMOC1,ATP1A2,SLC1A2,DPP6,GABRB1,GRID2,MYO16,LSAMP,NTM,DGKG,DCLK1,PTPRZ1,CST3,GPM6B,NTRK2,MAPK10,SLC1A3,DTNA,CLU,SPARCL1,LIFR,DMD,CTNND2,LAMA2,SPON1,PCDH9,GABBR2,TNIK,NRG3,GRIK1,GRIA1 |
4.542e-10 | -21.51 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 30 | 16828 | 48 |
DMD,LSAMP,MYO16,CLU,DPP6,PTPRT,CTNNA3,PPP2R2B,SLC1A3,HS6ST3,NTRK2,PDZRN4,CTNND2,NPAS3,SPON1,LIFR,GRID2,PTPRZ1,NRG3,TNIK,GRIA1,CPE,GRIA4,LAMA2,GABRB1,SOX6,DTNA,DCLK1,PRKG1,PCDH9 |
4.542e-10 | -21.51 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 30 | 16828 | 48 |
DTNA,GABRB1,SOX6,PRKG1,DCLK1,PCDH9,SPON1,NPAS3,LIFR,PTPRZ1,GRID2,TNIK,NRG3,CPE,GRIA1,GRIA4,LAMA2,SLC1A3,HS6ST3,NTRK2,CTNND2,PDZRN4,DMD,LSAMP,MYO16,DPP6,CLU,CTNNA3,PPP2R2B,PTPRT |
6.894e-10 | -21.10 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 17 | 16828 | 48 |
GRIA1,NRG3,GRIA4,LAMA2,PTPRT,CTNNA3,SPON1,MYO16,LSAMP,GRID2,PCDH9,SASH1,CTNND2,GABRB1,SOX6,PRKG1,HS6ST3 |
9.221e-10 | -20.80 | neuron differentiation | biological process | GO:0030182 | 1081 | 17 | 18204 | 48 |
GABRB1,DCLK1,NTRK2,SLC1A3,DMD,LAMA2,GPM6B,DGKG,MYO16,CTNND2,GFAP,PTPRZ1,GRID2,GPM6A,TNIK,PRKG1,NTM |
1.297e-09 | -20.46 | multicellular organism development | biological process | GO:0007275 | 3957 | 30 | 18204 | 48 |
NRG3,SLC1A2,GABRB1,CLU,LAMA2,DGKG,SMOC1,PCDH9,MYO16,CSMD1,QKI,CTNND2,GRIA1,GRID2,PTPRZ1,LSAMP,NTM,GPM6A,GRIK1,SLC1A3,DCLK1,NTRK2,DMD,GPM6B,SOX6,CPE,ATP1A2,GFAP,TNIK,PRKG1 |
1.687e-09 | -20.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 15 | 16828 | 48 |
SLC1A2,SOX6,GABRB1,HS6ST3,ATP1A2,NTRK2,PCDH9,GABBR2,LSAMP,GRID2,MYO16,NRG3,DPP6,CTNNA3,PTPRT |
1.689e-09 | -20.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 20 | 16828 | 48 |
CTNND2,PCDH9,NTRK2,DGKG,PRKG1,HS6ST3,GABRB1,SOX6,SLC1A3,LAMA2,GRIA4,CTNNA3,QKI,PPP2R2B,PTPRT,NRG3,MYO16,LSAMP,GRID2,SPON1 |
1.689e-09 | -20.20 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 20 | 16828 | 48 |
PCDH9,DGKG,NTRK2,CTNND2,GABRB1,SOX6,SLC1A3,PRKG1,HS6ST3,NRG3,GRIA4,LAMA2,QKI,CTNNA3,PPP2R2B,PTPRT,SPON1,MYO16,LSAMP,GRID2 |
2.628e-09 | -19.76 | generation of neurons | biological process | GO:0048699 | 1158 | 17 | 18204 | 48 |
MYO16,CTNND2,GFAP,PTPRZ1,GRID2,GPM6A,NTM,TNIK,PRKG1,GABRB1,DCLK1,NTRK2,SLC1A3,DMD,LAMA2,GPM6B,DGKG |
1.048e-08 | -18.37 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 17 | 16828 | 48 |
ATP1A2,NTRK2,PDZRN4,SOX6,GABRB1,SLC1A2,PRKG1,DCLK1,TNIK,NRG3,CTNNA3,PTPRT,GABBR2,NPAS3,MYO16,LSAMP,GRID2 |
1.048e-08 | -18.37 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 17 | 16828 | 48 |
CTNNA3,PTPRT,TNIK,NRG3,MYO16,LSAMP,GRID2,GABBR2,NPAS3,PDZRN4,ATP1A2,NTRK2,PRKG1,DCLK1,GABRB1,SOX6,SLC1A2 |
1.422e-08 | -18.07 | postsynaptic specialization | cellular component | GO:0099572 | 345 | 10 | 19108 | 49 |
GRID2,GABRB1,TNIK,CTNND2,GRIA1,NTRK2,GRIK1,GRIA4,PTPRT,DCLK1 |
2.258e-08 | -17.61 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 31 | 16828 | 48 |
DTNA,GABRB1,SOX6,PRKG1,DCLK1,DGKG,PCDH9,SPON1,LIFR,PTPRZ1,GRID2,GRIK1,NRG3,GRIA1,GLIS3,GRIA4,SLC1A3,HS6ST3,ATP1A2,SASH1,CTNND2,GABBR2,DMD,MYO16,SMOC1,CLU,DPP6,QKI,CTNNA3,PTPRT,GPM6A |
2.258e-08 | -17.61 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 31 | 16828 | 48 |
PCDH9,DGKG,DCLK1,PRKG1,SOX6,GABRB1,DTNA,GRIA4,GRIA1,GLIS3,NRG3,GRIK1,GRID2,PTPRZ1,LIFR,SPON1,CTNND2,SASH1,ATP1A2,HS6ST3,SLC1A3,GPM6A,PTPRT,CTNNA3,QKI,DPP6,CLU,SMOC1,MYO16,DMD,GABBR2 |
2.264e-08 | -17.60 | synaptic signaling | biological process | GO:0099536 | 459 | 11 | 18204 | 48 |
GRID2,GRIA1,DTNA,SLC1A3,NTRK2,GRIA4,GABBR2,GRIK1,SLC1A2,GABRB1,DMD |
2.942e-08 | -17.34 | plasma membrane | cellular component | GO:0005886 | 5538 | 33 | 19108 | 49 |
PTPRZ1,DCLK1,DGKG,NTM,LSAMP,MYO16,NTRK2,GPM6B,CST3,SLC1A2,ATP1A2,GPM6A,PTPRT,GRIA4,PRKG1,CPE,AQP4,GRID2,GABRB1,DPP6,PCDH9,GABBR2,LAMA2,GRIA1,GRIK1,NRG3,TNIK,DTNA,SLC1A3,MAPK10,CTNND2,DMD,LIFR |
4.709e-08 | -16.87 | ANF_receptor | pfam domains | PF01094 | 37 | 5 | 17795 | 48 |
GRIA1,GABBR2,GRID2,GRIK1,GRIA4 |
4.769e-08 | -16.86 | ANF_lig-bd_rcpt | interpro domains | IPR001828 | 37 | 5 | 18521 | 50 |
GRIA1,GRIA4,GRID2,GRIK1,GABBR2 |
5.732e-08 | -16.67 | synaptic membrane | cellular component | GO:0097060 | 400 | 10 | 19108 | 49 |
PTPRT,GRIA4,GABBR2,SLC1A2,GPM6A,GRID2,GABRB1,GRIA1,DMD,GRIK1 |
6.273e-08 | -16.58 | Peripla_BP_I | interpro domains | IPR028082 | 39 | 5 | 18521 | 50 |
GABBR2,GRID2,GRIK1,GRIA4,GRIA1 |
6.889e-08 | -16.49 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 35 | 16828 | 48 |
NTRK2,SASH1,SPARCL1,CTNND2,PDZRN4,AQP4,PHYHIPL,SLC1A3,HS6ST3,DPP6,CLU,CTNNA3,PPP2R2B,PTPRT,GPM6A,GABBR2,DMD,LSAMP,MYO16,SMOC1,PCDH9,SLC1A2,GABRB1,SOX6,PRKG1,DCLK1,NRG3,GLIS3,GRIA1,GRIA4,LAMA2,SPON1,NPAS3,PTPRZ1,GRID2 |
8.476e-08 | -16.28 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 43 | 16828 | 48 |
NTM,CLU,DPP6,QKI,PPP2R2B,CTNNA3,PTPRT,GPM6A,GABBR2,DMD,LSAMP,MYO16,SMOC1,NTRK2,SASH1,SPARCL1,CTNND2,PDZRN4,PHYHIPL,SLC1A3,HS6ST3,GRIK1,TNIK,NRG3,CPE,GLIS3,GRIA1,GRIA4,LAMA2,SPON1,NPAS3,LIFR,PTPRZ1,GRID2,DGKG,PCDH9,ZBTB20,SLC1A2,DTNA,SOX6,GABRB1,PRKG1,DCLK1 |
9.633e-08 | -16.16 | glial cell differentiation | biological process | GO:0010001 | 219 | 8 | 18204 | 48 |
GPM6B,GFAP,LAMA2,PTPRZ1,NTRK2,CLU,QKI,SOX6 |
9.748e-08 | -16.14 | postsynaptic density | cellular component | GO:0014069 | 317 | 9 | 19108 | 49 |
PTPRT,GRIA4,DCLK1,TNIK,GRID2,GRIK1,NTRK2,GRIA1,CTNND2 |
1.029e-07 | -16.09 | bone | COSMIC cancer mutations | bone | 8157 | 41 | 16828 | 48 |
GRID2,PTPRZ1,NPAS3,SPON1,LIFR,GRIA4,LAMA2,NRG3,TNIK,GRIA1,GLIS3,CPE,DCLK1,PRKG1,SOX6,GABRB1,DTNA,ZBTB20,DGKG,PCDH9,CST3,LSAMP,SMOC1,MYO16,GABBR2,DMD,PTPRT,PPP2R2B,CTNNA3,QKI,GPM6A,GPM6B,DPP6,HS6ST3,SLC1A3,PDZRN4,CTNND2,NTRK2,ATP1A2,SPARCL1,SASH1 |
1.043e-07 | -16.08 | neuron projection | cellular component | GO:0043005 | 1331 | 16 | 19108 | 49 |
GRIA1,NTRK2,GABBR2,PCDH9,LAMA2,DMD,CTNND2,GRID2,GABRB1,CLU,DTNA,SLC1A3,SLC1A2,ATP1A2,GPM6A,GRIA4 |
1.060e-07 | -16.06 | trunk | COSMIC cancer mutations | trunk | 3554 | 27 | 16828 | 48 |
SMOC1,LSAMP,DMD,GABBR2,PTPRT,PPP2R2B,CTNNA3,SLC1A3,PDZRN4,CTNND2,SPARCL1,SASH1,NTRK2,ATP1A2,GRID2,PTPRZ1,LIFR,NPAS3,GRIA4,LAMA2,GRIA1,GLIS3,CPE,NRG3,DCLK1,PCDH9,DGKG |
1.387e-07 | -15.79 | Lig_chan-Glu_bd | pfam domains | PF10613 | 18 | 4 | 17795 | 48 |
GRIA4,GRIA1,GRID2,GRIK1 |
1.387e-07 | -15.79 | Lig_chan | pfam domains | PF00060 | 18 | 4 | 17795 | 48 |
GRIK1,GRIA1,GRID2,GRIA4 |
1.398e-07 | -15.78 | Ionotropic_Glu_rcpt | interpro domains | IPR015683 | 18 | 4 | 18521 | 50 |
GRID2,GRIA4,GRIK1,GRIA1 |
1.398e-07 | -15.78 | Iono_Glu_rcpt_met | interpro domains | IPR001508 | 18 | 4 | 18521 | 50 |
GRIK1,GRID2,GRIA4,GRIA1 |
1.398e-07 | -15.78 | Iontro_rcpt_C | interpro domains | IPR001320 | 18 | 4 | 18521 | 50 |
GRIA4,GRID2,GRIK1,GRIA1 |
1.398e-07 | -15.78 | Glu/Gly-bd | interpro domains | IPR019594 | 18 | 4 | 18521 | 50 |
GRIA4,GRIK1,GRID2,GRIA1 |
1.459e-07 | -15.74 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 10 | 18204 | 48 |
GRIA1,GRID2,DTNA,SLC1A3,NTRK2,GRIK1,GABBR2,GRIA4,GABRB1,SLC1A2 |
1.481e-07 | -15.73 | asymmetric synapse | cellular component | GO:0032279 | 333 | 9 | 19108 | 49 |
DCLK1,CTNND2,GRIA1,NTRK2,GRIK1,GRIA4,PTPRT,GRID2,TNIK |
1.714e-07 | -15.58 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 3 | 18204 | 48 |
SLC1A3,SLC1A2,GFAP |
1.714e-07 | -15.58 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 3 | 18204 | 48 |
GFAP,SLC1A2,SLC1A3 |
1.860e-07 | -15.50 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 6 | 19454 | 50 |
LSAMP,DPP6,GPM6A,PHYHIPL,GPM6B,DCLK1 |
2.364e-07 | -15.26 | anatomical structure development | biological process | GO:0048856 | 5207 | 31 | 18204 | 48 |
SOX6,CPE,ATP1A2,GFAP,TNIK,PRKG1,SPARCL1,GRIK1,DCLK1,NTRK2,SLC1A3,DMD,GPM6B,MYO16,PCDH9,SMOC1,CSMD1,QKI,CTNND2,LSAMP,GRIA1,GRID2,PTPRZ1,GPM6A,NTM,SLC1A2,NRG3,GABRB1,CLU,LAMA2,DGKG |
2.647e-07 | -15.14 | dendritic spine | cellular component | GO:0043197 | 172 | 7 | 19108 | 49 |
GRIA1,ATP1A2,GPM6A,NTRK2,GRID2,GRIA4,LAMA2 |
2.863e-07 | -15.07 | neuron spine | cellular component | GO:0044309 | 174 | 7 | 19108 | 49 |
LAMA2,GRIA4,GPM6A,ATP1A2,GRID2,NTRK2,GRIA1 |
2.906e-07 | -15.05 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 38 | 16828 | 48 |
NTM,DPP6,GPM6B,GPM6A,CTNNA3,PPP2R2B,QKI,PTPRT,DMD,GABBR2,MYO16,SMOC1,LSAMP,SASH1,NTRK2,CTNND2,SLC1A3,HS6ST3,CPE,GRIA1,GLIS3,TNIK,GRIK1,NRG3,LAMA2,GRIA4,LIFR,SPON1,NPAS3,PTPRZ1,GRID2,PCDH9,DGKG,ZBTB20,GABRB1,SOX6,SLC1A2,PRKG1 |
3.213e-07 | -14.95 | neuron to neuron synapse | cellular component | GO:0098984 | 365 | 9 | 19108 | 49 |
GRIK1,NTRK2,GRIA1,DCLK1,CTNND2,TNIK,GRID2,PTPRT,GRIA4 |
3.407e-07 | -14.89 | transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | molecular function | GO:1904315 | 53 | 5 | 18094 | 50 |
GRIA1,GABRB1,GRIK1,GRID2,GRIA4 |
3.422e-07 | -14.89 | D-amino acid transport | biological process | GO:0042940 | 6 | 3 | 18204 | 48 |
GFAP,SLC1A2,SLC1A3 |
4.113e-07 | -14.70 | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | molecular function | GO:0099529 | 55 | 5 | 18094 | 50 |
GRIK1,GRIA4,GRID2,GABRB1,GRIA1 |
5.125e-07 | -14.48 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 10 | 18204 | 48 |
ATP1A2,NTRK2,SLC1A3,NRG3,GRIK1,GRIA4,LAMA2,GFAP,GRIA1,GRID2 |
5.155e-07 | -14.48 | postsynaptic membrane | cellular component | GO:0045211 | 280 | 8 | 19108 | 49 |
GABBR2,GRIA1,DMD,GRIK1,GRID2,PTPRT,GRIA4,GABRB1 |
5.221e-07 | -14.47 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 10 | 18204 | 48 |
GRIA1,GRID2,GFAP,LAMA2,GRIK1,GRIA4,NRG3,SLC1A3,NTRK2,ATP1A2 |
5.477e-07 | -14.42 | gliogenesis | biological process | GO:0042063 | 275 | 8 | 18204 | 48 |
SOX6,CLU,QKI,NTRK2,PTPRZ1,GFAP,GPM6B,LAMA2 |
5.517e-07 | -14.41 | - | gene3d domains | 3.40.50.2300 | 50 | 5 | 14470 | 47 |
GRIA1,GABBR2,GRIK1,GRIA4,GRID2 |
5.571e-07 | -14.40 | mouth | COSMIC cancer mutations | mouth | 9004 | 42 | 16828 | 48 |
GRID2,PTPRZ1,LIFR,NPAS3,SPON1,LAMA2,GRIA4,GRIA1,NRG3,GRIK1,TNIK,DCLK1,PRKG1,GABRB1,SOX6,DTNA,SLC1A2,ZBTB20,PCDH9,DGKG,SMOC1,MYO16,CST3,LSAMP,DMD,GABBR2,GPM6A,PTPRT,GFAP,PPP2R2B,QKI,CTNNA3,DPP6,CLU,NTM,HS6ST3,SLC1A3,PDZRN4,CTNND2,SASH1,NTRK2,ATP1A2 |
5.871e-07 | -14.35 | transmitter-gated channel activity | molecular function | GO:0022835 | 59 | 5 | 18094 | 50 |
GRIA1,GABRB1,GRIK1,GRIA4,GRID2 |
5.871e-07 | -14.35 | transmitter-gated monoatomic ion channel activity | molecular function | GO:0022824 | 59 | 5 | 18094 | 50 |
GABRB1,GRIA1,GRID2,GRIA4,GRIK1 |
7.226e-07 | -14.14 | PBPe | smart domains | SM00079 | 18 | 4 | 9717 | 40 |
GRIK1,GRIA1,GRID2,GRIA4 |
7.226e-07 | -14.14 | Lig_chan-Glu_bd | smart domains | SM00918 | 18 | 4 | 9717 | 40 |
GRIA1,GRIA4,GRID2,GRIK1 |
7.374e-07 | -14.12 | glutamate receptor activity | molecular function | GO:0008066 | 26 | 4 | 18094 | 50 |
GRIK1,GRIA4,GRID2,GRIA1 |
7.716e-07 | -14.07 | postsynaptic specialization membrane | cellular component | GO:0099634 | 125 | 6 | 19108 | 49 |
GRIK1,GRIA1,GABRB1,GRIA4,PTPRT,GRID2 |
8.103e-07 | -14.03 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 7 | 16828 | 48 |
PCDH9,NRG3,LAMA2,GRIA4,CTNNA3,HS6ST3,GRID2 |
8.268e-07 | -14.01 | Periplasmic binding protein-like II | gene3d domains | 3.40.190.10 | 23 | 4 | 14470 | 47 |
GRIK1,GRIA1,GRID2,GRIA4 |
8.373e-07 | -13.99 | NMDARECEPTOR | prints domains | PR00177 | 18 | 4 | 5227 | 23 |
GRIA4,GRIK1,GRID2,GRIA1 |
1.029e-06 | -13.79 | cell-cell signaling | biological process | GO:0007267 | 822 | 12 | 18204 | 48 |
CPE,GABRB1,SLC1A2,GRIK1,GABBR2,GRIA4,NTRK2,SLC1A3,DMD,DTNA,GRIA1,GRID2 |
1.164e-06 | -13.66 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 9 | 18204 | 48 |
SLC1A3,GRIK1,GABBR2,GRIA4,SLC1A2,GABRB1,GRIA1,GRID2,DTNA |
1.164e-06 | -13.66 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 9 | 18204 | 48 |
DTNA,GRID2,GRIA1,SLC1A3,SLC1A2,GABRB1,GABBR2,GRIA4,GRIK1 |
1.372e-06 | -13.50 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 7 | 10285 | 28 |
GRIK1,SLC1A3,GABBR2,GABRB1,GRIA1,SLC1A2,GRIA4 |
1.387e-06 | -13.49 | postsynaptic neurotransmitter receptor activity | molecular function | GO:0098960 | 70 | 5 | 18094 | 50 |
GABRB1,GRIA1,GRID2,GRIA4,GRIK1 |
1.482e-06 | -13.42 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 19 | 19108 | 49 |
LAMA2,GABBR2,PCDH9,NTRK2,GRIA1,CTNNA3,AQP4,GRIA4,ATP1A2,GPM6A,DTNA,CLU,SLC1A2,SLC1A3,GFAP,GABRB1,GRID2,CTNND2,DMD |
1.597e-06 | -13.35 | extracellular ligand-gated monoatomic ion channel activity | molecular function | GO:0005230 | 72 | 5 | 18094 | 50 |
GRID2,GRIA4,GRIK1,GABRB1,GRIA1 |
1.629e-06 | -13.33 | sarcolemma | cellular component | GO:0042383 | 142 | 6 | 19108 | 49 |
DMD,DTNA,ATP1A2,PRKG1,AQP4,LAMA2 |
1.697e-06 | -13.29 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 14 | 16828 | 48 |
PRKG1,SOX6,GABRB1,SLC1A2,PHYHIPL,DGKG,SMOC1,GRID2,LAMA2,PTPRT,QKI,CTNNA3,DPP6,NRG3 |
2.090e-06 | -13.08 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 37 | 16828 | 48 |
GABRB1,SOX6,SLC1A2,PRKG1,PCDH9,DGKG,LIFR,SPON1,PTPRZ1,GRID2,CPE,GLIS3,GRIA1,TNIK,GRIK1,NRG3,LAMA2,GRIA4,PHYHIPL,SLC1A3,HS6ST3,SPARCL1,SASH1,NTRK2,CTNND2,DMD,GABBR2,MYO16,SMOC1,LSAMP,CLU,DPP6,GPM6A,CTNNA3,QKI,PPP2R2B,PTPRT |
2.148e-06 | -13.05 | brain development | biological process | GO:0007420 | 724 | 11 | 18204 | 48 |
ATP1A2,SOX6,PCDH9,MYO16,PRKG1,GRID2,GRIA1,NTRK2,DCLK1,SLC1A2,NRG3 |
2.258e-06 | -13.00 | developmental process | biological process | GO:0032502 | 5716 | 31 | 18204 | 48 |
SMOC1,PCDH9,MYO16,CTNND2,QKI,CSMD1,PTPRZ1,GRID2,GRIA1,LSAMP,NTM,GPM6A,SLC1A2,GABRB1,NRG3,CLU,LAMA2,DGKG,SOX6,CPE,ATP1A2,GFAP,PRKG1,TNIK,GRIK1,SPARCL1,SLC1A3,NTRK2,DCLK1,GPM6B,DMD |
2.455e-06 | -12.92 | plasma membrane region | cellular component | GO:0098590 | 1278 | 14 | 19108 | 49 |
ATP1A2,GPM6A,SLC1A2,SLC1A3,AQP4,PTPRT,GRIA4,DMD,GABRB1,GRID2,GABBR2,GRIK1,GRIA1,TNIK |
2.779e-06 | -12.79 | tibia | COSMIC cancer mutations | tibia | 836 | 12 | 16828 | 48 |
PTPRT,CTNND2,QKI,GPM6A,LAMA2,TNIK,CPE,LSAMP,DCLK1,MYO16,PRKG1,DMD |
2.864e-06 | -12.76 | regulation of membrane potential | biological process | GO:0042391 | 463 | 9 | 18204 | 48 |
NTRK2,ATP1A2,GABRB1,GRIK1,GRIA4,DMD,CTNNA3,GRIA1,GRID2 |
2.881e-06 | -12.76 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 5 | 18204 | 48 |
NTRK2,CLU,GPM6B,SOX6,PTPRZ1 |
3.082e-06 | -12.69 | cell projection | cellular component | GO:0042995 | 2398 | 19 | 19108 | 49 |
AQP4,GRIA4,ATP1A2,GPM6A,CLU,DTNA,SLC1A3,SLC1A2,GFAP,GABRB1,GRID2,CTNND2,DMD,LAMA2,PCDH9,GABBR2,NTRK2,GRIA1,CTNNA3 |
3.154e-06 | -12.67 | dendrite | cellular component | GO:0030425 | 620 | 10 | 19108 | 49 |
GRIA1,CTNND2,NTRK2,GRID2,GABRB1,CLU,ATP1A2,GPM6A,GRIA4,LAMA2 |
3.246e-06 | -12.64 | dendritic tree | cellular component | GO:0097447 | 622 | 10 | 19108 | 49 |
NTRK2,CTNND2,GRIA1,GABRB1,GRID2,GPM6A,ATP1A2,CLU,LAMA2,GRIA4 |
3.353e-06 | -12.61 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 32 | 16828 | 48 |
DCLK1,PRKG1,GABRB1,DTNA,DGKG,GRID2,PTPRZ1,NPAS3,SPON1,LIFR,GRIA4,LAMA2,NRG3,GRIK1,GRIA1,HS6ST3,SLC1A3,CTNND2,NTRK2,ATP1A2,LSAMP,CST3,SMOC1,MYO16,DMD,PTPRT,PPP2R2B,GPM6A,GPM6B,CLU,DPP6,NTM |
3.353e-06 | -12.61 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 32 | 16828 | 48 |
PTPRZ1,GRID2,LIFR,SPON1,NPAS3,GRIA4,LAMA2,GRIA1,GRIK1,NRG3,PRKG1,DCLK1,DTNA,GABRB1,DGKG,MYO16,SMOC1,CST3,LSAMP,DMD,GPM6B,GPM6A,PPP2R2B,PTPRT,NTM,DPP6,CLU,HS6ST3,SLC1A3,CTNND2,ATP1A2,NTRK2 |
3.604e-06 | -12.53 | ionotropic glutamate receptor complex | cellular component | GO:0008328 | 41 | 4 | 19108 | 49 |
GRID2,GRIA4,GRIK1,GRIA1 |
3.631e-06 | -12.53 | multicellular organismal process | biological process | GO:0032501 | 6177 | 32 | 18204 | 48 |
ATP1A2,SOX6,CPE,PRKG1,TNIK,GFAP,DTNA,SLC1A3,DCLK1,NTRK2,GRIK1,GPM6B,DMD,CTNND2,QKI,CSMD1,SMOC1,PCDH9,MYO16,NTM,GPM6A,PTPRZ1,GRID2,GRIA1,LSAMP,AQP4,CLU,NRG3,SLC1A2,GABRB1,DGKG,LAMA2 |
3.650e-06 | -12.52 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 12 | 19454 | 50 |
DCLK1,SLC1A2,MAPK10,PPP2R2B,ATP1A2,LSAMP,NTM,CLU,SLC1A3,GPM6A,TNIK,CTNND2 |
4.088e-06 | -12.41 | head development | biological process | GO:0060322 | 774 | 11 | 18204 | 48 |
PRKG1,GRID2,GRIA1,NTRK2,ATP1A2,DCLK1,SOX6,NRG3,SLC1A2,MYO16,PCDH9 |
5.345e-06 | -12.14 | synaptic transmission, glutamatergic | biological process | GO:0035249 | 44 | 4 | 18204 | 48 |
GRIA1,GRIK1,GRIA4,GRID2 |
5.753e-06 | -12.07 | neurotransmitter receptor complex | cellular component | GO:0098878 | 46 | 4 | 19108 | 49 |
GRIK1,GRIA1,GRID2,GRIA4 |
5.855e-06 | -12.05 | glutamate receptor signaling pathway | biological process | GO:0007215 | 45 | 4 | 18204 | 48 |
GRIK1,GRIA1,GRID2,GRIA4 |
5.921e-06 | -12.04 | postsynaptic density membrane | cellular component | GO:0098839 | 101 | 5 | 19108 | 49 |
GRIA4,GRID2,PTPRT,GRIK1,GRIA1 |
6.985e-06 | -11.87 | neurotransmitter receptor activity | molecular function | GO:0030594 | 97 | 5 | 18094 | 50 |
GRIA1,GABRB1,GRIK1,GRID2,GRIA4 |
7.142e-06 | -11.85 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 11 | 19108 | 49 |
GRIA4,LAMA2,CLU,SLC1A3,ATP1A2,GPM6A,GRID2,GABRB1,GRIA1,CTNND2,NTRK2 |
7.151e-06 | -11.85 | cell development | biological process | GO:0048468 | 2236 | 18 | 18204 | 48 |
LAMA2,GPM6B,DMD,DGKG,GABRB1,CLU,SLC1A3,NTRK2,DCLK1,PTPRZ1,GFAP,TNIK,NTM,PRKG1,GPM6A,MYO16,CTNND2,QKI |
8.109e-06 | -11.72 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 5 | 18094 | 50 |
GRIK1,SLC1A2,SLC1A3,GRIA4,GRIA1 |
8.542e-06 | -11.67 | regulation of postsynaptic membrane potential | biological process | GO:0060078 | 106 | 5 | 18204 | 48 |
GRID2,GRIA4,GRIA1,GRIK1,GABRB1 |
8.607e-06 | -11.66 | receptor complex | cellular component | GO:0043235 | 409 | 8 | 19108 | 49 |
GABRB1,GRID2,LIFR,GRIK1,NTRK2,GRIA1,GRIA4,GABBR2 |
9.078e-06 | -11.61 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 8 | 19108 | 49 |
PTPRT,GPM6A,SLC1A2,TNIK,GRID2,SPARCL1,NRG3,GRIA1 |
9.792e-06 | -11.53 | cell morphogenesis | biological process | GO:0000902 | 687 | 10 | 18204 | 48 |
PTPRZ1,LAMA2,TNIK,PRKG1,GPM6A,MYO16,SLC1A3,CLU,CTNND2,DCLK1 |
1.023e-05 | -11.49 | forebrain development | biological process | GO:0030900 | 408 | 8 | 18204 | 48 |
NRG3,SLC1A2,PCDH9,ATP1A2,NTRK2,DCLK1,GRIA1,PRKG1 |
1.056e-05 | -11.46 | neuron projection development | biological process | GO:0031175 | 693 | 10 | 18204 | 48 |
MYO16,DCLK1,CTNND2,GFAP,GPM6B,LAMA2,PTPRZ1,GPM6A,PRKG1,TNIK |
1.084e-05 | -11.43 | ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0099507 | 16 | 3 | 18094 | 50 |
GABRB1,GRIA1,GRIA4 |
1.084e-05 | -11.43 | glutamate-gated receptor activity | molecular function | GO:0004970 | 16 | 3 | 18094 | 50 |
GRIA1,GRIA4,GRIK1 |
1.492e-05 | -11.11 | astrocyte projection | cellular component | GO:0097449 | 19 | 3 | 19108 | 49 |
GFAP,AQP4,SLC1A2 |
1.618e-05 | -11.03 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 3 | 18204 | 48 |
ATP1A2,GFAP,GPM6B |
1.677e-05 | -11.00 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 23 | 16828 | 48 |
DCLK1,HS6ST3,GABRB1,PHYHIPL,PDZRN4,CTNND2,PCDH9,DGKG,ATP1A2,SMOC1,MYO16,GRID2,PTPRZ1,DMD,LIFR,SPON1,LAMA2,PTPRT,DPP6,GLIS3,GRIA1,NRG3,GRIK1 |
1.696e-05 | -10.98 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 33 | 16828 | 48 |
CLU,DPP6,NTM,PTPRT,GFAP,CTNNA3,PPP2R2B,QKI,GPM6A,GABBR2,DMD,MYO16,SASH1,PDZRN4,CTNND2,SLC1A3,HS6ST3,NRG3,GRIK1,GRIA1,GRIA4,LAMA2,NPAS3,SPON1,LIFR,GRID2,DGKG,ZBTB20,SLC1A2,SOX6,GABRB1,DCLK1,PRKG1 |
1.892e-05 | -10.88 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 26 | 16828 | 48 |
GPM6A,PPP2R2B,CTNNA3,PTPRT,NTM,DPP6,MYO16,SMOC1,DMD,CTNND2,PDZRN4,NTRK2,HS6ST3,GRIA4,LAMA2,GRIA1,TNIK,GRIK1,NRG3,PTPRZ1,LIFR,ZBTB20,PCDH9,PRKG1,DCLK1,GABRB1 |
1.901e-05 | -10.87 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 3 | 18204 | 48 |
SLC1A3,GFAP,SLC1A2 |
1.942e-05 | -10.85 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 12 | 19454 | 50 |
QKI,SPARCL1,CLU,CPE,LSAMP,AQP4,ATP1A2,DPP6,PTPRZ1,GPM6A,SLC1A3,DMD |
2.134e-05 | -10.76 | Myelin_PLP | pfam domains | PF01275 | 3 | 2 | 17795 | 48 |
GPM6B,GPM6A |
2.139e-05 | -10.75 | Myelin_PLP | interpro domains | IPR001614 | 3 | 2 | 18521 | 50 |
GPM6A,GPM6B |
2.139e-05 | -10.75 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 2 | 18521 | 50 |
GPM6B,GPM6A |
2.145e-05 | -10.75 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 7 | 16828 | 48 |
GABRB1,GRID2,PRKG1,PPP2R2B,CTNNA3,GPM6A,GRIA4 |
2.377e-05 | -10.65 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 5 | 19454 | 50 |
GPM6A,DCLK1,GPM6B,NTM,CPE |
2.562e-05 | -10.57 | membrane | cellular component | GO:0016020 | 9220 | 38 | 19108 | 49 |
GRIA1,GRIK1,HS6ST3,NRG3,PPP2R2B,TNIK,GABBR2,PCDH9,LAMA2,CTNND2,DMD,LIFR,DTNA,CLU,SLC1A3,MAPK10,CSMD1,NTRK2,GPM6B,CST3,PTPRZ1,DCLK1,DGKG,NTM,MYO16,LSAMP,GRID2,GFAP,GABRB1,DPP6,SLC1A2,ATP1A2,GPM6A,PTPRT,GRIA4,PRKG1,CPE,AQP4 |
2.865e-05 | -10.46 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 17 | 18204 | 48 |
NRG3,DCLK1,NTRK2,CLU,SLC1A3,LAMA2,MYO16,SOX6,CPE,QKI,CSMD1,CTNND2,GRID2,PTPRZ1,GPM6A,TNIK,PRKG1 |
2.936e-05 | -10.44 | ionotropic glutamate receptor signaling pathway | biological process | GO:0035235 | 23 | 3 | 18204 | 48 |
GRIA4,GRIK1,GRIA1 |
3.118e-05 | -10.38 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 7 | 10285 | 28 |
GRIA4,SLC1A2,GRIA1,SLC1A3,GRIK1,GABRB1,GABBR2 |
3.248e-05 | -10.33 | GPM6A (glycoprotein M6A) | protein interactions | 2823 | 143 | 5 | 19454 | 50 |
DPP6,CPE,DCLK1,NTM,PHYHIPL |
3.471e-05 | -10.27 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 2 | 12186 | 42 |
GPM6B,GPM6A |
3.471e-05 | -10.27 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 2 | 12186 | 42 |
GPM6A,GPM6B |
3.595e-05 | -10.23 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 8 | 18204 | 48 |
PTPRZ1,LAMA2,MYO16,PRKG1,CTNND2,TNIK,GPM6A,DCLK1 |
3.866e-05 | -10.16 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 8 | 18204 | 48 |
MYO16,DCLK1,CTNND2,LAMA2,PTPRZ1,GPM6A,TNIK,PRKG1 |
3.935e-05 | -10.14 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 46 | 16828 | 48 |
LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,GABRB1,SOX6,DTNA,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20,DMD,MYO16,LSAMP,DPP6,CLU,GPM6A,GFAP,PPP2R2B,QKI,CTNNA3,SLC1A3,PHYHIPL,SASH1,PDZRN4,SPON1,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4,SLC1A2,GABBR2,SMOC1,NTM,PTPRT,HS6ST3,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2 |
3.986e-05 | -10.13 | scalp | COSMIC cancer mutations | scalp | 2110 | 17 | 16828 | 48 |
PDZRN4,ATP1A2,PRKG1,DCLK1,PHYHIPL,LAMA2,PPP2R2B,CTNNA3,GFAP,PTPRT,NTM,MYO16,PTPRZ1,GRID2,LSAMP,DMD,GABBR2 |
4.065e-05 | -10.11 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | REACTOME pathways | R-HSA-112314 | 146 | 5 | 10285 | 28 |
GRIK1,GRIA4,GABBR2,GABRB1,GRIA1 |
4.153e-05 | -10.09 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 8 | 18204 | 48 |
LAMA2,PTPRZ1,GPM6A,PRKG1,TNIK,MYO16,DCLK1,CTNND2 |
4.274e-05 | -10.06 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 28 |
SLC1A2,SLC1A3 |
4.274e-05 | -10.06 | Activation of AMPA receptors | REACTOME pathways | R-HSA-399710 | 4 | 2 | 10285 | 28 |
GRIA4,GRIA1 |
4.274e-05 | -10.06 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 28 |
SLC1A2,SLC1A3 |
4.286e-05 | -10.06 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 36 | 16828 | 48 |
SLC1A3,PHYHIPL,HS6ST3,NTRK2,ATP1A2,SASH1,CTNND2,GABBR2,LSAMP,SMOC1,MYO16,CLU,DPP6,PTPRT,QKI,PPP2R2B,CTNNA3,GPM6A,SLC1A2,SOX6,GABRB1,DCLK1,PRKG1,DGKG,PCDH9,SPON1,LIFR,GRID2,PTPRZ1,NRG3,TNIK,GRIA1,GLIS3,CPE,GRIA4,LAMA2 |
4.287e-05 | -10.06 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 3 | 18204 | 48 |
GFAP,SLC1A2,SLC1A3 |
4.474e-05 | -10.01 | AMPA glutamate receptor activity | molecular function | GO:0004971 | 4 | 2 | 18094 | 50 |
GRIA4,GRIA1 |
4.550e-05 | -10.00 | Htt (huntingtin) | protein interactions | 15194 | 77 | 4 | 19454 | 50 |
NTM,GFAP,LSAMP,GPM6A |
4.567e-05 | -9.99 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 13 | 16828 | 48 |
CPE,GLIS3,GRIA1,PTPRZ1,GRID2,SMOC1,GABBR2,NPAS3,CTNND2,ATP1A2,DGKG,NTRK2,SPARCL1 |
4.716e-05 | -9.96 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 5 | 7161 | 26 |
GRIA1,GRIA4,GRIK1,SLC1A3,SLC1A2 |
4.716e-05 | -9.96 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 5 | 7161 | 26 |
GRIK1,SLC1A3,SLC1A2,GRIA1,GRIA4 |
4.794e-05 | -9.95 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 43 | 16828 | 48 |
LIFR,NPAS3,PTPRZ1,GRID2,CPE,GLIS3,GRIA1,GRIK1,TNIK,NRG3,LAMA2,GRIA4,DTNA,GABRB1,SOX6,SLC1A2,PRKG1,DCLK1,PCDH9,DGKG,ZBTB20,DMD,GABBR2,MYO16,SMOC1,LSAMP,CST3,NTM,CLU,DPP6,GPM6B,CTNNA3,QKI,PPP2R2B,GFAP,PTPRT,SLC1A3,HS6ST3,SASH1,ATP1A2,NTRK2,CTNND2,PDZRN4 |
4.944e-05 | -9.91 | PLP | smart domains | SM00002 | 3 | 2 | 9717 | 40 |
GPM6A,GPM6B |
5.002e-05 | -9.90 | GRIK2 (glutamate ionotropic receptor kainate type subunit 2) | protein interactions | 2898 | 28 | 3 | 19454 | 50 |
GRIK1,GRIA1,GRID2 |
5.259e-05 | -9.85 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 4 | 18204 | 48 |
SLC1A3,NTRK2,GFAP,SLC1A2 |
5.542e-05 | -9.80 | MYELINPLP | prints domains | PR00214 | 3 | 2 | 5227 | 23 |
GPM6B,GPM6A |
5.560e-05 | -9.80 | nodular | COSMIC cancer mutations | nodular | 1515 | 14 | 16828 | 48 |
CPE,GRIA1,GLIS3,LAMA2,GABBR2,NPAS3,PTPRZ1,GRID2,SMOC1,ATP1A2,DGKG,NTRK2,SPARCL1,CTNND2 |
5.683e-05 | -9.78 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 5 | 18204 | 48 |
LAMA2,GFAP,GRIA1,NTRK2,SLC1A3 |
5.822e-05 | -9.75 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 19 | 16828 | 48 |
LAMA2,GRIA4,CTNNA3,PPP2R2B,PTPRT,GRIA1,NRG3,PTPRZ1,GRID2,LSAMP,LIFR,DMD,CTNND2,PDZRN4,SASH1,PCDH9,ATP1A2,DCLK1,SLC1A3 |
5.991e-05 | -9.72 | regulation of presynaptic membrane potential | biological process | GO:0099505 | 29 | 3 | 18204 | 48 |
GABRB1,GRIA1,GRIA4 |
5.991e-05 | -9.72 | negative regulation of amyloid-beta formation | biological process | GO:1902430 | 29 | 3 | 18204 | 48 |
SPON1,CLU,NTRK2 |
6.406e-05 | -9.66 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 46 | 16828 | 48 |
SLC1A3,PHYHIPL,SASH1,PDZRN4,DMD,MYO16,LSAMP,DPP6,CLU,GPM6A,GPM6B,GFAP,QKI,PPP2R2B,CTNNA3,SOX6,GABRB1,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20,LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,HS6ST3,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,GABBR2,SMOC1,NTM,PTPRT,SLC1A2,SPON1,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4 |
6.554e-05 | -9.63 | HAX1 (HCLS1 associated protein X-1) | protein interactions | 10456 | 397 | 7 | 19454 | 50 |
GPM6B,DCLK1,MAPK10,GPM6A,NTM,DPP6,CLU |
6.644e-05 | -9.62 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2 |
6.903e-05 | -9.58 | presynaptic membrane | cellular component | GO:0042734 | 168 | 5 | 19108 | 49 |
SLC1A2,GRIA1,GPM6A,GRIK1,GABRB1 |
7.047e-05 | -9.56 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 6 | 16828 | 48 |
MYO16,PDZRN4,PCDH9,NPAS3,NRG3,GABBR2 |
7.047e-05 | -9.56 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 6 | 16828 | 48 |
PCDH9,GABBR2,NRG3,NPAS3,MYO16,PDZRN4 |
7.270e-05 | -9.53 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 32 | 16828 | 48 |
AQP4,CTNND2,PDZRN4,SPARCL1,SASH1,ATP1A2,MYO16,SMOC1,DMD,GABBR2,GPM6A,CTNNA3,PTPRT,DPP6,PRKG1,DCLK1,SOX6,ZBTB20,PCDH9,PTPRZ1,GRID2,LIFR,SPON1,NPAS3,GRIA4,LAMA2,CPE,GRIA1,GLIS3,GRIK1,TNIK,NRG3 |
7.343e-05 | -9.52 | negative regulation of amyloid precursor protein catabolic process | biological process | GO:1902992 | 31 | 3 | 18204 | 48 |
SPON1,CLU,NTRK2 |
7.444e-05 | -9.51 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 50 |
SLC1A3,SLC1A2 |
7.444e-05 | -9.51 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 50 |
SLC1A2,SLC1A3 |
7.459e-05 | -9.50 | presynaptic active zone membrane | cellular component | GO:0048787 | 32 | 3 | 19108 | 49 |
GRIA1,GPM6A,GABRB1 |
7.526e-05 | -9.49 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 19 | 16828 | 48 |
NPAS3,MYO16,PTPRZ1,DPP6,GRIA1,CLU,NRG3,LAMA2,PTPRT,QKI,GABRB1,DTNA,SLC1A2,PCDH9,NTRK2,DGKG,ATP1A2,PDZRN4,CTNND2 |
7.700e-05 | -9.47 | cell body | cellular component | GO:0044297 | 556 | 8 | 19108 | 49 |
GRIA4,GFAP,GRIA1,SLC1A3,CTNND2,SLC1A2,ATP1A2,GPM6A |
8.087e-05 | -9.42 | ligand-gated ion channel signaling pathway | biological process | GO:1990806 | 32 | 3 | 18204 | 48 |
GRIK1,GRIA1,GRIA4 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
NTM,GPM6A,LSAMP |
8.683e-05 | -9.35 | cell communication | biological process | GO:0007154 | 5010 | 26 | 18204 | 48 |
TNIK,PRKG1,MAPK10,DTNA,ATP1A2,CPE,PTPRT,DMD,SLC1A3,NTRK2,DCLK1,GABBR2,GRIK1,SPARCL1,GRID2,GRIA1,CTNNA3,CTNND2,MYO16,DGKG,LIFR,CLU,GRIA4,SLC1A2,NRG3,GABRB1 |
8.752e-05 | -9.34 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 4 | 19454 | 50 |
NTM,GPM6B,DCLK1,GPM6A |
9.721e-05 | -9.24 | negative regulation of amide metabolic process | biological process | GO:0034249 | 34 | 3 | 18204 | 48 |
SPON1,CLU,NTRK2 |
1.014e-04 | -9.20 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
1.060e-04 | -9.15 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 4 | 18094 | 50 |
CLU,GRIA4,GRIA1,CST3 |
1.061e-04 | -9.15 | EF-hand_3 | pfam domains | PF09069 | 6 | 2 | 17795 | 48 |
DTNA,DMD |
1.061e-04 | -9.15 | EF-hand_2 | pfam domains | PF09068 | 6 | 2 | 17795 | 48 |
DTNA,DMD |
1.064e-04 | -9.15 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 2 | 18521 | 50 |
DMD,DTNA |
1.064e-04 | -9.15 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 2 | 18521 | 50 |
DMD,DTNA |
1.107e-04 | -9.11 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 33 | 16828 | 48 |
HS6ST3,CTNND2,PDZRN4,ATP1A2,SASH1,LSAMP,CST3,MYO16,SMOC1,QKI,PPP2R2B,CTNNA3,PTPRT,GFAP,GPM6A,NTM,DPP6,PRKG1,DCLK1,SLC1A2,DTNA,ZBTB20,DGKG,PCDH9,PTPRZ1,GRID2,SPON1,LAMA2,GRIA4,TNIK,GRIK1,NRG3,GRIA1 |
1.120e-04 | -9.10 | transmembrane transporter complex | cellular component | GO:1902495 | 434 | 7 | 19108 | 49 |
GRID2,GABRB1,DPP6,GRIA1,GRIK1,GRIA4,ATP1A2 |
1.145e-04 | -9.08 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 14 | 16828 | 48 |
DMD,LIFR,GRID2,PTPRZ1,MYO16,GRIK1,DPP6,CPE,QKI,LAMA2,DTNA,DGKG,PDZRN4,CTNND2 |
1.145e-04 | -9.08 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 14 | 16828 | 48 |
DMD,LIFR,GRID2,PTPRZ1,MYO16,GRIK1,DPP6,CPE,QKI,LAMA2,DTNA,DGKG,PDZRN4,CTNND2 |
1.158e-04 | -9.06 | glial cell projection | cellular component | GO:0097386 | 37 | 3 | 19108 | 49 |
SLC1A2,GFAP,AQP4 |
1.161e-04 | -9.06 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 43 | 16828 | 48 |
MYO16,SMOC1,CST3,LSAMP,DMD,GABBR2,GPM6B,QKI,CTNNA3,PPP2R2B,PTPRT,GFAP,NTM,DPP6,CLU,HS6ST3,SLC1A3,CTNND2,PDZRN4,SASH1,ATP1A2,NTRK2,PTPRZ1,GRID2,LIFR,NPAS3,GRIA4,LAMA2,CPE,GRIA1,GLIS3,GRIK1,TNIK,NRG3,PRKG1,DCLK1,DTNA,GABRB1,SOX6,SLC1A2,ZBTB20,PCDH9,DGKG |
1.176e-04 | -9.05 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 24 | 16828 | 48 |
GRIA1,GLIS3,CPE,GRIK1,TNIK,GRIA4,LAMA2,LIFR,GRID2,PTPRZ1,PCDH9,DGKG,DTNA,PRKG1,GPM6B,PTPRT,SMOC1,LSAMP,SPARCL1,SASH1,ATP1A2,AQP4,PDZRN4,CTNND2 |
1.207e-04 | -9.02 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 13 | 16828 | 48 |
PRKG1,HS6ST3,GABRB1,SOX6,PDZRN4,MYO16,GRID2,DMD,GABBR2,LAMA2,PTPRT,CTNNA3,NRG3 |
1.264e-04 | -8.98 | plasma membrane signaling receptor complex | cellular component | GO:0098802 | 191 | 5 | 19108 | 49 |
GRIK1,GRIA1,GABBR2,GRIA4,GRID2 |
1.294e-04 | -8.95 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 9 | 18094 | 50 |
GABRB1,ATP1A2,GRIK1,SLC1A2,SLC1A3,GRIA1,AQP4,GPM6A,GRIA4 |
1.306e-04 | -8.94 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 8 | 19108 | 49 |
GRIA4,GABBR2,ATP1A2,GRID2,DPP6,DMD,GRIA1,GRIK1 |
1.360e-04 | -8.90 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 3 | 18204 | 48 |
SLC1A3,GFAP,SLC1A2 |
1.402e-04 | -8.87 | humerus | COSMIC cancer mutations | humerus | 546 | 8 | 16828 | 48 |
PRKG1,GRID2,GABRB1,GPM6A,GRIA4,LAMA2,PPP2R2B,CTNNA3 |
1.407e-04 | -8.87 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 19 | 16828 | 48 |
DPP6,GRIA1,CLU,NRG3,GRIK1,TNIK,LAMA2,PTPRT,DMD,MYO16,GRID2,PTPRZ1,PCDH9,SASH1,SPARCL1,PDZRN4,CTNND2,DCLK1,PRKG1 |
1.407e-04 | -8.87 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 19 | 16828 | 48 |
DCLK1,PRKG1,SPARCL1,SASH1,PCDH9,PDZRN4,CTNND2,DMD,GRID2,PTPRZ1,MYO16,NRG3,GRIK1,TNIK,GRIA1,DPP6,CLU,PTPRT,LAMA2 |
1.483e-04 | -8.82 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 2 | 17795 | 48 |
SMOC1,SPARCL1 |
1.483e-04 | -8.82 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 48 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 2 | 18521 | 50 |
SPARCL1,SMOC1 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.584e-04 | -8.75 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 5 | 18094 | 50 |
GRIA1,GRIA4,SLC1A2,SLC1A3,GRIK1 |
1.584e-04 | -8.75 | ligand-gated monoatomic ion channel activity | molecular function | GO:0015276 | 186 | 5 | 18094 | 50 |
GRIA1,GABRB1,GRIK1,GRID2,GRIA4 |
1.603e-04 | -8.74 | cell differentiation | biological process | GO:0030154 | 3645 | 21 | 18204 | 48 |
MYO16,SOX6,SMOC1,QKI,CTNND2,GFAP,PTPRZ1,GRID2,GPM6A,NTM,TNIK,PRKG1,GABRB1,DCLK1,NTRK2,CLU,SLC1A3,DMD,LAMA2,GPM6B,DGKG |
1.623e-04 | -8.73 | cellular developmental process | biological process | GO:0048869 | 3648 | 21 | 18204 | 48 |
GFAP,PTPRZ1,GRID2,GPM6A,NTM,TNIK,PRKG1,MYO16,SOX6,SMOC1,QKI,CTNND2,DMD,LAMA2,GPM6B,DGKG,GABRB1,DCLK1,NTRK2,CLU,SLC1A3 |
1.624e-04 | -8.73 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 5 | 18094 | 50 |
GRIA4,GRIK1,SLC1A3,SLC1A2,GRIA1 |
1.624e-04 | -8.73 | ligand-gated channel activity | molecular function | GO:0022834 | 187 | 5 | 18094 | 50 |
GABRB1,GRIA1,GRID2,GRIA4,GRIK1 |
1.626e-04 | -8.72 | transporter complex | cellular component | GO:1990351 | 461 | 7 | 19108 | 49 |
GRIA4,ATP1A2,DPP6,GABRB1,GRID2,GRIK1,GRIA1 |
1.709e-04 | -8.67 | GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) | protein interactions | 2891 | 42 | 3 | 19454 | 50 |
GRID2,GPM6A,GRIA1 |
1.729e-04 | -8.66 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 48 |
GPM6A,CTNND2,PTPRT,LSAMP |
1.795e-04 | -8.63 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 2 | 19454 | 50 |
GFAP,NTM |
1.805e-04 | -8.62 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 19 | 16828 | 48 |
ZBTB20,CTNND2,SASH1,PCDH9,NTRK2,PRKG1,PHYHIPL,GPM6A,LAMA2,GRIA4,PTPRT,CTNNA3,GRIK1,MYO16,GRID2,PTPRZ1,LIFR,NPAS3,GABBR2 |
1.911e-04 | -8.56 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 9 | 18094 | 50 |
GRID2,GPM6A,GRIA4,GRIA1,ATP1A2,GRIK1,SLC1A3,SLC1A2,GABRB1 |
2.146e-04 | -8.45 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 47 |
SLC1A2,SLC1A3 |
2.175e-04 | -8.43 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 9 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2,GABRB1,GRIK1,GRIA4,GPM6A,GRIA1,GRID2 |
2.259e-04 | -8.40 | acidic amino acid transport | biological process | GO:0015800 | 45 | 3 | 18204 | 48 |
SLC1A2,NTRK2,SLC1A3 |
2.293e-04 | -8.38 | astrocyte end-foot | cellular component | GO:0097450 | 9 | 2 | 19108 | 49 |
AQP4,GFAP |
2.301e-04 | -8.38 | synapse organization | biological process | GO:0050808 | 333 | 6 | 18204 | 48 |
GPM6A,CTNND2,SPARCL1,NRG3,GRIA1,GRID2 |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.329e-04 | -8.36 | signaling | biological process | GO:0023052 | 4968 | 25 | 18204 | 48 |
DTNA,MAPK10,PRKG1,TNIK,CPE,ATP1A2,DMD,PTPRT,SPARCL1,GRIK1,GABBR2,DCLK1,NTRK2,SLC1A3,GRIA1,GRID2,MYO16,CTNND2,LIFR,DGKG,SLC1A2,GABRB1,NRG3,GRIA4,CLU |
2.339e-04 | -8.36 | human chr11p15.2 | chromosome location | human chr11p15.2 | 12 | 2 | 26134 | 50 |
SOX6,SPON1 |
2.339e-04 | -8.36 | ALB (albumin) | protein interactions | 213 | 342 | 6 | 19454 | 50 |
PPP2R2B,CST3,GFAP,DMD,PDZRN4,DGKG |
2.373e-04 | -8.35 | monoatomic ion channel complex | cellular component | GO:0034702 | 344 | 6 | 19108 | 49 |
GRIA1,GRIK1,GRID2,GABRB1,DPP6,GRIA4 |
2.392e-04 | -8.34 | GRIA1 (glutamate ionotropic receptor AMPA type subunit 1) | protein interactions | 2890 | 47 | 3 | 19454 | 50 |
GRID2,GRIA4,GRIA1 |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 42 |
SLC1A3,SLC1A2 |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 42 |
SLC1A2,SLC1A3 |
2.596e-04 | -8.26 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 40 | 16828 | 48 |
PRKG1,DCLK1,DTNA,SOX6,GABRB1,DGKG,PCDH9,PTPRZ1,GRID2,SPON1,NPAS3,LIFR,LAMA2,GRIA4,TNIK,GRIK1,NRG3,CPE,GRIA1,HS6ST3,CTNND2,PDZRN4,ATP1A2,NTRK2,SPARCL1,SASH1,CST3,MYO16,SMOC1,GABBR2,DMD,PPP2R2B,QKI,CTNNA3,PTPRT,GPM6B,GPM6A,NTM,CLU,DPP6 |
2.619e-04 | -8.25 | synapse assembly | biological process | GO:0007416 | 118 | 4 | 18204 | 48 |
GPM6A,NRG3,GRID2,GRIA1 |
2.635e-04 | -8.24 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 40 | 16828 | 48 |
PRKG1,DCLK1,DTNA,SOX6,GABRB1,DGKG,PCDH9,PTPRZ1,GRID2,SPON1,NPAS3,LIFR,LAMA2,GRIA4,GRIK1,TNIK,NRG3,CPE,GRIA1,HS6ST3,CTNND2,PDZRN4,ATP1A2,NTRK2,SASH1,SPARCL1,CST3,MYO16,SMOC1,GABBR2,DMD,PPP2R2B,CTNNA3,QKI,PTPRT,GPM6B,GPM6A,NTM,DPP6,CLU |
2.663e-04 | -8.23 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 33 | 16828 | 48 |
QKI,GFAP,PTPRT,NTM,CLU,MYO16,LSAMP,CST3,DMD,GABBR2,AQP4,CTNND2,PDZRN4,SASH1,ATP1A2,NTRK2,HS6ST3,GRIA4,LAMA2,GRIA1,GRIK1,NRG3,PTPRZ1,LIFR,SPON1,NPAS3,ZBTB20,PCDH9,DGKG,PRKG1,DCLK1,SOX6,SLC1A2 |
2.663e-04 | -8.23 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 33 | 16828 | 48 |
CLU,NTM,GFAP,PTPRT,QKI,DMD,GABBR2,MYO16,CST3,LSAMP,SASH1,NTRK2,ATP1A2,AQP4,PDZRN4,CTNND2,HS6ST3,GRIA1,NRG3,GRIK1,GRIA4,LAMA2,LIFR,NPAS3,SPON1,PTPRZ1,PCDH9,DGKG,ZBTB20,SOX6,SLC1A2,DCLK1,PRKG1 |
2.738e-04 | -8.20 | regulation of amyloid-beta formation | biological process | GO:1902003 | 48 | 3 | 18204 | 48 |
SPON1,NTRK2,CLU |
2.807e-04 | -8.18 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 13 | 16828 | 48 |
PDZRN4,PRKG1,HS6ST3,GABRB1,SOX6,LAMA2,PTPRT,CTNNA3,NRG3,MYO16,GRID2,DMD,GABBR2 |
2.810e-04 | -8.18 | membrane protein complex | cellular component | GO:0098796 | 1261 | 11 | 19108 | 49 |
GRIK1,GRIA1,GABBR2,DMD,DPP6,GABRB1,GRID2,ATP1A2,SLC1A2,SLC1A3,GRIA4 |
2.827e-04 | -8.17 | regulation of biological quality | biological process | GO:0065008 | 2936 | 18 | 18204 | 48 |
ATP1A2,QKI,CPE,GPM6A,PRKG1,GFAP,CTNNA3,GRID2,GRIA1,NTRK2,AQP4,CLU,GABRB1,GRIA4,GRIK1,DGKG,DMD,PTPRT |
2.879e-04 | -8.15 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 33 | 16828 | 48 |
CLU,DPP6,PPP2R2B,QKI,CTNNA3,PTPRT,GPM6A,GABBR2,LSAMP,MYO16,SMOC1,ATP1A2,NTRK2,SASH1,CTNND2,PHYHIPL,SLC1A3,HS6ST3,NRG3,CPE,GRIA1,GLIS3,GRIA4,LAMA2,SPON1,LIFR,GRID2,DGKG,PCDH9,SLC1A2,GABRB1,SOX6,PRKG1 |
3.023e-04 | -8.10 | cellular response to brain-derived neurotrophic factor stimulus | biological process | GO:1990416 | 10 | 2 | 18204 | 48 |
GRIA1,NTRK2 |
3.023e-04 | -8.10 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
3.023e-04 | -8.10 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 2 | 18204 | 48 |
ATP1A2,NTRK2 |
3.023e-04 | -8.10 | action potential propagation | biological process | GO:0098870 | 10 | 2 | 18204 | 48 |
ATP1A2,NTRK2 |
3.165e-04 | -8.06 | action potential | biological process | GO:0001508 | 124 | 4 | 18204 | 48 |
GRIA1,DMD,NTRK2,ATP1A2 |
3.173e-04 | -8.06 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 21 | 16828 | 48 |
HS6ST3,CTNND2,ZBTB20,ATP1A2,DGKG,SPARCL1,PCDH9,SASH1,PTPRZ1,GRID2,MYO16,GABBR2,SPON1,GFAP,PTPRT,GRIA4,LAMA2,GPM6A,TNIK,NRG3,GRIA1 |
3.199e-04 | -8.05 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 21 | 16828 | 48 |
SPON1,GABBR2,GRID2,PTPRZ1,MYO16,NRG3,TNIK,GRIA1,PTPRT,GFAP,GPM6A,LAMA2,GRIA4,HS6ST3,DGKG,ATP1A2,SASH1,PCDH9,SPARCL1,CTNND2,ZBTB20 |
3.342e-04 | -8.00 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 16 | 16828 | 48 |
NRG3,GRIK1,GRIA1,CTNNA3,DMD,PTPRZ1,SMOC1,MYO16,NTRK2,DGKG,ATP1A2,PCDH9,CTNND2,ZBTB20,SLC1A2,DCLK1 |
3.571e-04 | -7.94 | glial cell development | biological process | GO:0021782 | 128 | 4 | 18204 | 48 |
NTRK2,CLU,GPM6B,GFAP |
3.571e-04 | -7.94 | myelination | biological process | GO:0042552 | 128 | 4 | 18204 | 48 |
GPM6B,NTRK2,QKI,CLU |
3.590e-04 | -7.93 | transmembrane transport | biological process | GO:0055085 | 1264 | 11 | 18204 | 48 |
ATP1A2,AQP4,SLC1A3,SLC1A2,GABRB1,GRIA4,GRIK1,GPM6A,GFAP,GRID2,GRIA1 |
3.613e-04 | -7.93 | SYNM (synemin) | protein interactions | 23336 | 54 | 3 | 19454 | 50 |
PPP2R2B,GFAP,DTNA |
3.688e-04 | -7.91 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
3.688e-04 | -7.91 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
3.724e-04 | -7.90 | Neuroactive ligand-receptor interaction | KEGG pathways | ko04080 | 276 | 6 | 7161 | 26 |
GABRB1,GRIK1,GABBR2,GRID2,GRIA4,GRIA1 |
3.724e-04 | -7.90 | Neuroactive ligand-receptor interaction | KEGG pathways | hsa04080 | 276 | 6 | 7161 | 26 |
GABRB1,GRIK1,GABBR2,GRID2,GRIA4,GRIA1 |
3.788e-04 | -7.88 | axon ensheathment | biological process | GO:0008366 | 130 | 4 | 18204 | 48 |
CLU,QKI,NTRK2,GPM6B |
3.788e-04 | -7.88 | ensheathment of neurons | biological process | GO:0007272 | 130 | 4 | 18204 | 48 |
QKI,CLU,NTRK2,GPM6B |
3.838e-04 | -7.87 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 23 |
SLC1A3,SLC1A2 |
3.841e-04 | -7.86 | Nicotine addiction | KEGG pathways | hsa05033 | 40 | 3 | 7161 | 26 |
GABRB1,GRIA4,GRIA1 |
3.841e-04 | -7.86 | Nicotine addiction | KEGG pathways | ko05033 | 40 | 3 | 7161 | 26 |
GRIA1,GRIA4,GABRB1 |
3.858e-04 | -7.86 | SBP_bac_3 | pfam domains | PF00497 | 11 | 2 | 17795 | 48 |
GRIA1,GRIA4 |
3.863e-04 | -7.86 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 8 | 16828 | 48 |
NTM,PPP2R2B,PDZRN4,PTPRT,GABBR2,PTPRZ1,GRID2,DCLK1 |
3.868e-04 | -7.86 | Solute-binding_3/MltF_N | interpro domains | IPR001638 | 11 | 2 | 18521 | 50 |
GRIA4,GRIA1 |
3.986e-04 | -7.83 | cell surface | cellular component | GO:0009986 | 896 | 9 | 19108 | 49 |
DMD,GRIA1,LIFR,SLC1A3,SLC1A2,CLU,ATP1A2,PTPRT,AQP4 |
4.014e-04 | -7.82 | amino acid transport | biological process | GO:0006865 | 132 | 4 | 18204 | 48 |
SLC1A3,NTRK2,GFAP,SLC1A2 |
4.099e-04 | -7.80 | regulation of amyloid precursor protein catabolic process | biological process | GO:1902991 | 55 | 3 | 18204 | 48 |
NTRK2,CLU,SPON1 |
4.099e-04 | -7.80 | response to cocaine | biological process | GO:0042220 | 55 | 3 | 18204 | 48 |
GRIA1,SLC1A2,SLC1A3 |
4.203e-04 | -7.77 | OAS2 (2'-5'-oligoadenylate synthetase 2) | protein interactions | 4939 | 12 | 2 | 19454 | 50 |
PRKG1,SASH1 |
4.313e-04 | -7.75 | channel activity | molecular function | GO:0015267 | 502 | 7 | 18094 | 50 |
GRID2,GPM6A,GRIA4,GRIA1,AQP4,GRIK1,GABRB1 |
4.365e-04 | -7.74 | passive transmembrane transporter activity | molecular function | GO:0022803 | 503 | 7 | 18094 | 50 |
GRIA1,AQP4,GRID2,GPM6A,GRIA4,GABRB1,GRIK1 |
4.391e-04 | -7.73 | Retrograde endocannabinoid signaling | KEGG pathways | ko04723 | 101 | 4 | 7161 | 26 |
GABRB1,GRIA1,GRIA4,MAPK10 |
4.391e-04 | -7.73 | Retrograde endocannabinoid signaling | KEGG pathways | hsa04723 | 101 | 4 | 7161 | 26 |
MAPK10,GRIA4,GRIA1,GABRB1 |
4.405e-04 | -7.73 | femur | COSMIC cancer mutations | femur | 1197 | 11 | 16828 | 48 |
CTNNA3,GRIA4,LAMA2,NRG3,DPP6,PCDH9,GRID2,HS6ST3,PTPRZ1,GABBR2,SPON1 |
4.894e-04 | -7.62 | fn3 | pfam domains | PF00041 | 136 | 4 | 17795 | 48 |
LIFR,PTPRZ1,PTPRT,PHYHIPL |
5.030e-04 | -7.59 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 33 | 16828 | 48 |
CST3,MYO16,SMOC1,GABBR2,DMD,PPP2R2B,QKI,CTNNA3,PTPRT,GPM6B,SLC1A3,CTNND2,PDZRN4,ATP1A2,NTRK2,SPARCL1,SASH1,PTPRZ1,GRID2,NPAS3,LIFR,GRIA4,LAMA2,TNIK,NRG3,GRIA1,GLIS3,PRKG1,DCLK1,DTNA,SOX6,ZBTB20,DGKG |
5.290e-04 | -7.54 | neuron migration | biological process | GO:0001764 | 142 | 4 | 18204 | 48 |
PRKG1,GPM6A,NTRK2,DCLK1 |
5.298e-04 | -7.54 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 3 | 18204 | 48 |
GRIA1,NTRK2,ATP1A2 |
5.393e-04 | -7.53 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 7 | 16828 | 48 |
NPAS3,LIFR,SPARCL1,GABRB1,PRKG1,LAMA2,ZBTB20 |
5.776e-04 | -7.46 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 2 | 19454 | 50 |
CLU,GPM6A |
5.806e-04 | -7.45 | presynapse | cellular component | GO:0098793 | 569 | 7 | 19108 | 49 |
GPM6A,SLC1A2,TNIK,GABRB1,NTRK2,GRIK1,GRIA1 |
6.084e-04 | -7.40 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 17 | 16828 | 48 |
DCLK1,SOX6,SLC1A2,ZBTB20,CTNND2,PCDH9,DGKG,NTRK2,ATP1A2,SMOC1,MYO16,PTPRZ1,DMD,CTNNA3,GRIA1,NRG3,GRIK1 |
6.171e-04 | -7.39 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 3 | 5310 | 24 |
CST3,SLC1A2,GRIA1 |
6.172e-04 | -7.39 | animal organ development | biological process | GO:0048513 | 2846 | 17 | 18204 | 48 |
DMD,LAMA2,DCLK1,NTRK2,SLC1A2,NRG3,GPM6A,PRKG1,GRIA1,GRID2,ATP1A2,CSMD1,MYO16,PCDH9,CPE,SOX6,SMOC1 |
6.190e-04 | -7.39 | excitatory synapse | cellular component | GO:0060076 | 65 | 3 | 19108 | 49 |
GRID2,GPM6A,GRIA1 |
6.294e-04 | -7.37 | cAMP signaling pathway | KEGG pathways | hsa04024 | 198 | 5 | 7161 | 26 |
GABBR2,MAPK10,ATP1A2,GRIA1,GRIA4 |
6.294e-04 | -7.37 | cAMP signaling pathway | KEGG pathways | ko04024 | 198 | 5 | 7161 | 26 |
ATP1A2,GRIA1,GRIA4,MAPK10,GABBR2 |
6.409e-04 | -7.35 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 5 | 18521 | 50 |
DGKG,DMD,SPARCL1,SMOC1,DTNA |
6.451e-04 | -7.35 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 41 | 16828 | 48 |
GABBR2,DMD,LSAMP,MYO16,SMOC1,CLU,DPP6,PPP2R2B,QKI,CTNNA3,GFAP,PTPRT,GPM6A,PHYHIPL,SLC1A3,HS6ST3,ATP1A2,NTRK2,SPARCL1,SASH1,CTNND2,PDZRN4,AQP4,SPON1,NPAS3,PTPRZ1,GRID2,TNIK,NRG3,CPE,GRIA1,GRIA4,LAMA2,SLC1A2,DTNA,SOX6,GABRB1,PRKG1,DGKG,PCDH9,ZBTB20 |
6.532e-04 | -7.33 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 46 | 16828 | 48 |
DMD,LSAMP,CST3,MYO16,CLU,DPP6,GFAP,QKI,CTNNA3,PPP2R2B,GPM6A,SLC1A3,PHYHIPL,SASH1,PDZRN4,NPAS3,LIFR,NRG3,GRIK1,TNIK,GLIS3,CPE,SOX6,GABRB1,DCLK1,PRKG1,DGKG,PCDH9,ZBTB20,GABBR2,SMOC1,NTM,PTPRT,HS6ST3,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,SPON1,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4,SLC1A2 |
6.612e-04 | -7.32 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 28 | 18204 | 48 |
CPE,ATP1A2,ZBTB20,DTNA,GFAP,MAPK10,PRKG1,TNIK,SPARCL1,GRIK1,GABBR2,DCLK1,NTRK2,SLC1A3,DMD,PTPRT,MYO16,CTNND2,GRIA1,GRID2,SLC1A2,GABRB1,NRG3,GRIA4,CLU,AQP4,LIFR,DGKG |
6.654e-04 | -7.32 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 2 | 19454 | 50 |
CLU,CPE |
6.667e-04 | -7.31 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 50 |
SLC1A2,SLC1A3 |
6.700e-04 | -7.31 | long-term synaptic potentiation | biological process | GO:0060291 | 65 | 3 | 18204 | 48 |
GRIA1,GFAP,NTRK2 |
6.935e-04 | -7.27 | cell adhesion | biological process | GO:0007155 | 942 | 9 | 18204 | 48 |
LSAMP,CTNNA3,SPON1,GRID2,PTPRT,NTM,PCDH9,SPARCL1,CTNND2 |
7.118e-04 | -7.25 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 10 | 18204 | 48 |
PRKG1,TNIK,GPM6A,PTPRZ1,GFAP,GPM6B,LAMA2,CTNND2,DCLK1,MYO16 |
7.412e-04 | -7.21 | response to stimulus | biological process | GO:0050896 | 7803 | 32 | 18204 | 48 |
CTNND2,CSMD1,MYO16,GPM6A,GRID2,CST3,GRIA1,AQP4,CLU,NRG3,GABRB1,SLC1A2,GRIA4,DGKG,LIFR,ATP1A2,ZBTB20,CPE,SOX6,PRKG1,TNIK,GFAP,DTNA,MAPK10,DCLK1,NTRK2,SLC1A3,SPARCL1,GABBR2,GRIK1,DMD,PTPRT |
7.549e-04 | -7.19 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 6 | 19108 | 49 |
PTPRZ1,CLU,SPON1,SMOC1,SPARCL1,LAMA2 |
7.555e-04 | -7.19 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 2 | 19108 | 49 |
GRIA1,TNIK |
7.765e-04 | -7.16 | learning or memory | biological process | GO:0007611 | 276 | 5 | 18204 | 48 |
NTRK2,ATP1A2,CSMD1,PTPRZ1,GRIA1 |
7.765e-04 | -7.16 | telencephalon development | biological process | GO:0021537 | 276 | 5 | 18204 | 48 |
NTRK2,ATP1A2,SLC1A2,NRG3,GRIA1 |
7.844e-04 | -7.15 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 10 | 18094 | 50 |
SLC1A3,SLC1A2,GRIK1,ATP1A2,GABRB1,GRIA4,GPM6A,GRID2,GRIA1,AQP4 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
LSAMP,ZBTB20 |
8.180e-04 | -7.11 | monoatomic ion transport | biological process | GO:0006811 | 964 | 9 | 18204 | 48 |
GPM6A,GRIA1,GRID2,ATP1A2,SLC1A3,GABRB1,SLC1A2,GRIK1,GRIA4 |
8.442e-04 | -7.08 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 5 | 18094 | 50 |
GRIK1,SLC1A2,SLC1A3,GRIA4,GRIA1 |
9.039e-04 | -7.01 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 3 | 19108 | 49 |
ATP1A2,PCDH9,CTNNA3 |
9.282e-04 | -6.98 | import across plasma membrane | biological process | GO:0098739 | 165 | 4 | 18204 | 48 |
SLC1A3,ATP1A2,SLC1A2,GFAP |
9.401e-04 | -6.97 | peptide metabolic process | biological process | GO:0006518 | 73 | 3 | 18204 | 48 |
DMD,CPE,SLC1A2 |
9.431e-04 | -6.97 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 50 |
SLC1A3,SLC1A2,ATP1A2,GRIK1 |
9.442e-04 | -6.97 | ZZ | pfam domains | PF00569 | 17 | 2 | 17795 | 48 |
DTNA,DMD |
9.478e-04 | -6.96 | Unblocking of NMDA receptor, glutamate binding and activation | REACTOME pathways | R-HSA-438066 | 17 | 2 | 10285 | 28 |
GRIA1,GRIA4 |
9.478e-04 | -6.96 | Trafficking of GluR2-containing AMPA receptors | REACTOME pathways | R-HSA-416993 | 17 | 2 | 10285 | 28 |
GRIA4,GRIA1 |
9.648e-04 | -6.94 | GRIK5 (glutamate ionotropic receptor kainate type subunit 5) | protein interactions | 2901 | 18 | 2 | 19454 | 50 |
GRIK1,GRID2 |
9.755e-04 | -6.93 | cell projection organization | biological process | GO:0030030 | 1200 | 10 | 18204 | 48 |
GPM6A,PRKG1,TNIK,GFAP,GPM6B,LAMA2,PTPRZ1,DCLK1,CTNND2,MYO16 |
9.780e-04 | -6.93 | positive regulation of gliogenesis | biological process | GO:0014015 | 74 | 3 | 18204 | 48 |
QKI,PTPRZ1,GFAP |
9.830e-04 | -6.92 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 40 | 16828 | 48 |
SASH1,ATP1A2,NTRK2,CTNND2,PDZRN4,SLC1A3,HS6ST3,NTM,DPP6,GPM6B,GPM6A,PPP2R2B,CTNNA3,GFAP,PTPRT,DMD,GABBR2,MYO16,SMOC1,LSAMP,PCDH9,DGKG,ZBTB20,DTNA,GABRB1,SLC1A2,PRKG1,DCLK1,CPE,GLIS3,TNIK,GRIK1,NRG3,LAMA2,GRIA4,LIFR,SPON1,NPAS3,PTPRZ1,GRID2 |
9.830e-04 | -6.92 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 40 | 16828 | 48 |
LIFR,SPON1,NPAS3,PTPRZ1,GRID2,CPE,GLIS3,TNIK,GRIK1,NRG3,LAMA2,GRIA4,DTNA,GABRB1,SLC1A2,PRKG1,DCLK1,PCDH9,DGKG,ZBTB20,DMD,GABBR2,MYO16,SMOC1,LSAMP,NTM,DPP6,GPM6B,GPM6A,PPP2R2B,CTNNA3,GFAP,PTPRT,SLC1A3,HS6ST3,SASH1,ATP1A2,NTRK2,CTNND2,PDZRN4 |
9.912e-04 | -6.92 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 2 | 18094 | 50 |
PTPRT,PTPRZ1 |
9.912e-04 | -6.92 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 2 | 18094 | 50 |
PTPRZ1,PTPRT |
1.015e-03 | -6.89 | regulation of muscle contraction | biological process | GO:0006937 | 169 | 4 | 18204 | 48 |
ATP1A2,PRKG1,CTNNA3,DMD |
1.037e-03 | -6.87 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 6 | 18204 | 48 |
LAMA2,PTPRZ1,DCLK1,SLC1A3,PRKG1,CTNND2 |
1.062e-03 | -6.85 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 5 | 18204 | 48 |
NTRK2,QKI,GFAP,PTPRZ1,GRID2 |
1.067e-03 | -6.84 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 14 | 16828 | 48 |
PCDH9,SPARCL1,ATP1A2,CTNND2,GABRB1,DCLK1,CPE,GRIA1,NRG3,LAMA2,CTNNA3,PPP2R2B,LIFR,GRID2 |
1.067e-03 | -6.84 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 14 | 16828 | 48 |
SPARCL1,PCDH9,CPE,GRIA1,ATP1A2,NRG3,LAMA2,CTNNA3,CTNND2,PPP2R2B,LIFR,GABRB1,DCLK1,GRID2 |
1.070e-03 | -6.84 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 10 | 16828 | 48 |
GPM6B,CTNND2,TNIK,NTRK2,PRKG1,MYO16,DCLK1,LIFR,GABRB1,SOX6 |
1.071e-03 | -6.84 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 2 | 19108 | 49 |
TNIK,GRIA1 |
1.071e-03 | -6.84 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 2 | 19108 | 49 |
GPM6A,GRID2 |
1.077e-03 | -6.83 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 2 | 19454 | 50 |
PHYHIPL,GPM6A |
1.080e-03 | -6.83 | prostate | COSMIC cancer mutations | prostate | 13883 | 47 | 16828 | 48 |
NPAS3,LIFR,TNIK,GRIK1,NRG3,CPE,GLIS3,PRKG1,DCLK1,DTNA,SOX6,GABRB1,ZBTB20,DGKG,PCDH9,LSAMP,MYO16,DMD,CTNNA3,PPP2R2B,QKI,GFAP,GPM6B,GPM6A,DPP6,CLU,PHYHIPL,SLC1A3,PDZRN4,SASH1,PTPRZ1,GRID2,SPON1,GRIA4,LAMA2,GRIA1,SLC1A2,SMOC1,GABBR2,PTPRT,NTM,HS6ST3,CTNND2,AQP4,ATP1A2,NTRK2,SPARCL1 |
1.093e-03 | -6.82 | presynaptic active zone | cellular component | GO:0048786 | 79 | 3 | 19108 | 49 |
GABRB1,GPM6A,GRIA1 |
1.101e-03 | -6.81 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 40 | 16828 | 48 |
GABBR2,DMD,LSAMP,MYO16,SMOC1,NTM,DPP6,CTNNA3,QKI,PPP2R2B,PTPRT,GFAP,SLC1A3,HS6ST3,ATP1A2,NTRK2,SPARCL1,SASH1,CTNND2,PDZRN4,SPON1,NPAS3,LIFR,PTPRZ1,GRID2,TNIK,GRIK1,NRG3,CPE,GRIA1,GLIS3,GRIA4,LAMA2,SLC1A2,SOX6,GABRB1,PRKG1,DCLK1,DGKG,PCDH9 |
1.101e-03 | -6.81 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 40 | 16828 | 48 |
NRG3,GRIK1,TNIK,GRIA1,GLIS3,CPE,GRIA4,LAMA2,NPAS3,SPON1,LIFR,GRID2,PTPRZ1,DGKG,PCDH9,SLC1A2,SOX6,GABRB1,DCLK1,PRKG1,DPP6,NTM,PTPRT,GFAP,QKI,PPP2R2B,CTNNA3,GABBR2,DMD,LSAMP,SMOC1,MYO16,NTRK2,ATP1A2,SASH1,SPARCL1,PDZRN4,CTNND2,SLC1A3,HS6ST3 |
1.107e-03 | -6.81 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 50 |
SLC1A3,SLC1A2,ATP1A2,GRIK1,GRIA1,GRIA4,GPM6A |
1.113e-03 | -6.80 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 50 |
SLC1A3,SLC1A2 |
1.113e-03 | -6.80 | behavior | biological process | GO:0007610 | 619 | 7 | 18204 | 48 |
CSMD1,SLC1A3,ATP1A2,NTRK2,SLC1A2,GRIA1,PTPRZ1 |
1.137e-03 | -6.78 | Dopaminergic synapse | KEGG pathways | hsa04728 | 130 | 4 | 7161 | 26 |
MAPK10,PPP2R2B,GRIA4,GRIA1 |
1.137e-03 | -6.78 | Dopaminergic synapse | KEGG pathways | ko04728 | 130 | 4 | 7161 | 26 |
PPP2R2B,MAPK10,GRIA4,GRIA1 |
1.139e-03 | -6.78 | regulation of cardiac muscle contraction | biological process | GO:0055117 | 78 | 3 | 18204 | 48 |
ATP1A2,CTNNA3,DMD |
1.143e-03 | -6.77 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 8 | 16828 | 48 |
NTRK2,CTNND2,DTNA,DMD,SOX6,SLC1A3,PRKG1,GRID2 |
1.179e-03 | -6.74 | central nervous system neuron differentiation | biological process | GO:0021953 | 176 | 4 | 18204 | 48 |
NTRK2,DCLK1,GRID2,GABRB1 |
1.184e-03 | -6.74 | GRIP1 (glutamate receptor interacting protein 1) | protein interactions | 23426 | 81 | 3 | 19454 | 50 |
GRIK1,GRIA4,GRIA1 |
1.186e-03 | -6.74 | Znf_ZZ | interpro domains | IPR000433 | 19 | 2 | 18521 | 50 |
DTNA,DMD |
1.186e-03 | -6.74 | Znf_ZZ_sf | interpro domains | IPR043145 | 19 | 2 | 18521 | 50 |
DMD,DTNA |
1.192e-03 | -6.73 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 10 | 16828 | 48 |
NTRK2,TNIK,CTNND2,GPM6B,GABRB1,SOX6,LIFR,DCLK1,PRKG1,MYO16 |
1.194e-03 | -6.73 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 50 |
CST3,CTNND2 |
1.224e-03 | -6.71 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 43 | 16828 | 48 |
GRIA4,LAMA2,CPE,GRIA1,GLIS3,GRIK1,TNIK,NRG3,PTPRZ1,GRID2,LIFR,SPON1,NPAS3,ZBTB20,PCDH9,DGKG,PRKG1,DCLK1,DTNA,SOX6,GABRB1,SLC1A2,GPM6B,GPM6A,QKI,CTNNA3,PPP2R2B,PTPRT,NTM,DPP6,MYO16,LSAMP,CST3,DMD,GABBR2,CTNND2,PDZRN4,SASH1,SPARCL1,ATP1A2,NTRK2,PHYHIPL,SLC1A3 |
1.238e-03 | -6.69 | cervix | COSMIC cancer mutations | cervix | 11793 | 43 | 16828 | 48 |
CTNND2,PDZRN4,ATP1A2,NTRK2,SASH1,SPARCL1,PHYHIPL,SLC1A3,PPP2R2B,QKI,CTNNA3,PTPRT,GPM6B,GPM6A,NTM,DPP6,CST3,LSAMP,MYO16,GABBR2,DMD,ZBTB20,DGKG,PCDH9,PRKG1,DCLK1,SLC1A2,DTNA,GABRB1,SOX6,GRIA4,LAMA2,TNIK,GRIK1,NRG3,CPE,GRIA1,GLIS3,PTPRZ1,GRID2,SPON1,NPAS3,LIFR |
1.268e-03 | -6.67 | Long-term depression | KEGG pathways | hsa04730 | 60 | 3 | 7161 | 26 |
GRID2,PRKG1,GRIA1 |
1.268e-03 | -6.67 | Long-term depression | KEGG pathways | ko04730 | 60 | 3 | 7161 | 26 |
GRIA1,GRID2,PRKG1 |
1.271e-03 | -6.67 | regulation of amide metabolic process | biological process | GO:0034248 | 81 | 3 | 18204 | 48 |
CLU,NTRK2,SPON1 |
1.299e-03 | -6.65 | monoatomic ion channel activity | molecular function | GO:0005216 | 441 | 6 | 18094 | 50 |
GRIA1,GRIA4,GRID2,GPM6A,GABRB1,GRIK1 |
1.311e-03 | -6.64 | GABA receptor complex | cellular component | GO:1902710 | 21 | 2 | 19108 | 49 |
GABBR2,GABRB1 |
1.314e-03 | -6.63 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 6 | 18094 | 50 |
GRIA1,GPM6A,ATP1A2,GRIK1,SLC1A2,SLC1A3 |
1.332e-03 | -6.62 | - | gene3d domains | 1.10.287.70 | 148 | 4 | 14470 | 47 |
GRIA4,GRID2,GRIA1,GRIK1 |
1.394e-03 | -6.58 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 48 |
LAMA2,CTNNA3,GFAP,PTPRT,ATP1A2,PRKG1,MYO16,DCLK1,PTPRZ1,LSAMP,DMD,PHYHIPL |
1.444e-03 | -6.54 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 5 | 19454 | 50 |
CTNNA3,DMD,TNIK,DTNA,SASH1 |
1.447e-03 | -6.54 | CYSLTR2 (cysteinyl leukotriene receptor 2) | protein interactions | 57105 | 22 | 2 | 19454 | 50 |
PCDH9,GRIK1 |
1.454e-03 | -6.53 | SALM protein interactions at the synapses | REACTOME pathways | R-HSA-8849932 | 21 | 2 | 10285 | 28 |
GRIA4,GRIA1 |
1.479e-03 | -6.52 | cognition | biological process | GO:0050890 | 319 | 5 | 18204 | 48 |
GRIA1,PTPRZ1,CSMD1,NTRK2,ATP1A2 |
1.499e-03 | -6.50 | neuronal cell body | cellular component | GO:0043025 | 489 | 6 | 19108 | 49 |
GRIA4,GPM6A,ATP1A2,SLC1A3,CTNND2,GRIA1 |
1.510e-03 | -6.50 | vascular transport | biological process | GO:0010232 | 86 | 3 | 18204 | 48 |
SLC1A2,SLC1A3,ATP1A2 |
1.510e-03 | -6.50 | central nervous system neuron development | biological process | GO:0021954 | 86 | 3 | 18204 | 48 |
NTRK2,DCLK1,GABRB1 |
1.510e-03 | -6.50 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 3 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2 |
1.521e-03 | -6.49 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 48 |
ATP1A2,SLC1A3 |
1.521e-03 | -6.49 | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | biological process | GO:0010881 | 22 | 2 | 18204 | 48 |
DMD,ATP1A2 |
1.521e-03 | -6.49 | negative regulation of muscle contraction | biological process | GO:0045932 | 22 | 2 | 18204 | 48 |
PRKG1,ATP1A2 |
1.524e-03 | -6.49 | transporter activity | molecular function | GO:0005215 | 1211 | 10 | 18094 | 50 |
GPM6A,GRID2,GRIA4,GRIA1,AQP4,ATP1A2,GRIK1,SLC1A3,SLC1A2,GABRB1 |
1.663e-03 | -6.40 | relaxation of muscle | biological process | GO:0090075 | 23 | 2 | 18204 | 48 |
ATP1A2,PRKG1 |
1.669e-03 | -6.40 | GABA receptor activity | molecular function | GO:0016917 | 22 | 2 | 18094 | 50 |
GABBR2,GABRB1 |
1.705e-03 | -6.37 | - | gene3d domains | 3.30.60.90 | 19 | 2 | 14470 | 47 |
DMD,DTNA |
1.713e-03 | -6.37 | ZF_ZZ_1 | prosite domains | PS01357 | 18 | 2 | 12186 | 42 |
DTNA,DMD |
1.723e-03 | -6.36 | SNTG2 (syntrophin gamma 2) | protein interactions | 54221 | 24 | 2 | 19454 | 50 |
DMD,DTNA |
1.729e-03 | -6.36 | PDZ domain binding | molecular function | GO:0030165 | 86 | 3 | 18094 | 50 |
GRIA1,DTNA,GRID2 |
1.742e-03 | -6.35 | central_nervous_system-brainstem-primitive_neuroectodermal_tumour-medulloblastoma-WNT_subtype | COSMIC cancer mutations | central_nervous_system-brainstem-primitive_neuroectodermal_tumour-medulloblastoma-WNT_subtype | 181 | 4 | 16828 | 48 |
NPAS3,PPP2R2B,PDZRN4,GRID2 |
1.757e-03 | -6.34 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 4 | 19454 | 50 |
DCLK1,DTNA,ATP1A2,DMD |
1.763e-03 | -6.34 | signal transduction | biological process | GO:0007165 | 4637 | 22 | 18204 | 48 |
NTRK2,DCLK1,SPARCL1,GABBR2,GRIK1,DMD,PTPRT,ATP1A2,CPE,PRKG1,TNIK,DTNA,MAPK10,CLU,NRG3,GRIA4,DGKG,LIFR,CTNND2,MYO16,GRID2,GRIA1 |
1.777e-03 | -6.33 | WNT_subtype | COSMIC cancer mutations | WNT_subtype | 182 | 4 | 16828 | 48 |
GRID2,PDZRN4,PPP2R2B,NPAS3 |
1.791e-03 | -6.32 | regulation of cellular process | biological process | GO:0050794 | 11468 | 40 | 18204 | 48 |
GPM6B,DMD,PTPRT,DCLK1,NTRK2,NPAS3,SLC1A3,SPARCL1,GABBR2,GRIK1,TNIK,PRKG1,DTNA,GFAP,SASH1,MAPK10,ATP1A2,ZBTB20,SOX6,CPE,DPP6,DGKG,LAMA2,LIFR,CLU,GLIS3,SLC1A2,NRG3,GRIA4,GPM6A,SPON1,CTNNA3,PTPRZ1,CST3,GRID2,GRIA1,CTNND2,QKI,MYO16,SMOC1 |
1.820e-03 | -6.31 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 5 | 14470 | 47 |
DGKG,SMOC1,DTNA,SPARCL1,DMD |
1.824e-03 | -6.31 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 50 |
SLC1A2,SLC1A3 |
1.829e-03 | -6.30 | ear | COSMIC cancer mutations | ear | 624 | 7 | 16828 | 48 |
NPAS3,GABRB1,LIFR,SPARCL1,ZBTB20,LAMA2,PRKG1 |
1.852e-03 | -6.29 | gated channel activity | molecular function | GO:0022836 | 320 | 5 | 18094 | 50 |
GRID2,GRIA4,GRIK1,GABRB1,GRIA1 |
1.870e-03 | -6.28 | TNC (tenascin C) | protein interactions | 3371 | 25 | 2 | 19454 | 50 |
SMOC1,CLU |
1.891e-03 | -6.27 | ovary | COSMIC cancer mutations | ovary | 14770 | 48 | 16828 | 48 |
PTPRT,NTM,SMOC1,GABBR2,CTNND2,AQP4,NTRK2,ATP1A2,SPARCL1,HS6ST3,GRIA4,LAMA2,GRIA1,GRID2,PTPRZ1,SPON1,SLC1A2,GFAP,CTNNA3,PPP2R2B,QKI,GPM6A,GPM6B,DPP6,CLU,LSAMP,CST3,MYO16,DMD,PDZRN4,SASH1,SLC1A3,PHYHIPL,NRG3,TNIK,GRIK1,GLIS3,CPE,NPAS3,LIFR,ZBTB20,DGKG,PCDH9,DCLK1,PRKG1,GABRB1,SOX6,DTNA |
1.901e-03 | -6.27 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 28 |
SLC1A3,SLC1A2 |
1.911e-03 | -6.26 | ZF_ZZ_2 | prosite domains | PS50135 | 19 | 2 | 12186 | 42 |
DTNA,DMD |
1.912e-03 | -6.26 | ZnF_ZZ | smart domains | SM00291 | 16 | 2 | 9717 | 40 |
DTNA,DMD |
1.913e-03 | -6.26 | human chr10q11.23-q21.1 | chromosome location | human chr10q11.23-q21.1 | 1 | 1 | 26134 | 50 |
PRKG1 |
1.913e-03 | -6.26 | human chr20q12-q13.11 | chromosome location | human chr20q12-q13.11 | 1 | 1 | 26134 | 50 |
PTPRT |
1.913e-03 | -6.26 | human chrXp21.2-p21.1 | chromosome location | human chrXp21.2-p21.1 | 1 | 1 | 26134 | 50 |
DMD |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.913e-03 | -6.26 | human chr6q24.3-q25.1 | chromosome location | human chr6q24.3-q25.1 | 1 | 1 | 26134 | 50 |
SASH1 |
1.913e-03 | -6.26 | human chr3q27.2-q27.3 | chromosome location | human chr3q27.2-q27.3 | 1 | 1 | 26134 | 50 |
DGKG |
1.913e-03 | -6.26 | human chr4q22.1-q22.2 | chromosome location | human chr4q22.1-q22.2 | 1 | 1 | 26134 | 50 |
GRID2 |
1.929e-03 | -6.25 | HOMER1 (homer scaffold protein 1) | protein interactions | 9456 | 96 | 3 | 19454 | 50 |
TNIK,GRIK1,GRIA1 |
1.942e-03 | -6.24 | transmembrane signaling receptor activity | molecular function | GO:0004888 | 1251 | 10 | 18094 | 50 |
GRIA4,GRID2,PTPRT,PTPRZ1,GRIA1,GABBR2,GRIK1,LIFR,GABRB1,NTRK2 |
1.965e-03 | -6.23 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
1.965e-03 | -6.23 | positive regulation of amyloid precursor protein catabolic process | biological process | GO:1902993 | 25 | 2 | 18204 | 48 |
SPON1,CLU |
1.965e-03 | -6.23 | peptide biosynthetic process | biological process | GO:0043043 | 25 | 2 | 18204 | 48 |
DMD,SLC1A2 |
1.998e-03 | -6.22 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 48 |
DGKG,PCDH9,ZBTB20,DTNA,SOX6,GABRB1,PRKG1,DCLK1,TNIK,GRIK1,NRG3,CPE,GLIS3,NPAS3,LIFR,SASH1,PDZRN4,PHYHIPL,SLC1A3,DPP6,CLU,CTNNA3,QKI,PPP2R2B,GFAP,GPM6B,GPM6A,DMD,CST3,LSAMP,MYO16,SLC1A2,GRIA1,GRIA4,LAMA2,SPON1,PTPRZ1,GRID2,ATP1A2,NTRK2,SPARCL1,CTNND2,AQP4,HS6ST3,NTM,PTPRT,GABBR2,SMOC1 |
2.013e-03 | -6.21 | AMPA glutamate receptor complex | cellular component | GO:0032281 | 26 | 2 | 19108 | 49 |
GRIA1,GRIA4 |
2.048e-03 | -6.19 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 11 | 16828 | 48 |
MYO16,LSAMP,DMD,GRIA4,CTNNA3,PTPRT,DPP6,GRIA1,TNIK,GABRB1,CTNND2 |
2.055e-03 | -6.19 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 41 | 16828 | 48 |
HS6ST3,SLC1A3,PDZRN4,CTNND2,SASH1,SPARCL1,NTRK2,ATP1A2,SMOC1,MYO16,LSAMP,DMD,GABBR2,PTPRT,GFAP,CTNNA3,QKI,PPP2R2B,DPP6,NTM,DCLK1,PRKG1,SOX6,GABRB1,DTNA,SLC1A2,PCDH9,DGKG,GRID2,PTPRZ1,LIFR,NPAS3,SPON1,GRIA4,LAMA2,GLIS3,GRIA1,CPE,NRG3,GRIK1,TNIK |
2.063e-03 | -6.18 | Nuclear signaling by ERBB4 | REACTOME pathways | R-HSA-1251985 | 25 | 2 | 10285 | 28 |
GFAP,NRG3 |
2.085e-03 | -6.17 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 48 |
GABRB1,SOX6,DTNA,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20,LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,SLC1A3,PHYHIPL,SASH1,PDZRN4,DMD,MYO16,LSAMP,CST3,DPP6,CLU,GPM6A,GPM6B,GFAP,QKI,CTNNA3,PPP2R2B,SLC1A2,SPON1,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4,HS6ST3,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,GABBR2,SMOC1,NTM,PTPRT |
2.085e-03 | -6.17 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 48 |
SLC1A2,GRIA1,LAMA2,GRIA4,SPON1,PTPRZ1,GRID2,ATP1A2,NTRK2,SPARCL1,CTNND2,AQP4,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,DGKG,PCDH9,ZBTB20,DTNA,GABRB1,SOX6,PRKG1,DCLK1,TNIK,GRIK1,NRG3,CPE,GLIS3,NPAS3,LIFR,SASH1,PDZRN4,PHYHIPL,SLC1A3,CLU,DPP6,QKI,PPP2R2B,CTNNA3,GFAP,GPM6B,GPM6A,DMD,CST3,LSAMP,MYO16 |
2.125e-03 | -6.15 | central nervous system myelination | biological process | GO:0022010 | 26 | 2 | 18204 | 48 |
CLU,GPM6B |
2.125e-03 | -6.15 | axon ensheathment in central nervous system | biological process | GO:0032291 | 26 | 2 | 18204 | 48 |
GPM6B,CLU |
2.132e-03 | -6.15 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 3 | 18204 | 48 |
SLC1A3,GFAP,SLC1A2 |
2.147e-03 | -6.14 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | KEGG pathways | ko05412 | 72 | 3 | 7161 | 26 |
DMD,CTNNA3,LAMA2 |
2.147e-03 | -6.14 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | KEGG pathways | hsa05412 | 72 | 3 | 7161 | 26 |
DMD,LAMA2,CTNNA3 |
2.176e-03 | -6.13 | FN3_dom | interpro domains | IPR003961 | 203 | 4 | 18521 | 50 |
LIFR,PTPRT,PHYHIPL,PTPRZ1 |
2.176e-03 | -6.13 | FN3_sf | interpro domains | IPR036116 | 203 | 4 | 18521 | 50 |
PTPRT,LIFR,PTPRZ1,PHYHIPL |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
DMD,DTNA |
2.181e-03 | -6.13 | HPCAL4 (hippocalcin like 4) | protein interactions | 51440 | 27 | 2 | 19454 | 50 |
GPM6A,AQP4 |
2.241e-03 | -6.10 | biological regulation | biological process | GO:0065007 | 12501 | 42 | 18204 | 48 |
PTPRT,DMD,GPM6B,GRIK1,GABBR2,SPARCL1,NPAS3,SLC1A3,NTRK2,DCLK1,MAPK10,SASH1,GFAP,DTNA,PRKG1,TNIK,DPP6,SOX6,CPE,ZBTB20,ATP1A2,LIFR,LAMA2,DGKG,GRIA4,GABRB1,NRG3,SLC1A2,CLU,GLIS3,AQP4,GRIA1,GRID2,PTPRZ1,CST3,SPON1,CTNNA3,GPM6A,SMOC1,MYO16,QKI,CTNND2 |
2.253e-03 | -6.10 | breast-carcinoma-ductal_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductal_carcinoma | 14824 | 48 | 16828 | 48 |
SLC1A2,GRIA1,GRIA4,LAMA2,SPON1,GRID2,PTPRZ1,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,PCDH9,DGKG,ZBTB20,SOX6,GABRB1,DTNA,DCLK1,PRKG1,GLIS3,CPE,NRG3,GRIK1,TNIK,LIFR,NPAS3,SASH1,PDZRN4,SLC1A3,PHYHIPL,DPP6,CLU,GPM6A,GPM6B,GFAP,PPP2R2B,CTNNA3,QKI,DMD,MYO16,CST3,LSAMP |
2.260e-03 | -6.09 | regulation of striated muscle contraction | biological process | GO:0006942 | 99 | 3 | 18204 | 48 |
ATP1A2,DMD,CTNNA3 |
2.260e-03 | -6.09 | regulation of neurotransmitter transport | biological process | GO:0051588 | 99 | 3 | 18204 | 48 |
GFAP,GPM6B,ATP1A2 |
2.291e-03 | -6.08 | regulation of cardiac muscle contraction by calcium ion signaling | biological process | GO:0010882 | 27 | 2 | 18204 | 48 |
ATP1A2,DMD |
2.325e-03 | -6.06 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 48 |
GRIA1,SLC1A2,SLC1A3 |
2.397e-03 | -6.03 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 48 |
SPON1,GRID2,PTPRZ1,GRIA1,GRIA4,LAMA2,SLC1A2,GABBR2,SMOC1,NTM,PTPRT,HS6ST3,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,NPAS3,LIFR,NRG3,GRIK1,TNIK,GLIS3,CPE,GABRB1,SOX6,DTNA,DCLK1,PRKG1,DGKG,PCDH9,ZBTB20,DMD,LSAMP,CST3,MYO16,DPP6,CLU,GFAP,QKI,CTNNA3,PPP2R2B,GPM6A,GPM6B,SLC1A3,PHYHIPL,SASH1,PDZRN4 |
2.463e-03 | -6.01 | glial cell proliferation | biological process | GO:0014009 | 28 | 2 | 18204 | 48 |
CLU,GFAP |
2.463e-03 | -6.01 | positive regulation of oligodendrocyte differentiation | biological process | GO:0048714 | 28 | 2 | 18204 | 48 |
PTPRZ1,QKI |
2.463e-03 | -6.01 | startle response | biological process | GO:0001964 | 28 | 2 | 18204 | 48 |
CSMD1,GRID2 |
2.514e-03 | -5.99 | CACNG2 (calcium voltage-gated channel auxiliary subunit gamma 2) | protein interactions | 10369 | 29 | 2 | 19454 | 50 |
GRIA4,GRIA1 |
2.529e-03 | -5.98 | cerebellum development | biological process | GO:0021549 | 103 | 3 | 18204 | 48 |
GRID2,MYO16,PRKG1 |
2.552e-03 | -5.97 | regulation of biological process | biological process | GO:0050789 | 12079 | 41 | 18204 | 48 |
QKI,CTNND2,SMOC1,MYO16,GPM6A,GRIA1,GRID2,PTPRZ1,CST3,CTNNA3,SPON1,GLIS3,CLU,GRIA4,SLC1A2,GABRB1,NRG3,DGKG,LIFR,LAMA2,ZBTB20,ATP1A2,DPP6,SOX6,CPE,TNIK,PRKG1,MAPK10,SASH1,DTNA,GFAP,SLC1A3,NPAS3,NTRK2,DCLK1,GRIK1,GABBR2,SPARCL1,PTPRT,DMD,GPM6B |
2.563e-03 | -5.97 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 8 | 16828 | 48 |
DCLK1,HS6ST3,GRID2,PCDH9,GLIS3,CTNNA3,PTPRT,PDZRN4 |
2.564e-03 | -5.97 | perinuclear endoplasmic reticulum lumen | cellular component | GO:0099020 | 1 | 1 | 19108 | 49 |
CLU |
2.570e-03 | -5.96 | Ptk2 (protein tyrosine kinase 2) | protein interactions | 25614 | 1 | 1 | 19454 | 50 |
DMD |
2.570e-03 | -5.96 | Bdnf (brain derived neurotrophic factor) | protein interactions | 12064 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | DAG1 (dystroglycan 1) | protein interactions | 281439 | 1 | 1 | 19454 | 50 |
LAMA2 |
2.570e-03 | -5.96 | IML3 (Iml3p) | protein interactions | 852404 | 1 | 1 | 19454 | 50 |
GFAP |
2.570e-03 | -5.96 | Dynlt1 (dynein light chain Tctex-type 1) | protein interactions | 83462 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.585e-03 | -5.96 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 11 | 16828 | 48 |
LAMA2,PTPRT,PDZRN4,DPP6,PCDH9,DGKG,NRG3,PTPRZ1,GABRB1,DTNA,NPAS3 |
2.620e-03 | -5.94 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 7 | 16828 | 48 |
SPARCL1,NTRK2,TNIK,DCLK1,MYO16,PRKG1,LIFR |
2.620e-03 | -5.94 | regulation of synaptic plasticity | biological process | GO:0048167 | 219 | 4 | 18204 | 48 |
NTRK2,GRID2,GRIA1,GFAP |
2.623e-03 | -5.94 | cell junction organization | biological process | GO:0034330 | 532 | 6 | 18204 | 48 |
GRID2,GRIA1,NRG3,SPARCL1,CTNND2,GPM6A |
2.637e-03 | -5.94 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 48 |
ATP1A2 |
2.637e-03 | -5.94 | positive regulation of neurofibrillary tangle assembly | biological process | GO:1902998 | 1 | 1 | 18204 | 48 |
CLU |
2.637e-03 | -5.94 | trans-synaptic signaling by neuropeptide, modulating synaptic transmission | biological process | GO:0099551 | 1 | 1 | 18204 | 48 |
NTRK2 |
2.637e-03 | -5.94 | directional guidance of interneurons involved in migration from the subpallium to the cortex | biological process | GO:0021840 | 1 | 1 | 18204 | 48 |
NRG3 |
2.637e-03 | -5.94 | regulation of neuronal signal transduction | biological process | GO:1902847 | 1 | 1 | 18204 | 48 |
CLU |
2.637e-03 | -5.94 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 48 |
CST3 |
2.637e-03 | -5.94 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 48 |
ATP1A2 |
2.637e-03 | -5.94 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 48 |
CST3 |
2.637e-03 | -5.94 | trans-synaptic signaling by neuropeptide | biological process | GO:0099540 | 1 | 1 | 18204 | 48 |
NTRK2 |
2.637e-03 | -5.94 | chemorepulsion involved in interneuron migration from the subpallium to the cortex | biological process | GO:0021842 | 1 | 1 | 18204 | 48 |
NRG3 |
2.641e-03 | -5.94 | gamma-aminobutyric acid signaling pathway | biological process | GO:0007214 | 29 | 2 | 18204 | 48 |
GABRB1,GABBR2 |
2.690e-03 | -5.92 | GRIA3 (glutamate ionotropic receptor AMPA type subunit 3) | protein interactions | 2892 | 30 | 2 | 19454 | 50 |
GRIA1,GRIA4 |
2.697e-03 | -5.92 | STAR_dimer | pfam domains | PF16544 | 1 | 1 | 17795 | 48 |
QKI |
2.697e-03 | -5.92 | Quaking_NLS | pfam domains | PF16551 | 1 | 1 | 17795 | 48 |
QKI |
2.697e-03 | -5.92 | LIFR_N | pfam domains | PF18207 | 1 | 1 | 17795 | 48 |
LIFR |
2.697e-03 | -5.92 | GBR2_CC | pfam domains | PF18455 | 1 | 1 | 17795 | 48 |
GABBR2 |
2.697e-03 | -5.92 | PKcGMP_CC | pfam domains | PF16808 | 1 | 1 | 17795 | 48 |
PRKG1 |
2.700e-03 | -5.91 | GBR2_CC | interpro domains | IPR041689 | 1 | 1 | 18521 | 50 |
GABBR2 |
2.700e-03 | -5.91 | SMOC1_EC | interpro domains | IPR037639 | 1 | 1 | 18521 | 50 |
SMOC1 |
2.700e-03 | -5.91 | Quaking_NLS | interpro domains | IPR032367 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | SASH1_SAM_repeat2 | interpro domains | IPR037630 | 1 | 1 | 18521 | 50 |
SASH1 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | PKcGMP_CC | interpro domains | IPR031831 | 1 | 1 | 18521 | 50 |
PRKG1 |
2.700e-03 | -5.91 | GPCR_3_GABA_rcpt_B2 | interpro domains | IPR002457 | 1 | 1 | 18521 | 50 |
GABBR2 |
2.700e-03 | -5.91 | SASH1_SAM_repeat1 | interpro domains | IPR037627 | 1 | 1 | 18521 | 50 |
SASH1 |
2.700e-03 | -5.91 | STAR_dimer | interpro domains | IPR032377 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | SASH1_SH3 | interpro domains | IPR035720 | 1 | 1 | 18521 | 50 |
SASH1 |
2.700e-03 | -5.91 | LIFR_N | interpro domains | IPR040901 | 1 | 1 | 18521 | 50 |
LIFR |
2.700e-03 | -5.91 | C1_DGKgamma_rpt2 | interpro domains | IPR047475 | 1 | 1 | 18521 | 50 |
DGKG |
2.700e-03 | -5.91 | Clusterin_CS | interpro domains | IPR033986 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | MYSc_Myo16 | interpro domains | IPR036042 | 1 | 1 | 18521 | 50 |
MYO16 |
2.700e-03 | -5.91 | NTRK2 | interpro domains | IPR020455 | 1 | 1 | 18521 | 50 |
NTRK2 |
2.700e-03 | -5.91 | Clusterin | interpro domains | IPR016016 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.709e-03 | -5.91 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 7 | 16828 | 48 |
SPARCL1,NTRK2,TNIK,DCLK1,MYO16,PRKG1,LIFR |
2.751e-03 | -5.90 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 47 | 16828 | 48 |
SLC1A3,PHYHIPL,SASH1,PDZRN4,DMD,MYO16,LSAMP,CLU,DPP6,GPM6A,GPM6B,GFAP,QKI,CTNNA3,PPP2R2B,GABRB1,SOX6,DTNA,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20,LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,HS6ST3,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,GABBR2,SMOC1,NTM,PTPRT,SLC1A2,SPON1,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4 |
2.763e-03 | -5.89 | internal N(7)-methylguanine-containing RNA reader activity | molecular function | GO:0160089 | 1 | 1 | 18094 | 50 |
QKI |
2.763e-03 | -5.89 | brain-derived neurotrophic factor receptor activity | molecular function | GO:0060175 | 1 | 1 | 18094 | 50 |
NTRK2 |
2.825e-03 | -5.87 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
2.870e-03 | -5.85 | SNTG1 (syntrophin gamma 1) | protein interactions | 54212 | 31 | 2 | 19454 | 50 |
DTNA,DMD |
2.884e-03 | -5.85 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-follicular_lymphoma | 208 | 4 | 16828 | 48 |
GRID2,SMOC1,TNIK,PCDH9 |
2.897e-03 | -5.84 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 50 |
SLC1A3,SLC1A2 |
2.897e-03 | -5.84 | G-protein alpha-subunit binding | molecular function | GO:0001965 | 29 | 2 | 18094 | 50 |
GRIA1,SASH1 |
2.918e-03 | -5.84 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 21 | 16828 | 48 |
LAMA2,CTNNA3,PPP2R2B,PTPRT,CLU,GRIA1,GLIS3,DPP6,PTPRZ1,GRID2,GABBR2,SPON1,NPAS3,AQP4,CTNND2,PDZRN4,SASH1,SPARCL1,DCLK1,SOX6,SLC1A3 |
2.934e-03 | -5.83 | extracellular matrix | cellular component | GO:0031012 | 559 | 6 | 19108 | 49 |
CLU,PTPRZ1,SMOC1,SPON1,SPARCL1,LAMA2 |
2.960e-03 | -5.82 | external encapsulating structure | cellular component | GO:0030312 | 560 | 6 | 19108 | 49 |
SPARCL1,LAMA2,PTPRZ1,CLU,SMOC1,SPON1 |
2.983e-03 | -5.81 | cell-cell adhesion | biological process | GO:0098609 | 546 | 6 | 18204 | 48 |
CTNND2,SPARCL1,PCDH9,PTPRT,GRID2,CTNNA3 |
3.015e-03 | -5.80 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0010880 | 31 | 2 | 18204 | 48 |
DMD,ATP1A2 |
3.028e-03 | -5.80 | large_intestine-colon | COSMIC cancer mutations | large_intestine-colon | 1291 | 10 | 16828 | 48 |
DMD,MYO16,PTPRZ1,SASH1,DPP6,GRIA1,GRIK1,LAMA2,ZBTB20,PTPRT |
3.057e-03 | -5.79 | GRIA4 (glutamate ionotropic receptor AMPA type subunit 4) | protein interactions | 2893 | 32 | 2 | 19454 | 50 |
GRIA1,GRIA4 |
3.060e-03 | -5.79 | Ig-like_fold | interpro domains | IPR013783 | 721 | 7 | 18521 | 50 |
LSAMP,NTRK2,PHYHIPL,PTPRZ1,LIFR,PTPRT,NTM |
3.127e-03 | -5.77 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 27 | 16828 | 48 |
GRIA1,GLIS3,NRG3,GRIA4,LAMA2,GRID2,PTPRZ1,PCDH9,DGKG,ZBTB20,SOX6,GABRB1,DTNA,PRKG1,CLU,GPM6A,PTPRT,CTNNA3,DMD,SMOC1,MYO16,SPARCL1,SASH1,NTRK2,ATP1A2,PDZRN4,SLC1A3 |
3.143e-03 | -5.76 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 27 | 16828 | 48 |
NRG3,GRIA1,GLIS3,LAMA2,GRIA4,PTPRZ1,GRID2,DGKG,PCDH9,ZBTB20,DTNA,SOX6,GABRB1,PRKG1,CLU,CTNNA3,PTPRT,GPM6A,DMD,MYO16,SMOC1,ATP1A2,NTRK2,SASH1,SPARCL1,PDZRN4,SLC1A3 |
3.175e-03 | -5.75 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 8 | 16828 | 48 |
DCLK1,GRID2,HS6ST3,PTPRT,PDZRN4,CTNNA3,GLIS3,PCDH9 |
3.206e-03 | -5.74 | regulation of gliogenesis | biological process | GO:0014013 | 112 | 3 | 18204 | 48 |
QKI,PTPRZ1,GFAP |
3.211e-03 | -5.74 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
3.211e-03 | -5.74 | peptidyl-tyrosine dephosphorylation | biological process | GO:0035335 | 32 | 2 | 18204 | 48 |
PTPRZ1,PTPRT |
3.220e-03 | -5.74 | beta-catenin binding | molecular function | GO:0008013 | 107 | 3 | 18094 | 50 |
CTNND2,PTPRT,CTNNA3 |
3.248e-03 | -5.73 | - | gene3d domains | 1.20.5.4010 | 1 | 1 | 14470 | 47 |
QKI |
3.288e-03 | -5.72 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 48 |
DCLK1,CTNND2,PRKG1 |
3.288e-03 | -5.72 | metencephalon development | biological process | GO:0022037 | 113 | 3 | 18204 | 48 |
PRKG1,MYO16,GRID2 |
3.330e-03 | -5.70 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 3 | 16828 | 48 |
NRG3,PRKG1,QKI |
3.356e-03 | -5.70 | Kazal_2 | pfam domains | PF07648 | 32 | 2 | 17795 | 48 |
SMOC1,SPARCL1 |
3.357e-03 | -5.70 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | 217 | 4 | 16828 | 48 |
DTNA,DMD,LAMA2,PTPRT |
3.367e-03 | -5.69 | PRKCA (protein kinase C alpha) | protein interactions | 5578 | 395 | 5 | 19454 | 50 |
GFAP,PRKG1,GRIA4,GPM6A,GRIA1 |
3.371e-03 | -5.69 | Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | REACTOME pathways | R-HSA-399721 | 32 | 2 | 10285 | 28 |
GRIA4,GRIA1 |
3.371e-03 | -5.69 | Trafficking of AMPA receptors | REACTOME pathways | R-HSA-399719 | 32 | 2 | 10285 | 28 |
GRIA1,GRIA4 |
3.412e-03 | -5.68 | response to auditory stimulus | biological process | GO:0010996 | 33 | 2 | 18204 | 48 |
SLC1A3,ATP1A2 |
3.426e-03 | -5.68 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 8 | 16828 | 48 |
GABBR2,NPAS3,PTPRZ1,ATP1A2,DGKG,SPARCL1,PPP2R2B,CTNNA3 |
3.447e-03 | -5.67 | CLUSTERIN_1 | prosite domains | PS00492 | 1 | 1 | 12186 | 42 |
CLU |
3.447e-03 | -5.67 | CLUSTERIN_2 | prosite domains | PS00493 | 1 | 1 | 12186 | 42 |
CLU |
3.705e-03 | -5.60 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 13 | 16828 | 48 |
GABRB1,PCDH9,AQP4,GABBR2,LSAMP,PTPRZ1,MYO16,NRG3,GFAP,PTPRT,CTNNA3,PPP2R2B,GPM6A |
3.709e-03 | -5.60 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 21 | 16828 | 48 |
CLU,GRIA1,GLIS3,DPP6,PTPRT,PPP2R2B,CTNNA3,LAMA2,NPAS3,GABBR2,SPON1,GRID2,PTPRZ1,SASH1,SPARCL1,PDZRN4,CTNND2,AQP4,SLC1A3,SOX6,DCLK1 |
3.714e-03 | -5.60 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 9 | 16828 | 48 |
GRID2,PRKG1,MYO16,GABRB1,LIFR,CTNND2,PPP2R2B,CTNNA3,NTM |
3.717e-03 | -5.59 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 8 | 16828 | 48 |
SPARCL1,DGKG,ATP1A2,PPP2R2B,CTNNA3,NPAS3,GABBR2,PTPRZ1 |
3.821e-03 | -5.57 | NK-T_cell_lymphoma | COSMIC cancer mutations | NK-T_cell_lymphoma | 225 | 4 | 16828 | 48 |
DMD,DTNA,LAMA2,PTPRT |
3.823e-03 | -5.57 | human chr8p23.2 | chromosome location | human chr8p23.2 | 2 | 1 | 26134 | 50 |
CSMD1 |
3.832e-03 | -5.56 | regulation of cardiac muscle cell contraction | biological process | GO:0086004 | 35 | 2 | 18204 | 48 |
CTNNA3,ATP1A2 |
3.857e-03 | -5.56 | OSBPL1A (oxysterol binding protein like 1A) | protein interactions | 114876 | 36 | 2 | 19454 | 50 |
DMD,CTNNA3 |
3.858e-03 | -5.56 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 11 | 18204 | 48 |
CLU,NTRK2,GPM6B,ZBTB20,QKI,ATP1A2,SOX6,PTPRZ1,GRID2,GFAP,SASH1 |
3.860e-03 | -5.56 | regulation of neuron apoptotic process | biological process | GO:0043523 | 244 | 4 | 18204 | 48 |
GRID2,PTPRZ1,NTRK2,CLU |
3.893e-03 | -5.55 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 48 |
DTNA,DMD,ATP1A2 |
3.898e-03 | -5.55 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-polycythaemia_vera | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-polycythaemia_vera | 369 | 5 | 16828 | 48 |
NTRK2,CTNND2,CTNNA3,DCLK1,LAMA2 |
3.898e-03 | -5.55 | polycythaemia_vera | COSMIC cancer mutations | polycythaemia_vera | 369 | 5 | 16828 | 48 |
NTRK2,DCLK1,LAMA2,CTNND2,CTNNA3 |
3.904e-03 | -5.55 | functioning | COSMIC cancer mutations | functioning | 1803 | 12 | 16828 | 48 |
SLC1A2,DMD,PTPRZ1,MYO16,GRIK1,DGKG,NRG3,NTRK2,PCDH9,GRIA1,CTNNA3,ZBTB20 |
3.904e-03 | -5.55 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 12 | 16828 | 48 |
GRIK1,NTRK2,DGKG,NRG3,PCDH9,GRIA1,CTNNA3,ZBTB20,SLC1A2,DMD,PTPRZ1,MYO16 |
3.973e-03 | -5.53 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 4 | 18204 | 48 |
PTPRZ1,GFAP,QKI,NTRK2 |
3.973e-03 | -5.53 | regulation of synapse organization | biological process | GO:0050807 | 246 | 4 | 18204 | 48 |
PTPRT,GRID2,NTRK2,GPM6A |
4.049e-03 | -5.51 | Salivary secretion | KEGG pathways | ko04970 | 90 | 3 | 7161 | 26 |
ATP1A2,CST3,PRKG1 |
4.049e-03 | -5.51 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 3 | 7161 | 26 |
PRKG1,ATP1A2,CST3 |
4.071e-03 | -5.50 | SERTAD2 (SERTA domain containing 2) | protein interactions | 9792 | 37 | 2 | 19454 | 50 |
CTNNA3,PPP2R2B |
4.071e-03 | -5.50 | TRNAU1AP (tRNA selenocysteine 1 associated protein 1) | protein interactions | 54952 | 37 | 2 | 19454 | 50 |
QKI,ZBTB20 |
4.071e-03 | -5.50 | MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2) | protein interactions | 9863 | 37 | 2 | 19454 | 50 |
CTNND2,GRID2 |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
GPM6A,CST3 |
4.079e-03 | -5.50 | ovary-other-neoplasm | COSMIC cancer mutations | ovary-other-neoplasm | 12717 | 44 | 16828 | 48 |
PDZRN4,SASH1,PHYHIPL,SLC1A3,GPM6B,GPM6A,QKI,CTNNA3,PPP2R2B,GFAP,CLU,DPP6,MYO16,LSAMP,DMD,ZBTB20,PCDH9,DGKG,PRKG1,DCLK1,GABRB1,SOX6,CPE,GLIS3,TNIK,GRIK1,NRG3,LIFR,AQP4,CTNND2,SPARCL1,ATP1A2,NTRK2,HS6ST3,PTPRT,NTM,SMOC1,GABBR2,SLC1A2,LAMA2,GRIA4,GRIA1,GRID2,SPON1 |
4.148e-03 | -5.49 | regulation of muscle system process | biological process | GO:0090257 | 249 | 4 | 18204 | 48 |
DMD,CTNNA3,PRKG1,ATP1A2 |
4.150e-03 | -5.48 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 20 | 16828 | 48 |
PTPRT,CTNNA3,GPM6A,GPM6B,TNIK,GLIS3,GRID2,PTPRZ1,NPAS3,PDZRN4,CTNND2,AQP4,DGKG,NTRK2,ATP1A2,SASH1,PCDH9,PRKG1,SLC1A2,SOX6 |
4.163e-03 | -5.48 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 20 | 16828 | 48 |
PDZRN4,CTNND2,AQP4,DGKG,NTRK2,ATP1A2,PCDH9,SASH1,PRKG1,SLC1A2,SOX6,PTPRT,CTNNA3,GPM6A,GPM6B,TNIK,GLIS3,GRID2,PTPRZ1,NPAS3 |
4.188e-03 | -5.48 | FN3 | prosite domains | PS50853 | 192 | 4 | 12186 | 42 |
PTPRZ1,PHYHIPL,LIFR,PTPRT |
4.201e-03 | -5.47 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 50 |
SLC1A3,SLC1A2 |
4.275e-03 | -5.45 | response to antibiotic | biological process | GO:0046677 | 37 | 2 | 18204 | 48 |
SLC1A3,GRIA1 |
4.281e-03 | -5.45 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 6 | 18094 | 50 |
PTPRZ1,CTNND2,CTNNA3,CPE,GFAP,PTPRT |
4.321e-03 | -5.44 | neuron projection terminus | cellular component | GO:0044306 | 128 | 3 | 19108 | 49 |
SLC1A2,DMD,NTRK2 |
4.328e-03 | -5.44 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 4 | 18204 | 48 |
GPM6A,NTRK2,PTPRT,GRID2 |
4.352e-03 | -5.44 | CDCA8 (cell division cycle associated 8) | protein interactions | 55143 | 128 | 3 | 19454 | 50 |
PPP2R2B,GPM6B,DCLK1 |
4.400e-03 | -5.43 | NTKRECEPTOR2 | prints domains | PR01941 | 1 | 1 | 5227 | 23 |
NTRK2 |
4.400e-03 | -5.43 | GABAB2RECPTR | prints domains | PR01178 | 1 | 1 | 5227 | 23 |
GABBR2 |
4.400e-03 | -5.43 | AQUAPORIN4 | prints domains | PR02016 | 1 | 1 | 5227 | 23 |
AQP4 |
4.481e-03 | -5.41 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 13 | 16828 | 48 |
PTPRZ1,DCLK1,PRKG1,GABBR2,DMD,SOX6,DTNA,PDZRN4,GFAP,LAMA2,NTRK2,TNIK,ATP1A2 |
4.562e-03 | -5.39 | response to amino acid | biological process | GO:0043200 | 127 | 3 | 18204 | 48 |
NTRK2,SLC1A2,GRIA1 |
4.590e-03 | -5.38 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 10 | 16828 | 48 |
ATP1A2,GRIK1,PCDH9,SASH1,CPE,CTNND2,PDZRN4,PHYHIPL,SMOC1,DCLK1 |
4.594e-03 | -5.38 | Arrhythmogenic Right Ventricular Cardiomyopathy | WikiPathways | WP2118 | 76 | 3 | 5310 | 24 |
DMD,CTNNA3,LAMA2 |
4.617e-03 | -5.38 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 20 | 16828 | 48 |
AQP4,PDZRN4,CTNND2,PCDH9,SASH1,NTRK2,DGKG,ATP1A2,PRKG1,SOX6,SLC1A2,GPM6A,GPM6B,PTPRT,CTNNA3,GLIS3,TNIK,GRID2,PTPRZ1,NPAS3 |
4.642e-03 | -5.37 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 12 | 18204 | 48 |
NRG3,CPE,GRIK1,GRIA4,NTRK2,CTNND2,LIFR,GRIA1,GRID2,PTPRT,MAPK10,TNIK |
4.684e-03 | -5.36 | DISC1 (DISC1 scaffold protein) | protein interactions | 27185 | 427 | 5 | 19454 | 50 |
TNIK,DMD,CTNNA3,CLU,SPARCL1 |
4.692e-03 | -5.36 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 16 | 18204 | 48 |
PTPRZ1,GRID2,CST3,SASH1,CTNNA3,GFAP,PRKG1,SOX6,QKI,ZBTB20,ATP1A2,DMD,GPM6B,LAMA2,CLU,NTRK2 |
4.741e-03 | -5.35 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 48 |
SLC1A3,ATP1A2 |
4.741e-03 | -5.35 | maintenance of blood-brain barrier | biological process | GO:0035633 | 39 | 2 | 18204 | 48 |
DMD,LAMA2 |
4.741e-03 | -5.35 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
4.744e-03 | -5.35 | CTNNBIP1 (catenin beta interacting protein 1) | protein interactions | 56998 | 40 | 2 | 19454 | 50 |
PPP2R2B,CTNNA3 |
4.838e-03 | -5.33 | axon development | biological process | GO:0061564 | 420 | 5 | 18204 | 48 |
LAMA2,GPM6B,PTPRZ1,DCLK1,PRKG1 |
4.855e-03 | -5.33 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 3 | 7161 | 26 |
GRIA4,GRIA1,PRKG1 |
4.855e-03 | -5.33 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 3 | 7161 | 26 |
PRKG1,GRIA4,GRIA1 |
4.899e-03 | -5.32 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 4 | 18204 | 48 |
GRID2,PTPRT,PCDH9,SPARCL1 |
4.934e-03 | -5.31 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 10 | 16828 | 48 |
PDZRN4,CTNND2,CPE,PCDH9,SASH1,ATP1A2,GRIK1,SMOC1,DCLK1,PHYHIPL |
4.974e-03 | -5.30 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 3 | 18204 | 48 |
SLC1A2,GFAP,SLC1A3 |
4.980e-03 | -5.30 | TAFA2 (TAFA chemokine like family member 2) | protein interactions | 338811 | 41 | 2 | 19454 | 50 |
LIFR,CPE |
5.085e-03 | -5.28 | essential_thrombocythaemia | COSMIC cancer mutations | essential_thrombocythaemia | 393 | 5 | 16828 | 48 |
GRIA4,PDZRN4,SASH1,DTNA,DMD |
5.085e-03 | -5.28 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | 393 | 5 | 16828 | 48 |
PDZRN4,GRIA4,DTNA,SASH1,DMD |
5.094e-03 | -5.28 | system process | biological process | GO:0003008 | 2015 | 12 | 18204 | 48 |
CSMD1,ATP1A2,GRIA1,GRID2,PTPRZ1,DTNA,PRKG1,SLC1A2,SLC1A3,AQP4,NTRK2,DMD |
5.122e-03 | -5.27 | axonal spine | cellular component | GO:0044308 | 2 | 1 | 19108 | 49 |
GRIA1 |
5.122e-03 | -5.27 | perisynaptic space | cellular component | GO:0099544 | 2 | 1 | 19108 | 49 |
GRIA1 |
5.122e-03 | -5.27 | G protein-coupled GABA receptor complex | cellular component | GO:1902712 | 2 | 1 | 19108 | 49 |
GABBR2 |
5.134e-03 | -5.27 | Frrs1l (ferric-chelate reductase 1 like) | protein interactions | 230235 | 2 | 1 | 19454 | 50 |
GRIA1 |
5.134e-03 | -5.27 | TRIM39-RPP21 (TRIM39-RPP21 readthrough) | protein interactions | 202658 | 2 | 1 | 19454 | 50 |
PRKG1 |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | URA1 (dihydroorotate dehydrogenase) | protein interactions | 853664 | 2 | 1 | 19454 | 50 |
GFAP |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Snta1 (syntrophin, alpha 1) | protein interactions | 362242 | 2 | 1 | 19454 | 50 |
DMD |
5.134e-03 | -5.27 | TARP (TCR gamma alternate reading frame protein) | protein interactions | 445347 | 2 | 1 | 19454 | 50 |
GRIA1 |
5.220e-03 | -5.26 | E7 (early protein) | protein interactions | 1489425 | 42 | 2 | 19454 | 50 |
SASH1,CLU |
5.228e-03 | -5.25 | regulation of actin filament-based movement | biological process | GO:1903115 | 41 | 2 | 18204 | 48 |
ATP1A2,CTNNA3 |
5.265e-03 | -5.25 | amide binding | molecular function | GO:0033218 | 254 | 4 | 18094 | 50 |
CST3,GRIA1,CLU,GRIA4 |
5.267e-03 | -5.25 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 48 |
CST3 |
5.267e-03 | -5.25 | regulation of neurofibrillary tangle assembly | biological process | GO:1902996 | 2 | 1 | 18204 | 48 |
CLU |
5.267e-03 | -5.25 | negative regulation of inositol phosphate biosynthetic process | biological process | GO:0010920 | 2 | 1 | 18204 | 48 |
PRKG1 |
5.267e-03 | -5.25 | negative regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905869 | 2 | 1 | 18204 | 48 |
QKI |
5.267e-03 | -5.25 | myofibroblast contraction | biological process | GO:1990764 | 2 | 1 | 18204 | 48 |
QKI |
5.267e-03 | -5.25 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 48 |
CST3 |
5.388e-03 | -5.22 | Thyroglob_assoc | pfam domains | PF16597 | 2 | 1 | 17795 | 48 |
SMOC1 |
5.388e-03 | -5.22 | Spond_N | pfam domains | PF06468 | 2 | 1 | 17795 | 48 |
SPON1 |
5.388e-03 | -5.22 | Reeler | pfam domains | PF02014 | 2 | 1 | 17795 | 48 |
SPON1 |
5.388e-03 | -5.22 | LIFR_D2 | pfam domains | PF17971 | 2 | 1 | 17795 | 48 |
LIFR |
5.388e-03 | -5.22 | Clusterin | pfam domains | PF01093 | 2 | 1 | 17795 | 48 |
CLU |
5.388e-03 | -5.22 | PHYHIP_C | pfam domains | PF19281 | 2 | 1 | 17795 | 48 |
PHYHIPL |
5.388e-03 | -5.22 | LIF-R_Ig-like | pfam domains | PF21177 | 2 | 1 | 17795 | 48 |
LIFR |
5.392e-03 | -5.22 | Clusterin_C | interpro domains | IPR016015 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Clusterin-like | interpro domains | IPR000753 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Spondin_N | interpro domains | IPR009465 | 2 | 1 | 18521 | 50 |
SPON1 |
5.392e-03 | -5.22 | LIFR_D2 | interpro domains | IPR040817 | 2 | 1 | 18521 | 50 |
LIFR |
5.392e-03 | -5.22 | PHYHIP/PHYHIPL | interpro domains | IPR042868 | 2 | 1 | 18521 | 50 |
PHYHIPL |
5.392e-03 | -5.22 | STKc_cGK | interpro domains | IPR035014 | 2 | 1 | 18521 | 50 |
PRKG1 |
5.392e-03 | -5.22 | Dystrophin/utrophin | interpro domains | IPR035436 | 2 | 1 | 18521 | 50 |
DMD |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Spondin_N_sf | interpro domains | IPR038678 | 2 | 1 | 18521 | 50 |
SPON1 |
5.392e-03 | -5.22 | cGMP_dep_kinase | interpro domains | IPR002374 | 2 | 1 | 18521 | 50 |
PRKG1 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | PHYIP/PHIPL_C | interpro domains | IPR045545 | 2 | 1 | 18521 | 50 |
PHYHIPL |
5.392e-03 | -5.22 | LIF-R-like_Ig-like | interpro domains | IPR048497 | 2 | 1 | 18521 | 50 |
LIFR |
5.392e-03 | -5.22 | Clusterin_N | interpro domains | IPR016014 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | DCX_chordates | interpro domains | IPR017302 | 2 | 1 | 18521 | 50 |
DCLK1 |
5.407e-03 | -5.22 | organic acid transmembrane transport | biological process | GO:1903825 | 135 | 3 | 18204 | 48 |
SLC1A2,GFAP,SLC1A3 |
5.409e-03 | -5.22 | I-set | pfam domains | PF07679 | 132 | 3 | 17795 | 48 |
LSAMP,NTM,NTRK2 |
5.432e-03 | -5.22 | Ig_I-set | interpro domains | IPR013098 | 132 | 3 | 18521 | 50 |
NTM,LSAMP,NTRK2 |
5.438e-03 | -5.21 | Activation of Na-permeable Kainate Receptors | REACTOME pathways | R-HSA-451307 | 2 | 1 | 10285 | 28 |
GRIK1 |
5.481e-03 | -5.21 | regulation of amino acid transport | biological process | GO:0051955 | 42 | 2 | 18204 | 48 |
ATP1A2,PRKG1 |
5.489e-03 | -5.21 | Activation of NMDA receptor upon glutamate binding and postsynaptic events | REACTOME pathways | R-HSA-442755 | 41 | 2 | 10285 | 28 |
GRIA1,GRIA4 |
5.519e-03 | -5.20 | G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potential | molecular function | GO:0150047 | 2 | 1 | 18094 | 50 |
GABRB1 |
5.519e-03 | -5.20 | cGMP-dependent protein kinase activity | molecular function | GO:0004692 | 2 | 1 | 18094 | 50 |
PRKG1 |
5.519e-03 | -5.20 | leukemia inhibitory factor receptor activity | molecular function | GO:0004923 | 2 | 1 | 18094 | 50 |
LIFR |
5.562e-03 | -5.19 | peptide binding | molecular function | GO:0042277 | 258 | 4 | 18094 | 50 |
CLU,GRIA4,GRIA1,CST3 |
5.579e-03 | -5.19 | chondrosarcoma | COSMIC cancer mutations | chondrosarcoma | 1181 | 9 | 16828 | 48 |
LAMA2,DPP6,CPE,LSAMP,GRID2,DCLK1,MYO16,SPON1,DMD |
5.672e-03 | -5.17 | face | COSMIC cancer mutations | face | 2139 | 13 | 16828 | 48 |
PPP2R2B,CTNNA3,GFAP,PTPRT,AQP4,GPM6A,NRG3,PCDH9,PTPRZ1,LSAMP,MYO16,GABBR2,GABRB1 |
5.727e-03 | -5.16 | Y_phosphatase | pfam domains | PF00102 | 42 | 2 | 17795 | 48 |
PTPRZ1,PTPRT |
5.737e-03 | -5.16 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 48 |
ATP1A2,PRKG1,SLC1A3,SLC1A2 |
5.740e-03 | -5.16 | PTP_cat | interpro domains | IPR000242 | 42 | 2 | 18521 | 50 |
PTPRZ1,PTPRT |
5.934e-03 | -5.13 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 18 | 16828 | 48 |
DGKG,ATP1A2,SASH1,PCDH9,PDZRN4,CTNND2,ZBTB20,PRKG1,GRIA1,PTPRT,CTNNA3,LAMA2,NPAS3,SPON1,LIFR,GRID2,PTPRZ1,MYO16 |
5.946e-03 | -5.12 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 48 |
MYO16,GRID2,PTPRZ1,NTM,TNIK |
5.980e-03 | -5.12 | neurotransmitter transport | biological process | GO:0006836 | 140 | 3 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2 |
6.002e-03 | -5.12 | mammary gland morphogenesis | biological process | GO:0060443 | 44 | 2 | 18204 | 48 |
NRG3,CSMD1 |
6.005e-03 | -5.12 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 50 |
SLC1A2,SLC1A3 |
6.024e-03 | -5.11 | Signaling by ERBB4 | REACTOME pathways | R-HSA-1236394 | 43 | 2 | 10285 | 28 |
GFAP,NRG3 |
6.045e-03 | -5.11 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 5 | 18204 | 48 |
GRID2,GFAP,TNIK,DGKG,NTRK2 |
6.107e-03 | -5.10 | axon | cellular component | GO:0030424 | 650 | 6 | 19108 | 49 |
NTRK2,GRIA1,GPM6A,DTNA,PCDH9,SLC1A2 |
6.117e-03 | -5.10 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 10 | 16828 | 48 |
SLC1A2,MYO16,ATP1A2,NTRK2,GRIA1,CLU,QKI,CTNND2,PTPRT,PDZRN4 |
6.117e-03 | -5.10 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 10 | 16828 | 48 |
SLC1A2,MYO16,ATP1A2,NTRK2,GRIA1,CLU,QKI,CTNND2,PTPRT,PDZRN4 |
6.145e-03 | -5.09 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 27 | 16828 | 48 |
DPP6,GPM6B,CTNNA3,QKI,PTPRT,DMD,GABBR2,MYO16,NTRK2,AQP4,CTNND2,PDZRN4,PHYHIPL,CPE,GRIA1,NRG3,GRIA4,LAMA2,SPON1,NPAS3,PTPRZ1,GRID2,PCDH9,DGKG,ZBTB20,SOX6,DCLK1 |
6.219e-03 | -5.08 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 48 |
SLC1A3,GABRB1,SLC1A2 |
6.219e-03 | -5.08 | response to acid chemical | biological process | GO:0001101 | 142 | 3 | 18204 | 48 |
GRIA1,SLC1A2,NTRK2 |
6.234e-03 | -5.08 | RADX (RPA1 related single stranded DNA binding protein, X-linked) | protein interactions | 55086 | 46 | 2 | 19454 | 50 |
SOX6,GABBR2 |
6.270e-03 | -5.07 | cell communication involved in cardiac conduction | biological process | GO:0086065 | 45 | 2 | 18204 | 48 |
ATP1A2,CTNNA3 |
6.316e-03 | -5.06 | signaling receptor activity | molecular function | GO:0038023 | 1474 | 10 | 18094 | 50 |
NTRK2,GABRB1,GABBR2,GRIK1,LIFR,PTPRZ1,GRIA1,GRID2,GRIA4,PTPRT |
6.316e-03 | -5.06 | molecular transducer activity | molecular function | GO:0060089 | 1474 | 10 | 18094 | 50 |
GRIK1,LIFR,GABBR2,NTRK2,GABRB1,PTPRT,GRID2,GRIA4,GRIA1,PTPRZ1 |
6.412e-03 | -5.05 | stomach-carcinoma-adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-adenocarcinoma | 15150 | 48 | 16828 | 48 |
GLIS3,CPE,NRG3,GRIK1,TNIK,LIFR,NPAS3,ZBTB20,PCDH9,DGKG,DCLK1,PRKG1,SOX6,GABRB1,DTNA,GPM6A,GPM6B,GFAP,QKI,CTNNA3,PPP2R2B,CLU,DPP6,MYO16,LSAMP,CST3,DMD,PDZRN4,SASH1,SLC1A3,PHYHIPL,LAMA2,GRIA4,GRIA1,GRID2,PTPRZ1,SPON1,SLC1A2,PTPRT,NTM,SMOC1,GABBR2,AQP4,CTNND2,SPARCL1,NTRK2,ATP1A2,HS6ST3 |
6.441e-03 | -5.05 | membrane raft | cellular component | GO:0045121 | 290 | 4 | 19108 | 49 |
DMD,SLC1A2,ATP1A2,GPM6B |
6.486e-03 | -5.04 | F-spondin domain | gene3d domains | 2.60.40.2130 | 2 | 1 | 14470 | 47 |
SPON1 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
GPM6A,PTPRZ1 |
6.500e-03 | -5.04 | BDNF (brain derived neurotrophic factor) | protein interactions | 627 | 47 | 2 | 19454 | 50 |
NTRK2,CPE |
6.544e-03 | -5.03 | positive regulation of glial cell differentiation | biological process | GO:0045687 | 46 | 2 | 18204 | 48 |
PTPRZ1,QKI |
6.544e-03 | -5.03 | regulation of oligodendrocyte differentiation | biological process | GO:0048713 | 46 | 2 | 18204 | 48 |
QKI,PTPRZ1 |
6.582e-03 | -5.02 | Non-integrin membrane-ECM interactions | REACTOME pathways | R-HSA-3000171 | 45 | 2 | 10285 | 28 |
DMD,LAMA2 |
6.597e-03 | -5.02 | membrane microdomain | cellular component | GO:0098857 | 292 | 4 | 19108 | 49 |
DMD,SLC1A2,ATP1A2,GPM6B |
6.665e-03 | -5.01 | cell junction assembly | biological process | GO:0034329 | 285 | 4 | 18204 | 48 |
GPM6A,NRG3,GRIA1,GRID2 |
6.702e-03 | -5.01 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 48 |
SPON1,PTPRZ1,GRID2,GRIA1,LAMA2,GRIA4,SLC1A2,GABBR2,SMOC1,PTPRT,HS6ST3,ATP1A2,NTRK2,SPARCL1,CTNND2,AQP4,NPAS3,LIFR,GRIK1,TNIK,NRG3,CPE,GLIS3,DTNA,GABRB1,SOX6,PRKG1,DCLK1,DGKG,PCDH9,ZBTB20,DMD,LSAMP,MYO16,CLU,DPP6,QKI,CTNNA3,PPP2R2B,GFAP,GPM6B,GPM6A,PHYHIPL,SLC1A3,SASH1,PDZRN4 |
6.702e-03 | -5.01 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 48 |
SLC1A2,SPON1,PTPRZ1,GRID2,GRIA1,LAMA2,GRIA4,HS6ST3,SPARCL1,ATP1A2,NTRK2,AQP4,CTNND2,GABBR2,SMOC1,PTPRT,DTNA,SOX6,GABRB1,PRKG1,DCLK1,PCDH9,DGKG,ZBTB20,LIFR,NPAS3,CPE,GLIS3,TNIK,GRIK1,NRG3,PHYHIPL,SLC1A3,SASH1,PDZRN4,DMD,MYO16,LSAMP,DPP6,CLU,GPM6B,GPM6A,CTNNA3,QKI,PPP2R2B,GFAP |
6.772e-03 | -4.99 | PATE1 (prostate and testis expressed 1) | protein interactions | 160065 | 48 | 2 | 19454 | 50 |
SMOC1,CPE |
6.782e-03 | -4.99 | localization | biological process | GO:0051179 | 4474 | 20 | 18204 | 48 |
GFAP,GRIA1,GRID2,GPM6A,TNIK,DPP6,CPE,ATP1A2,QKI,DMD,GPM6B,SLC1A2,GABRB1,GRIK1,GRIA4,DCLK1,NTRK2,CLU,SLC1A3,AQP4 |
6.815e-03 | -4.99 | regulation of nervous system development | biological process | GO:0051960 | 456 | 5 | 18204 | 48 |
PTPRZ1,GRID2,GFAP,QKI,NTRK2 |
6.824e-03 | -4.99 | Schwann cell differentiation | biological process | GO:0014037 | 47 | 2 | 18204 | 48 |
LAMA2,NTRK2 |
6.881e-03 | -4.98 | TNIK (TRAF2 and NCK interacting kinase) | protein interactions | 23043 | 151 | 3 | 19454 | 50 |
PRKG1,TNIK,CLU |
6.882e-03 | -4.98 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 42 |
SPARCL1 |
6.882e-03 | -4.98 | SPONDIN | prosite domains | PS51020 | 2 | 1 | 12186 | 42 |
SPON1 |
6.882e-03 | -4.98 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 42 |
SPARCL1 |
6.884e-03 | -4.98 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 4 | 16828 | 48 |
SASH1,LIFR,GRIA4,CTNNA3 |
6.960e-03 | -4.97 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 26 | 16828 | 48 |
SOX6,DTNA,DGKG,ZBTB20,NPAS3,LIFR,GRID2,PTPRZ1,NRG3,GLIS3,GRIA1,GRIA4,LAMA2,SLC1A3,NTRK2,ATP1A2,SASH1,SPARCL1,PDZRN4,CTNND2,DMD,CST3,SMOC1,MYO16,PTPRT,GPM6B |
6.987e-03 | -4.96 | skin-neck-malignant_melanoma | COSMIC cancer mutations | skin-neck-malignant_melanoma | 1223 | 9 | 16828 | 48 |
CTNND2,CTNNA3,PTPRT,LAMA2,ATP1A2,SASH1,GRID2,DCLK1,PHYHIPL |
7.101e-03 | -4.95 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 48 |
CSMD1,SLC1A3,GRID2 |
7.109e-03 | -4.95 | regulation of sodium ion transmembrane transporter activity | biological process | GO:2000649 | 48 | 2 | 18204 | 48 |
ATP1A2,DMD |
7.110e-03 | -4.95 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 13 | 16828 | 48 |
GFAP,LAMA2,TNIK,PTPRZ1,GABBR2,DMD,PDZRN4,NTRK2,ATP1A2,DCLK1,PRKG1,SOX6,DTNA |
7.145e-03 | -4.94 | Kazal_dom_sf | interpro domains | IPR036058 | 47 | 2 | 18521 | 50 |
SPARCL1,SMOC1 |
7.155e-03 | -4.94 | TYR_PHOSPHATASE_PTP | prosite domains | PS50055 | 37 | 2 | 12186 | 42 |
PTPRT,PTPRZ1 |
7.272e-03 | -4.92 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 48 |
NRG3,PRKG1,QKI |
7.284e-03 | -4.92 | neck | COSMIC cancer mutations | neck | 1231 | 9 | 16828 | 48 |
ATP1A2,SASH1,PTPRT,CTNNA3,CTNND2,LAMA2,PHYHIPL,GRID2,DCLK1 |
7.322e-03 | -4.92 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 5 | 18204 | 48 |
GRIA1,GABRB1,SLC1A2,SLC1A3,ATP1A2 |
7.399e-03 | -4.91 | oligodendrocyte development | biological process | GO:0014003 | 49 | 2 | 18204 | 48 |
GPM6B,CLU |
7.399e-03 | -4.91 | ARRB1 (arrestin beta 1) | protein interactions | 408 | 301 | 4 | 19454 | 50 |
DGKG,SASH1,MAPK10,DMD |
7.443e-03 | -4.90 | Kazal_dom | interpro domains | IPR002350 | 48 | 2 | 18521 | 50 |
SPARCL1,SMOC1 |
7.524e-03 | -4.89 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 6 | 18094 | 50 |
GPM6A,GRIA1,ATP1A2,GRIK1,SLC1A2,SLC1A3 |
7.581e-03 | -4.88 | intercalated disc | cellular component | GO:0014704 | 51 | 2 | 19108 | 49 |
CTNNA3,ATP1A2 |
7.674e-03 | -4.87 | G protein-coupled receptor heterodimeric complex | cellular component | GO:0038039 | 3 | 1 | 19108 | 49 |
GABBR2 |
7.689e-03 | -4.87 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 48 |
NTRK2,SLC1A3,SLC1A2,GFAP |
7.689e-03 | -4.87 | muscle system process | biological process | GO:0003012 | 297 | 4 | 18204 | 48 |
PRKG1,ATP1A2,DMD,DTNA |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Lep (leptin) | protein interactions | 16846 | 3 | 1 | 19454 | 50 |
CLU |
7.691e-03 | -4.87 | Slc8a1 (solute carrier family 8 (sodium/calcium exchanger), member 1) | protein interactions | 20541 | 3 | 1 | 19454 | 50 |
DMD |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Itgb1 (integrin subunit beta 1) | protein interactions | 24511 | 3 | 1 | 19454 | 50 |
DMD |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.694e-03 | -4.87 | cellular response to nerve growth factor stimulus | biological process | GO:1990090 | 50 | 2 | 18204 | 48 |
NTRK2,GRIA1 |
7.774e-03 | -4.86 | hindbrain development | biological process | GO:0030902 | 154 | 3 | 18204 | 48 |
GRID2,MYO16,PRKG1 |
7.774e-03 | -4.86 | learning | biological process | GO:0007612 | 154 | 3 | 18204 | 48 |
ATP1A2,NTRK2,CSMD1 |
7.779e-03 | -4.86 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 48 |
NTRK2,SLC1A3,SLC1A2,GFAP |
7.788e-03 | -4.86 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 6 | 18204 | 48 |
GFAP,GRID2,GPM6A,NTRK2,TNIK,DGKG |
7.890e-03 | -4.84 | positive regulation of Schwann cell proliferation | biological process | GO:0010625 | 3 | 1 | 18204 | 48 |
GFAP |
7.890e-03 | -4.84 | cellular response to amine stimulus | biological process | GO:0071418 | 3 | 1 | 18204 | 48 |
GRIA1 |
7.890e-03 | -4.84 | mammary placode formation | biological process | GO:0060596 | 3 | 1 | 18204 | 48 |
NRG3 |
7.890e-03 | -4.84 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 48 |
SLC1A2 |
7.890e-03 | -4.84 | Schwann cell proliferation | biological process | GO:0014010 | 3 | 1 | 18204 | 48 |
GFAP |
7.890e-03 | -4.84 | negative regulation of serotonin uptake | biological process | GO:0051612 | 3 | 1 | 18204 | 48 |
GPM6B |
7.890e-03 | -4.84 | trans-synaptic signaling by BDNF, modulating synaptic transmission | biological process | GO:0099183 | 3 | 1 | 18204 | 48 |
NTRK2 |
7.890e-03 | -4.84 | immune complex clearance | biological process | GO:0002434 | 3 | 1 | 18204 | 48 |
CLU |
7.890e-03 | -4.84 | negative regulation of neurotransmitter uptake | biological process | GO:0051581 | 3 | 1 | 18204 | 48 |
GPM6B |
7.890e-03 | -4.84 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 48 |
SLC1A2 |
7.890e-03 | -4.84 | protein targeting to lysosome involved in chaperone-mediated autophagy | biological process | GO:0061740 | 3 | 1 | 18204 | 48 |
CLU |
7.890e-03 | -4.84 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 48 |
ATP1A2 |
7.928e-03 | -4.84 | EPB41L1 (erythrocyte membrane protein band 4.1 like 1) | protein interactions | 2036 | 159 | 3 | 19454 | 50 |
GRIA4,GPM6A,GRIA1 |
8.049e-03 | -4.82 | KAZAL | smart domains | SM00280 | 33 | 2 | 9717 | 40 |
SMOC1,SPARCL1 |
8.071e-03 | -4.82 | SLY | pfam domains | PF12485 | 3 | 1 | 17795 | 48 |
SASH1 |
8.071e-03 | -4.82 | NYAP_C | pfam domains | PF15452 | 3 | 1 | 17795 | 48 |
MYO16 |
8.071e-03 | -4.82 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 48 |
NTRK2 |
8.071e-03 | -4.82 | NYAP_N | pfam domains | PF15439 | 3 | 1 | 17795 | 48 |
MYO16 |
8.071e-03 | -4.82 | DAG_kinase_N | pfam domains | PF14513 | 3 | 1 | 17795 | 48 |
DGKG |
8.078e-03 | -4.82 | NYAP_N | interpro domains | IPR039482 | 3 | 1 | 18521 | 50 |
MYO16 |
8.078e-03 | -4.82 | Heparan_SO4-6-sulfoTrfase | interpro domains | IPR010635 | 3 | 1 | 18521 | 50 |
HS6ST3 |
8.078e-03 | -4.82 | SPIDER | interpro domains | IPR021090 | 3 | 1 | 18521 | 50 |
SASH1 |
8.078e-03 | -4.82 | DAG_kinase_typeI_N | interpro domains | IPR029477 | 3 | 1 | 18521 | 50 |
DGKG |
8.078e-03 | -4.82 | Reeler_sf | interpro domains | IPR042307 | 3 | 1 | 18521 | 50 |
SPON1 |
8.078e-03 | -4.82 | Neuregulin | interpro domains | IPR040180 | 3 | 1 | 18521 | 50 |
NRG3 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | GABAAb_rcpt | interpro domains | IPR002289 | 3 | 1 | 18521 | 50 |
GABRB1 |
8.078e-03 | -4.82 | GPCR3_GABA-B | interpro domains | IPR002455 | 3 | 1 | 18521 | 50 |
GABBR2 |
8.078e-03 | -4.82 | DGK_typeI_N_sf | interpro domains | IPR038199 | 3 | 1 | 18521 | 50 |
DGKG |
8.078e-03 | -4.82 | MAPK_JNK | interpro domains | IPR008351 | 3 | 1 | 18521 | 50 |
MAPK10 |
8.078e-03 | -4.82 | NYAP_C | interpro domains | IPR029353 | 3 | 1 | 18521 | 50 |
MYO16 |
8.078e-03 | -4.82 | Reeler_dom | interpro domains | IPR002861 | 3 | 1 | 18521 | 50 |
SPON1 |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.183e-03 | -4.81 | Immunoglobulins | gene3d domains | 2.60.40.10 | 721 | 7 | 14470 | 47 |
PTPRT,LIFR,PHYHIPL,PTPRZ1,LSAMP,NTRK2,NTM |
8.200e-03 | -4.80 | pancreas-carcinoma-acinar_carcinoma | COSMIC cancer mutations | pancreas-carcinoma-acinar_carcinoma | 1978 | 12 | 16828 | 48 |
PTPRZ1,DMD,LIFR,SPON1,LAMA2,QKI,GRIA1,PHYHIPL,ZBTB20,CTNND2,SASH1,ATP1A2 |
8.200e-03 | -4.80 | acinar_carcinoma | COSMIC cancer mutations | acinar_carcinoma | 1978 | 12 | 16828 | 48 |
PHYHIPL,SASH1,ATP1A2,ZBTB20,CTNND2,LIFR,DMD,SPON1,PTPRZ1,GRIA1,LAMA2,QKI |
8.216e-03 | -4.80 | CLb | smart domains | SM00030 | 2 | 1 | 9717 | 40 |
CLU |
8.216e-03 | -4.80 | CLa | smart domains | SM00035 | 2 | 1 | 9717 | 40 |
CLU |
8.268e-03 | -4.80 | G protein-coupled GABA receptor activity | molecular function | GO:0004965 | 3 | 1 | 18094 | 50 |
GABBR2 |
8.268e-03 | -4.80 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 50 |
SLC1A2 |
8.268e-03 | -4.80 | neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | molecular function | GO:0099583 | 3 | 1 | 18094 | 50 |
GRIA1 |
8.268e-03 | -4.80 | heparan sulfate 6-O-sulfotransferase activity | molecular function | GO:0017095 | 3 | 1 | 18094 | 50 |
HS6ST3 |
8.268e-03 | -4.80 | JUN kinase activity | molecular function | GO:0004705 | 3 | 1 | 18094 | 50 |
MAPK10 |
8.268e-03 | -4.80 | oncostatin-M receptor activity | molecular function | GO:0004924 | 3 | 1 | 18094 | 50 |
LIFR |
8.295e-03 | -4.79 | endoplasmic reticulum lumen | cellular component | GO:0005788 | 312 | 4 | 19108 | 49 |
SPON1,CLU,CST3,SPARCL1 |
8.301e-03 | -4.79 | response to nerve growth factor | biological process | GO:1990089 | 52 | 2 | 18204 | 48 |
NTRK2,GRIA1 |
8.392e-03 | -4.78 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 28 |
SLC1A2,SLC1A3 |
8.483e-03 | -4.77 | negative regulation of protein metabolic process | biological process | GO:0051248 | 893 | 7 | 18204 | 48 |
CST3,PTPRT,SPON1,DMD,CLU,QKI,NTRK2 |
8.483e-03 | -4.77 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 48 |
SLC1A3,SLC1A2,GABRB1 |
8.507e-03 | -4.77 | NOS1 (nitric oxide synthase 1) | protein interactions | 4842 | 54 | 2 | 19454 | 50 |
DMD,HS6ST3 |
8.567e-03 | -4.76 | - | gene3d domains | 3.30.60.30 | 43 | 2 | 14470 | 47 |
SMOC1,SPARCL1 |
8.593e-03 | -4.76 | transport | biological process | GO:0006810 | 3615 | 17 | 18204 | 48 |
GPM6B,GABRB1,SLC1A2,GRIK1,GRIA4,DCLK1,NTRK2,SLC1A3,CLU,AQP4,GFAP,GRIA1,GRID2,GPM6A,CPE,ATP1A2,QKI |
8.612e-03 | -4.75 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
8.764e-03 | -4.74 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 6 | 18204 | 48 |
GFAP,GRID2,NTRK2,GPM6A,DGKG,TNIK |
8.782e-03 | -4.74 | CGMPKINASE | prints domains | PR00104 | 2 | 1 | 5227 | 23 |
PRKG1 |
8.917e-03 | -4.72 | INSYN1 (inhibitory synaptic factor 1) | protein interactions | 388135 | 166 | 3 | 19454 | 50 |
DTNA,DMD,TNIK |
9.109e-03 | -4.70 | response to light stimulus | biological process | GO:0009416 | 312 | 4 | 18204 | 48 |
MAPK10,SLC1A2,SLC1A3,ATP1A2 |
9.125e-03 | -4.70 | CSTL1 (cystatin like 1) | protein interactions | 128817 | 56 | 2 | 19454 | 50 |
CPE,CLU |
9.125e-03 | -4.70 | SEPTIN3 (septin 3) | protein interactions | 55964 | 56 | 2 | 19454 | 50 |
PRKG1,GPM6A |
9.129e-03 | -4.70 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 48 |
DMD,GRIA1,ATP1A2,AQP4,ZBTB20,SLC1A3 |
9.229e-03 | -4.69 | negative regulation of neuron apoptotic process | biological process | GO:0043524 | 164 | 3 | 18204 | 48 |
PTPRZ1,CLU,NTRK2 |
9.272e-03 | -4.68 | medullary_carcinoma | COSMIC cancer mutations | medullary_carcinoma | 290 | 4 | 16828 | 48 |
PRKG1,GFAP,NRG3,SLC1A2 |
9.272e-03 | -4.68 | thyroid-carcinoma-medullary_carcinoma | COSMIC cancer mutations | thyroid-carcinoma-medullary_carcinoma | 290 | 4 | 16828 | 48 |
NRG3,SLC1A2,PRKG1,GFAP |
9.303e-03 | -4.68 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 5 | 18521 | 50 |
PRKG1,MAPK10,TNIK,NTRK2,DCLK1 |
9.344e-03 | -4.67 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 9 | 18204 | 48 |
NTRK2,QKI,SOX6,GPM6B,GFAP,LAMA2,SASH1,PTPRZ1,GRID2 |
9.391e-03 | -4.67 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 48 |
GFAP,QKI,CTNNA3,PPP2R2B,GPM6A,GPM6B,DPP6,CLU,LSAMP,MYO16,DMD,PDZRN4,SASH1,SLC1A3,PHYHIPL,NRG3,TNIK,GRIK1,GLIS3,CPE,NPAS3,LIFR,ZBTB20,DGKG,PCDH9,DCLK1,PRKG1,GABRB1,SOX6,DTNA,PTPRT,NTM,SMOC1,GABBR2,CTNND2,NTRK2,ATP1A2,SPARCL1,HS6ST3,GRIA4,LAMA2,GRIA1,GRID2,PTPRZ1,SPON1,SLC1A2 |
9.475e-03 | -4.66 | Ser/Thr_kinase_AS | interpro domains | IPR008271 | 308 | 4 | 18521 | 50 |
TNIK,DCLK1,MAPK10,PRKG1 |
9.564e-03 | -4.65 | side of membrane | cellular component | GO:0098552 | 715 | 6 | 19108 | 49 |
LSAMP,GFAP,AQP4,LIFR,NTM,DTNA |
9.576e-03 | -4.65 | cardiac muscle cell action potential | biological process | GO:0086001 | 56 | 2 | 18204 | 48 |
DMD,ATP1A2 |
9.713e-03 | -4.63 | Reeler domain | gene3d domains | 2.60.40.4060 | 3 | 1 | 14470 | 47 |
SPON1 |
9.713e-03 | -4.63 | Diacylglycerol kinase alpha | gene3d domains | 1.10.238.110 | 3 | 1 | 14470 | 47 |
DGKG |
9.713e-03 | -4.63 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 47 |
CTNNA3 |
9.813e-03 | -4.62 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 7 | 16828 | 48 |
PTPRZ1,PRKG1,DCLK1,TNIK,NTRK2,LIFR,GABRB1 |
9.813e-03 | -4.62 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 7 | 16828 | 48 |
NTRK2,TNIK,GABRB1,LIFR,PTPRZ1,DCLK1,PRKG1 |
9.840e-03 | -4.62 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 23 | 16828 | 48 |
CTNNA3,PPP2R2B,QKI,PTPRT,GPM6B,CLU,LSAMP,GABBR2,DMD,CTNND2,PDZRN4,NTRK2,SPARCL1,SLC1A3,GRIA4,TNIK,GRIA1,PTPRZ1,NPAS3,LIFR,DGKG,PRKG1,DCLK1 |
9.840e-03 | -4.62 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 23 | 16828 | 48 |
GRIA4,GRIA1,TNIK,PTPRZ1,LIFR,NPAS3,DGKG,PRKG1,DCLK1,GPM6B,PPP2R2B,CTNNA3,QKI,PTPRT,CLU,LSAMP,DMD,GABBR2,CTNND2,PDZRN4,SPARCL1,NTRK2,SLC1A3 |
9.871e-03 | -4.62 | cell-cell junction | cellular component | GO:0005911 | 513 | 5 | 19108 | 49 |
ATP1A2,CTNND2,CTNNA3,PCDH9,GRIA1 |
9.908e-03 | -4.61 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 48 |
ATP1A2,SLC1A2 |
9.953e-03 | -4.61 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 6 | 16828 | 48 |
TNIK,DCLK1,MYO16,PRKG1,LAMA2,QKI |
1.005e-02 | -4.60 | PTPc | smart domains | SM00194 | 37 | 2 | 9717 | 40 |
PTPRT,PTPRZ1 |
1.005e-02 | -4.60 | GABA receptor activation | REACTOME pathways | R-HSA-977443 | 56 | 2 | 10285 | 28 |
GABRB1,GABBR2 |
1.009e-02 | -4.60 | VEGFA (vascular endothelial growth factor A) | protein interactions | 7422 | 59 | 2 | 19454 | 50 |
PTPRZ1,CLU |
1.013e-02 | -4.59 | SMCHD1 (structural maintenance of chromosomes flexible hinge domain containing 1) | protein interactions | 23347 | 174 | 3 | 19454 | 50 |
DGKG,SOX6,PHYHIPL |
1.017e-02 | -4.59 | protein phosphorylation | biological process | GO:0006468 | 503 | 5 | 18204 | 48 |
PRKG1,TNIK,DCLK1,NTRK2,MAPK10 |
1.017e-02 | -4.59 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-virilizing_syndrome_producing | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-virilizing_syndrome_producing | 298 | 4 | 16828 | 48 |
CTNNA3,CTNND2,DCLK1,ATP1A2 |
1.022e-02 | -4.58 | syntrophin complex | cellular component | GO:0016013 | 4 | 1 | 19108 | 49 |
DMD |
1.024e-02 | -4.58 | CENPS-CORT (CENPS-CORT readthrough) | protein interactions | 100526739 | 4 | 1 | 19454 | 50 |
CTNNA3 |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | IER5L (immediate early response 5 like) | protein interactions | 389792 | 4 | 1 | 19454 | 50 |
PPP2R2B |
1.024e-02 | -4.58 | regulation of sodium ion transmembrane transport | biological process | GO:1902305 | 58 | 2 | 18204 | 48 |
DMD,ATP1A2 |
1.030e-02 | -4.58 | REELIN | prosite domains | PS51019 | 3 | 1 | 12186 | 42 |
SPON1 |
1.037e-02 | -4.57 | neuron projection membrane | cellular component | GO:0032589 | 60 | 2 | 19108 | 49 |
SLC1A2,GRIA1 |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
DMD,DTNA |
1.051e-02 | -4.56 | oviduct epithelium development | biological process | GO:0035846 | 4 | 1 | 18204 | 48 |
CSMD1 |
1.051e-02 | -4.56 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 48 |
CST3 |
1.051e-02 | -4.56 | leukemia inhibitory factor signaling pathway | biological process | GO:0048861 | 4 | 1 | 18204 | 48 |
LIFR |
1.051e-02 | -4.56 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 48 |
ATP1A2 |
1.051e-02 | -4.56 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 48 |
ATP1A2 |
1.051e-02 | -4.56 | negative regulation of protein kinase C signaling | biological process | GO:0090038 | 4 | 1 | 18204 | 48 |
DGKG |
1.051e-02 | -4.56 | oncostatin-M-mediated signaling pathway | biological process | GO:0038165 | 4 | 1 | 18204 | 48 |
LIFR |
1.051e-02 | -4.56 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 48 |
ATP1A2 |
1.051e-02 | -4.56 | brain-derived neurotrophic factor receptor signaling pathway | biological process | GO:0031547 | 4 | 1 | 18204 | 48 |
NTRK2 |
1.051e-02 | -4.56 | positive regulation of inclusion body assembly | biological process | GO:0090261 | 4 | 1 | 18204 | 48 |
CLU |
1.051e-02 | -4.56 | regulation of serotonin uptake | biological process | GO:0051611 | 4 | 1 | 18204 | 48 |
GPM6B |
1.051e-02 | -4.56 | regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion | biological process | GO:0014809 | 4 | 1 | 18204 | 48 |
DMD |
1.051e-02 | -4.56 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 48 |
CPE |
1.051e-02 | -4.56 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 48 |
SOX6 |
1.051e-02 | -4.56 | trans-synaptic signaling by BDNF | biological process | GO:0099191 | 4 | 1 | 18204 | 48 |
NTRK2 |
1.059e-02 | -4.55 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 48 |
DMD,SLC1A2,SLC1A3,PRKG1,ATP1A2 |
1.076e-02 | -4.53 | PP2A_PR55 | interpro domains | IPR000009 | 4 | 1 | 18521 | 50 |
PPP2R2B |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA3 |
1.076e-02 | -4.53 | PP2A_PR55_CS | interpro domains | IPR018067 | 4 | 1 | 18521 | 50 |
PPP2R2B |
1.076e-02 | -4.53 | PRKG1 (protein kinase cGMP-dependent 1) | protein interactions | 5592 | 61 | 2 | 19454 | 50 |
PRKG1,TNIK |
1.076e-02 | -4.53 | CP (ceruloplasmin) | protein interactions | 1356 | 61 | 2 | 19454 | 50 |
PPP2R2B,CLU |
1.077e-02 | -4.53 | ERBB4 (erb-b2 receptor tyrosine kinase 4) | protein interactions | 2066 | 178 | 3 | 19454 | 50 |
NTRK2,PTPRT,NRG3 |
1.093e-02 | -4.52 | regulation of smooth muscle contraction | biological process | GO:0006940 | 60 | 2 | 18204 | 48 |
PRKG1,ATP1A2 |
1.101e-02 | -4.51 | ciliary neurotrophic factor receptor activity | molecular function | GO:0004897 | 4 | 1 | 18094 | 50 |
LIFR |
1.101e-02 | -4.51 | brain-derived neurotrophic factor binding | molecular function | GO:0048403 | 4 | 1 | 18094 | 50 |
NTRK2 |
1.106e-02 | -4.50 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 48 |
PTPRZ1,GRID2,SPON1,GRIA4,LAMA2,GRIA1,SLC1A2,SMOC1,GABBR2,PTPRT,NTM,HS6ST3,CTNND2,SPARCL1,ATP1A2,NTRK2,LIFR,NPAS3,CPE,GLIS3,GRIK1,TNIK,NRG3,PRKG1,DCLK1,DTNA,SOX6,GABRB1,ZBTB20,PCDH9,DGKG,MYO16,LSAMP,DMD,GPM6B,GPM6A,QKI,CTNNA3,PPP2R2B,GFAP,DPP6,CLU,PHYHIPL,SLC1A3,PDZRN4,SASH1 |
1.106e-02 | -4.50 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 48 |
DMD,MYO16,LSAMP,CLU,DPP6,GPM6A,GPM6B,GFAP,QKI,PPP2R2B,CTNNA3,SLC1A3,PHYHIPL,SASH1,PDZRN4,LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,SOX6,GABRB1,DTNA,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20,GABBR2,SMOC1,NTM,PTPRT,HS6ST3,SPARCL1,NTRK2,ATP1A2,CTNND2,SPON1,GRID2,PTPRZ1,GRIA1,GRIA4,LAMA2,SLC1A2 |
1.110e-02 | -4.50 | ZKSCAN1 (zinc finger with KRAB and SCAN domains 1) | protein interactions | 7586 | 62 | 2 | 19454 | 50 |
QKI,PRKG1 |
1.118e-02 | -4.49 | phosphotransferase activity, alcohol group as acceptor | molecular function | GO:0016773 | 686 | 6 | 18094 | 50 |
TNIK,DCLK1,NTRK2,PRKG1,MAPK10,DGKG |
1.121e-02 | -4.49 | EF_Hand_1_Ca_BS | interpro domains | IPR018247 | 172 | 3 | 18521 | 50 |
SPARCL1,DGKG,SMOC1 |
1.123e-02 | -4.49 | PRTYPHPHTASE | prints domains | PR00700 | 37 | 2 | 5227 | 23 |
PTPRT,PTPRZ1 |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.144e-02 | -4.47 | DCAF16 (DDB1 and CUL4 associated factor 16) | protein interactions | 54876 | 63 | 2 | 19454 | 50 |
DGKG,SMOC1 |
1.144e-02 | -4.47 | KCNA4 (potassium voltage-gated channel subfamily A member 4) | protein interactions | 3739 | 63 | 2 | 19454 | 50 |
DMD,DTNA |
1.161e-02 | -4.46 | GSN (gelsolin) | protein interactions | 2934 | 183 | 3 | 19454 | 50 |
TNIK,DTNA,PPP2R2B |
1.161e-02 | -4.46 | MAPK9 (mitogen-activated protein kinase 9) | protein interactions | 5601 | 183 | 3 | 19454 | 50 |
GFAP,MAPK10,CLU |
1.172e-02 | -4.45 | muscle structure development | biological process | GO:0061061 | 521 | 5 | 18204 | 48 |
LAMA2,SOX6,DMD,PRKG1,QKI |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
DTNA,GFAP |
1.179e-02 | -4.44 | PDZK1 (PDZ domain containing 1) | protein interactions | 5174 | 64 | 2 | 19454 | 50 |
SLC1A3,GFAP |
1.181e-02 | -4.44 | Tyr_Pase_cat | interpro domains | IPR003595 | 61 | 2 | 18521 | 50 |
PTPRZ1,PTPRT |
1.183e-02 | -4.44 | KAZAL_2 | prosite domains | PS51465 | 48 | 2 | 12186 | 42 |
SMOC1,SPARCL1 |
1.185e-02 | -4.44 | phosphorylation | biological process | GO:0016310 | 729 | 6 | 18204 | 48 |
MAPK10,PRKG1,TNIK,DGKG,NTRK2,DCLK1 |
1.187e-02 | -4.43 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 31 | 16828 | 48 |
SPON1,NPAS3,LIFR,PTPRZ1,GRID2,NRG3,CPE,GRIA1,LAMA2,GRIA4,SOX6,PRKG1,DCLK1,DGKG,PCDH9,ZBTB20,GABBR2,DMD,MYO16,DPP6,CTNNA3,QKI,PTPRT,GPM6B,PHYHIPL,ATP1A2,NTRK2,SASH1,CTNND2,PDZRN4,AQP4 |
1.205e-02 | -4.42 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 48 | 16828 | 48 |
LIFR,NPAS3,CPE,GLIS3,TNIK,GRIK1,NRG3,DTNA,SOX6,GABRB1,PRKG1,DCLK1,PCDH9,DGKG,ZBTB20,DMD,MYO16,LSAMP,CST3,CLU,DPP6,GPM6B,GPM6A,CTNNA3,QKI,PPP2R2B,GFAP,PHYHIPL,SLC1A3,SASH1,PDZRN4,SPON1,PTPRZ1,GRID2,GRIA1,GRIA4,LAMA2,SLC1A2,GABBR2,SMOC1,NTM,PTPRT,HS6ST3,SPARCL1,ATP1A2,NTRK2,AQP4,CTNND2 |
1.215e-02 | -4.41 | HPX (hemopexin) | protein interactions | 3263 | 65 | 2 | 19454 | 50 |
CLU,PPP2R2B |
1.227e-02 | -4.40 | regulation of developmental process | biological process | GO:0050793 | 2540 | 13 | 18204 | 48 |
LAMA2,GPM6B,DGKG,NTRK2,PTPRZ1,CST3,GRID2,SASH1,GFAP,TNIK,SMOC1,SOX6,QKI |
1.237e-02 | -4.39 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 2 | 18204 | 48 |
CTNND2,DCLK1 |
1.274e-02 | -4.36 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 2 | 18204 | 48 |
NTRK2,GRID2 |
1.276e-02 | -4.36 | neurofibrillary tangle | cellular component | GO:0097418 | 5 | 1 | 19108 | 49 |
CLU |
1.276e-02 | -4.36 | kainate selective glutamate receptor complex | cellular component | GO:0032983 | 5 | 1 | 19108 | 49 |
GRIK1 |
1.279e-02 | -4.36 | ADCYAP1R1 (ADCYAP receptor type I) | protein interactions | 117 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.279e-02 | -4.36 | PPP1R17 (protein phosphatase 1 regulatory subunit 17) | protein interactions | 10842 | 5 | 1 | 19454 | 50 |
PRKG1 |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | TAAR1 (trace amine associated receptor 1) | protein interactions | 134864 | 5 | 1 | 19454 | 50 |
GRIK1 |
1.279e-02 | -4.36 | EPPIN (epididymal peptidase inhibitor) | protein interactions | 57119 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | RVS161 (amphiphysin-like protein RVS161) | protein interactions | 850367 | 5 | 1 | 19454 | 50 |
GFAP |
1.287e-02 | -4.35 | ARMC1 (armadillo repeat containing 1) | protein interactions | 55156 | 67 | 2 | 19454 | 50 |
GPM6A,GPM6B |
1.291e-02 | -4.35 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 44 | 16828 | 48 |
PCDH9,DGKG,ZBTB20,DTNA,GABRB1,SOX6,PRKG1,DCLK1,GLIS3,GRIK1,TNIK,NRG3,LIFR,NPAS3,SASH1,PDZRN4,SLC1A3,CLU,DPP6,GPM6B,GPM6A,PPP2R2B,CTNNA3,QKI,GFAP,DMD,MYO16,CST3,LSAMP,SLC1A2,GRIA1,LAMA2,GRIA4,SPON1,PTPRZ1,GRID2,ATP1A2,NTRK2,CTNND2,HS6ST3,NTM,PTPRT,GABBR2,SMOC1 |
1.308e-02 | -4.34 | virilizing_syndrome_producing | COSMIC cancer mutations | virilizing_syndrome_producing | 321 | 4 | 16828 | 48 |
ATP1A2,CTNNA3,CTNND2,DCLK1 |
1.312e-02 | -4.33 | cellular response to ammonium ion | biological process | GO:0071242 | 5 | 1 | 18204 | 48 |
GRIA1 |
1.312e-02 | -4.33 | neuron-glial cell signaling | biological process | GO:0150099 | 5 | 1 | 18204 | 48 |
GABBR2 |
1.312e-02 | -4.33 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 1 | 18204 | 48 |
CLU |
1.312e-02 | -4.33 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 48 |
ATP1A2 |
1.312e-02 | -4.33 | central nervous system myelin maintenance | biological process | GO:0032286 | 5 | 1 | 18204 | 48 |
CLU |
1.312e-02 | -4.33 | negative regulation of glutamate secretion | biological process | GO:0014050 | 5 | 1 | 18204 | 48 |
PRKG1 |
1.312e-02 | -4.33 | ciliary neurotrophic factor-mediated signaling pathway | biological process | GO:0070120 | 5 | 1 | 18204 | 48 |
LIFR |
1.312e-02 | -4.33 | spinal cord oligodendrocyte cell differentiation | biological process | GO:0021529 | 5 | 1 | 18204 | 48 |
SOX6 |
1.312e-02 | -4.33 | conditioned place preference | biological process | GO:1990708 | 5 | 1 | 18204 | 48 |
CSMD1 |
1.312e-02 | -4.33 | synaptic signaling via neuropeptide | biological process | GO:0099538 | 5 | 1 | 18204 | 48 |
NTRK2 |
1.312e-02 | -4.33 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
1.313e-02 | -4.33 | Kinase-like_dom_sf | interpro domains | IPR011009 | 523 | 5 | 18521 | 50 |
MAPK10,PRKG1,NTRK2,TNIK,DCLK1 |
1.315e-02 | -4.33 | GABAARBETA | prints domains | PR01160 | 3 | 1 | 5227 | 23 |
GABRB1 |
1.315e-02 | -4.33 | JNKMAPKINASE | prints domains | PR01772 | 3 | 1 | 5227 | 23 |
MAPK10 |
1.315e-02 | -4.33 | GABABRECEPTR | prints domains | PR01176 | 3 | 1 | 5227 | 23 |
GABBR2 |
1.315e-02 | -4.33 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 23 |
NTRK2 |
1.324e-02 | -4.32 | FAM162A (family with sequence similarity 162 member A) | protein interactions | 26355 | 68 | 2 | 19454 | 50 |
CTNNA3,GPM6B |
1.324e-02 | -4.32 | CADPS (calcium dependent secretion activator) | protein interactions | 8618 | 68 | 2 | 19454 | 50 |
DMD,GPM6A |
1.332e-02 | -4.32 | human chr4q21.3 | chromosome location | human chr4q21.3 | 7 | 1 | 26134 | 50 |
MAPK10 |
1.332e-02 | -4.32 | human chr7q36.2 | chromosome location | human chr7q36.2 | 7 | 1 | 26134 | 50 |
DPP6 |
1.332e-02 | -4.32 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 50 |
PCDH9 |
1.336e-02 | -4.32 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 48 |
NTM,GRID2,PTPRZ1,MYO16 |
1.342e-02 | -4.31 | Laminin_I | pfam domains | PF06008 | 5 | 1 | 17795 | 48 |
LAMA2 |
1.342e-02 | -4.31 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 48 |
CTNNA3 |
1.342e-02 | -4.31 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 48 |
PCDH9 |
1.342e-02 | -4.31 | Laminin_II | pfam domains | PF06009 | 5 | 1 | 17795 | 48 |
LAMA2 |
1.342e-02 | -4.31 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 48 |
SPARCL1 |
1.343e-02 | -4.31 | Laminin_aI | interpro domains | IPR009254 | 5 | 1 | 18521 | 50 |
LAMA2 |
1.343e-02 | -4.31 | Laminin_dom_II | interpro domains | IPR010307 | 5 | 1 | 18521 | 50 |
LAMA2 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA3 |
1.343e-02 | -4.31 | DCX/DCDC2-like | interpro domains | IPR049626 | 5 | 1 | 18521 | 50 |
DCLK1 |
1.343e-02 | -4.31 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 50 |
PCDH9 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | BBP-like | interpro domains | IPR045071 | 5 | 1 | 18521 | 50 |
QKI |
1.353e-02 | -4.30 | extracellular matrix binding | molecular function | GO:0050840 | 64 | 2 | 18094 | 50 |
SMOC1,SPARCL1 |
1.354e-02 | -4.30 | NGF-independant TRKA activation | REACTOME pathways | R-HSA-187024 | 5 | 1 | 10285 | 28 |
NTRK2 |
1.372e-02 | -4.29 | PR55_2 | prosite domains | PS01025 | 4 | 1 | 12186 | 42 |
PPP2R2B |
1.372e-02 | -4.29 | PR55_1 | prosite domains | PS01024 | 4 | 1 | 12186 | 42 |
PPP2R2B |
1.374e-02 | -4.29 | kainate selective glutamate receptor activity | molecular function | GO:0015277 | 5 | 1 | 18094 | 50 |
GRIK1 |
1.374e-02 | -4.29 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 50 |
NTRK2 |
1.381e-02 | -4.28 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 5 | 16828 | 48 |
PRKG1,DCLK1,TNIK,NTRK2,SASH1 |
1.398e-02 | -4.27 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 14 | 16828 | 48 |
GLIS3,DPP6,CTNNA3,PTPRT,LAMA2,SPON1,GABBR2,NPAS3,PTPRZ1,SPARCL1,CTNND2,PDZRN4,AQP4,SOX6 |
1.398e-02 | -4.27 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 14 | 16828 | 48 |
PTPRZ1,NPAS3,SPON1,GABBR2,PTPRT,CTNNA3,LAMA2,GLIS3,DPP6,SOX6,PDZRN4,CTNND2,AQP4,SPARCL1 |
1.399e-02 | -4.27 | MBD3L1 (methyl-CpG binding domain protein 3 like 1) | protein interactions | 85509 | 70 | 2 | 19454 | 50 |
ZBTB20,CTNNA3 |
1.409e-02 | -4.26 | Pkinase | pfam domains | PF00069 | 347 | 4 | 17795 | 48 |
TNIK,MAPK10,DCLK1,PRKG1 |
1.418e-02 | -4.26 | skin-sole-malignant_melanoma | COSMIC cancer mutations | skin-sole-malignant_melanoma | 5 | 1 | 16828 | 48 |
DMD |
1.430e-02 | -4.25 | regulation of multicellular organismal development | biological process | GO:2000026 | 1484 | 9 | 18204 | 48 |
PTPRZ1,GRID2,SASH1,LAMA2,GFAP,GPM6B,QKI,NTRK2,SOX6 |
1.434e-02 | -4.24 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 50 |
SLC1A3,SLC1A2 |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
GPM6A,TNIK |
1.449e-02 | -4.23 | Amyotrophic lateral sclerosis (ALS) | KEGG pathways | hsa05014 | 51 | 2 | 7161 | 26 |
GRIA1,SLC1A2 |
1.449e-02 | -4.23 | Amyotrophic lateral sclerosis (ALS) | KEGG pathways | ko05014 | 51 | 2 | 7161 | 26 |
GRIA1,SLC1A2 |
1.450e-02 | -4.23 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 48 |
NTM,MYO16,PTPRZ1,GRID2 |
1.458e-02 | -4.23 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 47 | 16828 | 48 |
SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,SLC1A2,GRIA1,GRIA4,LAMA2,SPON1,GRID2,PTPRZ1,SASH1,PDZRN4,SLC1A3,PHYHIPL,DPP6,CLU,GPM6A,GPM6B,GFAP,PPP2R2B,CTNNA3,QKI,DMD,MYO16,CST3,LSAMP,PCDH9,DGKG,ZBTB20,SOX6,GABRB1,DCLK1,PRKG1,GLIS3,CPE,NRG3,TNIK,GRIK1,LIFR,NPAS3 |
1.467e-02 | -4.22 | cardiac conduction | biological process | GO:0061337 | 70 | 2 | 18204 | 48 |
CTNNA3,ATP1A2 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | 14773 | 47 | 16828 | 48 |
SASH1,PDZRN4,PHYHIPL,SLC1A3,CLU,DPP6,GPM6B,GPM6A,QKI,CTNNA3,PPP2R2B,GFAP,DMD,MYO16,CST3,LSAMP,PCDH9,DGKG,ZBTB20,DTNA,SOX6,GABRB1,PRKG1,DCLK1,CPE,GLIS3,GRIK1,TNIK,NRG3,LIFR,NPAS3,SPARCL1,ATP1A2,NTRK2,AQP4,CTNND2,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,SLC1A2,GRIA1,LAMA2,GRIA4,PTPRZ1,GRID2 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 14773 | 47 | 16828 | 48 |
PHYHIPL,SLC1A3,PDZRN4,SASH1,LSAMP,CST3,MYO16,DMD,CTNNA3,PPP2R2B,QKI,GFAP,GPM6B,GPM6A,CLU,DPP6,PRKG1,DCLK1,DTNA,GABRB1,SOX6,ZBTB20,DGKG,PCDH9,NPAS3,LIFR,GRIK1,TNIK,NRG3,CPE,GLIS3,HS6ST3,CTNND2,AQP4,ATP1A2,NTRK2,SPARCL1,SMOC1,GABBR2,PTPRT,NTM,SLC1A2,PTPRZ1,GRID2,LAMA2,GRIA4,GRIA1 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | 14773 | 47 | 16828 | 48 |
DPP6,CLU,GPM6A,GPM6B,GFAP,QKI,PPP2R2B,CTNNA3,DMD,MYO16,LSAMP,CST3,SASH1,PDZRN4,SLC1A3,PHYHIPL,GLIS3,CPE,NRG3,GRIK1,TNIK,LIFR,NPAS3,PCDH9,DGKG,ZBTB20,SOX6,GABRB1,DTNA,DCLK1,PRKG1,NTM,PTPRT,GABBR2,SMOC1,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,HS6ST3,GRIA1,LAMA2,GRIA4,GRID2,PTPRZ1,SLC1A2 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | 14773 | 47 | 16828 | 48 |
GRIA1,GRIA4,LAMA2,PTPRZ1,GRID2,SLC1A2,NTM,PTPRT,GABBR2,SMOC1,ATP1A2,NTRK2,SPARCL1,CTNND2,AQP4,HS6ST3,GRIK1,TNIK,NRG3,CPE,GLIS3,NPAS3,LIFR,DGKG,PCDH9,ZBTB20,DTNA,GABRB1,SOX6,PRKG1,DCLK1,CLU,DPP6,QKI,PPP2R2B,CTNNA3,GFAP,GPM6B,GPM6A,DMD,CST3,LSAMP,MYO16,SASH1,PDZRN4,PHYHIPL,SLC1A3 |
1.474e-02 | -4.22 | classic | COSMIC cancer mutations | classic | 14774 | 47 | 16828 | 48 |
SLC1A2,GRIA1,LAMA2,GRIA4,GRID2,PTPRZ1,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,DGKG,PCDH9,ZBTB20,GABRB1,SOX6,DTNA,DCLK1,PRKG1,NRG3,GRIK1,TNIK,GLIS3,CPE,NPAS3,LIFR,SASH1,PDZRN4,SLC1A3,PHYHIPL,CLU,DPP6,GFAP,CTNNA3,QKI,PPP2R2B,GPM6A,GPM6B,DMD,CST3,LSAMP,MYO16 |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.490e-02 | -4.21 | medulla | COSMIC cancer mutations | medulla | 14778 | 47 | 16828 | 48 |
NTM,PTPRT,GABBR2,SMOC1,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,HS6ST3,GRIA1,GRIA4,LAMA2,GRID2,PTPRZ1,SLC1A2,DPP6,CLU,GPM6A,GPM6B,GFAP,PPP2R2B,QKI,CTNNA3,DMD,MYO16,CST3,LSAMP,SASH1,PDZRN4,SLC1A3,PHYHIPL,GLIS3,CPE,NRG3,GRIK1,TNIK,LIFR,NPAS3,PCDH9,DGKG,ZBTB20,SOX6,GABRB1,DTNA,DCLK1,PRKG1 |
1.495e-02 | -4.20 | desmoplastic | COSMIC cancer mutations | desmoplastic | 14779 | 47 | 16828 | 48 |
GABBR2,SMOC1,NTM,PTPRT,HS6ST3,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4,SLC1A2,DMD,MYO16,CST3,LSAMP,CLU,DPP6,GPM6A,GPM6B,GFAP,PPP2R2B,QKI,CTNNA3,SLC1A3,PHYHIPL,SASH1,PDZRN4,LIFR,NPAS3,GLIS3,CPE,NRG3,TNIK,GRIK1,SOX6,GABRB1,DTNA,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20 |
1.505e-02 | -4.20 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 7 | 16828 | 48 |
MYO16,GRID2,LIFR,GABRB1,PPP2R2B,CTNNA3,CTNND2 |
1.510e-02 | -4.19 | Common Pathways Underlying Drug Addiction | WikiPathways | WP2636 | 42 | 2 | 5310 | 24 |
GRIA4,GRIA1 |
1.526e-02 | -4.18 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 46 | 16828 | 48 |
GABRB1,SOX6,DTNA,DCLK1,PRKG1,PCDH9,DGKG,ZBTB20,LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,SLC1A3,SASH1,PDZRN4,DMD,MYO16,LSAMP,CST3,CLU,DPP6,GPM6A,GFAP,QKI,CTNNA3,PPP2R2B,SLC1A2,SPON1,GRID2,PTPRZ1,GRIA1,GRIA4,LAMA2,HS6ST3,SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,GABBR2,SMOC1,NTM,PTPRT |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | DEFB116 (defensin beta 116) | protein interactions | 245930 | 6 | 1 | 19454 | 50 |
HS6ST3 |
1.532e-02 | -4.18 | LBX2 (ladybird homeobox 2) | protein interactions | 85474 | 6 | 1 | 19454 | 50 |
GFAP |
1.532e-02 | -4.18 | Taok2 (TAO kinase 2) | protein interactions | 381921 | 6 | 1 | 19454 | 50 |
CLU |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | PBP2 (Pbp2p) | protein interactions | 852533 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | LIF (LIF interleukin 6 family cytokine) | protein interactions | 3976 | 6 | 1 | 19454 | 50 |
LIFR |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | TPPP3 (tubulin polymerization promoting protein family member 3) | protein interactions | 51673 | 6 | 1 | 19454 | 50 |
PPP2R2B |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | GRID2IP (Grid2 interacting protein) | protein interactions | 392862 | 6 | 1 | 19454 | 50 |
GRID2 |
1.532e-02 | -4.18 | Rara (retinoic acid receptor, alpha) | protein interactions | 19401 | 6 | 1 | 19454 | 50 |
MAPK10 |
1.532e-02 | -4.18 | DAZ4 (deleted in azoospermia 4) | protein interactions | 57135 | 6 | 1 | 19454 | 50 |
QKI |
1.548e-02 | -4.17 | regulation of extracellular matrix organization | biological process | GO:1903053 | 72 | 2 | 18204 | 48 |
CST3,LAMA2 |
1.556e-02 | -4.16 | intracellular signal transduction | biological process | GO:0035556 | 1505 | 9 | 18204 | 48 |
TNIK,PRKG1,DGKG,DMD,MAPK10,DCLK1,ATP1A2,NRG3,MYO16 |
1.560e-02 | -4.16 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 48 |
LAMA2,PTPRZ1,DCLK1,PRKG1 |
1.568e-02 | -4.16 | kinase activity | molecular function | GO:0016301 | 739 | 6 | 18094 | 50 |
TNIK,NTRK2,DCLK1,MAPK10,PRKG1,DGKG |
1.572e-02 | -4.15 | ST14 (ST14 transmembrane serine protease matriptase) | protein interactions | 6768 | 205 | 3 | 19454 | 50 |
SPON1,SMOC1,CPE |
1.572e-02 | -4.15 | UTRN (utrophin) | protein interactions | 7402 | 205 | 3 | 19454 | 50 |
DMD,DTNA,SASH1 |
1.572e-02 | -4.15 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 1 | 18204 | 48 |
NRG3 |
1.572e-02 | -4.15 | intracellular water homeostasis | biological process | GO:0009992 | 6 | 1 | 18204 | 48 |
AQP4 |
1.572e-02 | -4.15 | regulation of protein autoubiquitination | biological process | GO:1902498 | 6 | 1 | 18204 | 48 |
SASH1 |
1.572e-02 | -4.15 | cellular response to histamine | biological process | GO:0071420 | 6 | 1 | 18204 | 48 |
GABRB1 |
1.572e-02 | -4.15 | bundle of His cell-Purkinje myocyte adhesion involved in cell communication | biological process | GO:0086073 | 6 | 1 | 18204 | 48 |
CTNNA3 |
1.572e-02 | -4.15 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 48 |
CST3 |
1.572e-02 | -4.15 | oviduct development | biological process | GO:0060066 | 6 | 1 | 18204 | 48 |
CSMD1 |
1.572e-02 | -4.15 | relaxation of vascular associated smooth muscle | biological process | GO:0060087 | 6 | 1 | 18204 | 48 |
PRKG1 |
1.572e-02 | -4.15 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 48 |
SLC1A3 |
1.572e-02 | -4.15 | response to ammonium ion | biological process | GO:0060359 | 6 | 1 | 18204 | 48 |
GRIA1 |
1.572e-02 | -4.15 | positive regulation of synaptic transmission, cholinergic | biological process | GO:0032224 | 6 | 1 | 18204 | 48 |
LAMA2 |
1.572e-02 | -4.15 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 48 |
NRG3 |
1.572e-02 | -4.15 | protein targeting to vacuole involved in autophagy | biological process | GO:0071211 | 6 | 1 | 18204 | 48 |
CLU |
1.573e-02 | -4.15 | caecum | COSMIC cancer mutations | caecum | 14248 | 46 | 16828 | 48 |
PDZRN4,SASH1,SLC1A3,GPM6A,QKI,CTNNA3,PPP2R2B,GFAP,CLU,DPP6,MYO16,CST3,LSAMP,DMD,ZBTB20,PCDH9,DGKG,PRKG1,DCLK1,DTNA,SOX6,GABRB1,CPE,GLIS3,GRIK1,TNIK,NRG3,LIFR,NPAS3,AQP4,CTNND2,SPARCL1,ATP1A2,NTRK2,HS6ST3,PTPRT,NTM,SMOC1,GABBR2,SLC1A2,GRIA4,LAMA2,GRIA1,PTPRZ1,GRID2,SPON1 |
1.576e-02 | -4.15 | Spinal Cord Injury | WikiPathways | WP2431 | 119 | 3 | 5310 | 24 |
PTPRZ1,GFAP,AQP4 |
1.587e-02 | -4.14 | neuromuscular junction | cellular component | GO:0031594 | 75 | 2 | 19108 | 49 |
LAMA2,GRIA1 |
1.588e-02 | -4.14 | vasculogenesis | biological process | GO:0001570 | 73 | 2 | 18204 | 48 |
QKI,NTRK2 |
1.594e-02 | -4.14 | HDAC9 (histone deacetylase 9) | protein interactions | 9734 | 75 | 2 | 19454 | 50 |
MAPK10,GFAP |
1.595e-02 | -4.14 | regulation of signaling | biological process | GO:0023051 | 3534 | 16 | 18204 | 48 |
DGKG,PTPRT,LAMA2,SLC1A3,CLU,NTRK2,GRIA4,GRIK1,NRG3,TNIK,GRID2,GRIA1,GFAP,SASH1,CTNND2,ATP1A2 |
1.604e-02 | -4.13 | scaffold protein binding | molecular function | GO:0097110 | 70 | 2 | 18094 | 50 |
GRIA1,GRID2 |
1.608e-02 | -4.13 | DPPIV_N | pfam domains | PF00930 | 6 | 1 | 17795 | 48 |
DPP6 |
1.608e-02 | -4.13 | TSP1_spondin | pfam domains | PF19028 | 6 | 1 | 17795 | 48 |
SPON1 |
1.609e-02 | -4.13 | TSP1_spondin_dom | interpro domains | IPR044004 | 6 | 1 | 18521 | 50 |
SPON1 |
1.609e-02 | -4.13 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 50 |
GLIS3 |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | Peptidase_S9B_N | interpro domains | IPR002469 | 6 | 1 | 18521 | 50 |
DPP6 |
1.623e-02 | -4.12 | Activation of TRKA receptors | REACTOME pathways | R-HSA-187015 | 6 | 1 | 10285 | 28 |
NTRK2 |
1.624e-02 | -4.12 | regulation of cell communication | biological process | GO:0010646 | 3541 | 16 | 18204 | 48 |
PTPRT,LAMA2,DGKG,GRIK1,GRIA4,NRG3,SLC1A3,CLU,NTRK2,GRIA1,GRID2,SASH1,GFAP,TNIK,CTNND2,ATP1A2 |
1.624e-02 | -4.12 | Protein-protein interactions at synapses | REACTOME pathways | R-HSA-6794362 | 72 | 2 | 10285 | 28 |
GRIA1,GRIA4 |
1.647e-02 | -4.11 | ciliary neurotrophic factor receptor binding | molecular function | GO:0005127 | 6 | 1 | 18094 | 50 |
LIFR |
1.647e-02 | -4.11 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 50 |
ATP1A2 |
1.647e-02 | -4.11 | beta-2 adrenergic receptor binding | molecular function | GO:0031698 | 6 | 1 | 18094 | 50 |
GRIA1 |
1.647e-02 | -4.11 | glutamate-gated calcium ion channel activity | molecular function | GO:0022849 | 6 | 1 | 18094 | 50 |
GRIA1 |
1.672e-02 | -4.09 | regulation of calcium ion transmembrane transporter activity | biological process | GO:1901019 | 75 | 2 | 18204 | 48 |
DMD,ATP1A2 |
1.701e-02 | -4.07 | bone-tibia-chondrosarcoma | COSMIC cancer mutations | bone-tibia-chondrosarcoma | 70 | 2 | 16828 | 48 |
DMD,CPE |
1.705e-02 | -4.07 | Tyr_Pase_AS | interpro domains | IPR016130 | 74 | 2 | 18521 | 50 |
PTPRT,PTPRZ1 |
1.721e-02 | -4.06 | regulation of neurogenesis | biological process | GO:0050767 | 377 | 4 | 18204 | 48 |
NTRK2,QKI,GFAP,PTPRZ1 |
1.744e-02 | -4.05 | regulation of heart contraction | biological process | GO:0008016 | 208 | 3 | 18204 | 48 |
CTNNA3,DMD,ATP1A2 |
1.746e-02 | -4.05 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 2 |
ATP1A2 |
1.746e-02 | -4.05 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 2 |
ATP1A2 |
1.749e-02 | -4.05 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 23 |
CTNNA3 |
1.749e-02 | -4.05 | PP2APR55 | prints domains | PR00600 | 4 | 1 | 5227 | 23 |
PPP2R2B |
1.754e-02 | -4.04 | establishment of localization | biological process | GO:0051234 | 3887 | 17 | 18204 | 48 |
GPM6B,SLC1A3,CLU,AQP4,DCLK1,NTRK2,GRIK1,GRIA4,SLC1A2,GABRB1,GPM6A,GRIA1,GRID2,GFAP,QKI,ATP1A2,CPE |
1.757e-02 | -4.04 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 48 |
ATP1A2,GRIK1 |
1.757e-02 | -4.04 | neural retina development | biological process | GO:0003407 | 77 | 2 | 18204 | 48 |
GPM6A,NTRK2 |
1.757e-02 | -4.04 | regulation of organic acid transport | biological process | GO:0032890 | 77 | 2 | 18204 | 48 |
ATP1A2,PRKG1 |
1.759e-02 | -4.04 | KRTAP3-2 (keratin associated protein 3-2) | protein interactions | 83897 | 79 | 2 | 19454 | 50 |
NTM,GFAP |
1.759e-02 | -4.04 | STMN2 (stathmin 2) | protein interactions | 11075 | 79 | 2 | 19454 | 50 |
CTNNA3,MAPK10 |
1.761e-02 | -4.04 | protein serine kinase activity | molecular function | GO:0106310 | 362 | 4 | 18094 | 50 |
DCLK1,MAPK10,TNIK,PRKG1 |
1.782e-02 | -4.03 | G protein-coupled receptor dimeric complex | cellular component | GO:0038037 | 7 | 1 | 19108 | 49 |
GABBR2 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | CYP4F8 (cytochrome P450 family 4 subfamily F member 8) | protein interactions | 11283 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | C7 (complement C7) | protein interactions | 730 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Dlgap4 (DLG associated protein 4) | protein interactions | 228836 | 7 | 1 | 19454 | 50 |
DMD |
1.786e-02 | -4.03 | CDH10 (cadherin 10) | protein interactions | 1008 | 7 | 1 | 19454 | 50 |
CTNNA3 |
1.786e-02 | -4.03 | CDH24 (cadherin 24) | protein interactions | 64403 | 7 | 1 | 19454 | 50 |
CTNNA3 |
1.786e-02 | -4.03 | Pum2 (pumilio RNA-binding family member 2) | protein interactions | 80913 | 7 | 1 | 19454 | 50 |
QKI |
1.786e-02 | -4.03 | GRIK3 (glutamate ionotropic receptor kainate type subunit 3) | protein interactions | 2899 | 7 | 1 | 19454 | 50 |
GRIK1 |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.786e-02 | -4.03 | C8B (complement C8 beta chain) | protein interactions | 732 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | SOAT2 (sterol O-acyltransferase 2) | protein interactions | 8435 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.793e-02 | -4.02 | large_cell | COSMIC cancer mutations | large_cell | 14845 | 47 | 16828 | 48 |
SASH1,PDZRN4,SLC1A3,PHYHIPL,CLU,DPP6,GFAP,CTNNA3,QKI,PPP2R2B,GPM6A,GPM6B,DMD,CST3,LSAMP,MYO16,DGKG,PCDH9,ZBTB20,SOX6,GABRB1,DTNA,DCLK1,PRKG1,NRG3,TNIK,GRIK1,GLIS3,CPE,NPAS3,LIFR,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,SLC1A2,GRIA1,GRIA4,LAMA2,GRID2,PTPRZ1 |
1.795e-02 | -4.02 | acute_lymphoblastic_T_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_T_cell_leukaemia | 739 | 6 | 16828 | 48 |
SASH1,SOX6,GABRB1,GRIA1,CTNNA3,PTPRT |
1.795e-02 | -4.02 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia | 739 | 6 | 16828 | 48 |
PTPRT,CTNNA3,GRIA1,SASH1,SOX6,GABRB1 |
1.801e-02 | -4.02 | TMED7 (transmembrane p24 trafficking protein 7) | protein interactions | 51014 | 80 | 2 | 19454 | 50 |
GPM6A,SMOC1 |
1.801e-02 | -4.02 | TRIM9 (tripartite motif containing 9) | protein interactions | 114088 | 80 | 2 | 19454 | 50 |
MYO16,GFAP |
1.801e-02 | -4.02 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 5 | 18204 | 48 |
GRIA1,ATP1A2,SLC1A3,AQP4,ZBTB20 |
1.827e-02 | -4.00 | myosin binding | molecular function | GO:0017022 | 75 | 2 | 18094 | 50 |
DMD,GRIA1 |
1.832e-02 | -4.00 | chaperone-mediated autophagy | biological process | GO:0061684 | 7 | 1 | 18204 | 48 |
CLU |
1.832e-02 | -4.00 | relaxation of smooth muscle | biological process | GO:0044557 | 7 | 1 | 18204 | 48 |
PRKG1 |
1.832e-02 | -4.00 | positive regulation of long-term synaptic depression | biological process | GO:1900454 | 7 | 1 | 18204 | 48 |
GRID2 |
1.832e-02 | -4.00 | regulation of skeletal muscle contraction by calcium ion signaling | biological process | GO:0014722 | 7 | 1 | 18204 | 48 |
DMD |
1.832e-02 | -4.00 | mammary gland branching involved in pregnancy | biological process | GO:0060745 | 7 | 1 | 18204 | 48 |
CSMD1 |
1.832e-02 | -4.00 | response to fungicide | biological process | GO:0060992 | 7 | 1 | 18204 | 48 |
GRIA1 |
1.832e-02 | -4.00 | regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905868 | 7 | 1 | 18204 | 48 |
QKI |
1.832e-02 | -4.00 | cerebellar granule cell differentiation | biological process | GO:0021707 | 7 | 1 | 18204 | 48 |
GRID2 |
1.832e-02 | -4.00 | interneuron migration from the subpallium to the cortex | biological process | GO:0021830 | 7 | 1 | 18204 | 48 |
NRG3 |
1.832e-02 | -4.00 | cerebellar granular layer formation | biological process | GO:0021684 | 7 | 1 | 18204 | 48 |
GRID2 |
1.832e-02 | -4.00 | regulation of testosterone biosynthetic process | biological process | GO:2000224 | 7 | 1 | 18204 | 48 |
PRKG1 |
1.832e-02 | -4.00 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 48 |
PTPRZ1 |
1.832e-02 | -4.00 | cardiac muscle cell-cardiac muscle cell adhesion | biological process | GO:0086042 | 7 | 1 | 18204 | 48 |
CTNNA3 |
1.843e-02 | -3.99 | KLHL15 (kelch like family member 15) | protein interactions | 80311 | 81 | 2 | 19454 | 50 |
PPP2R2B,DCLK1 |
1.844e-02 | -3.99 | regulation of glial cell differentiation | biological process | GO:0045685 | 79 | 2 | 18204 | 48 |
QKI,PTPRZ1 |
1.850e-02 | -3.99 | Viral myocarditis | KEGG pathways | hsa05416 | 58 | 2 | 7161 | 26 |
DMD,LAMA2 |
1.865e-02 | -3.98 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 4 | 18521 | 50 |
NTRK2,TNIK,DCLK1,PRKG1 |
1.873e-02 | -3.98 | Filament_head | pfam domains | PF04732 | 7 | 1 | 17795 | 48 |
GFAP |
1.875e-02 | -3.98 | Intermed_filament_DNA-bd | interpro domains | IPR006821 | 7 | 1 | 18521 | 50 |
GFAP |
1.875e-02 | -3.98 | Hematopoietin_rcpt_Gp130_CS | interpro domains | IPR003529 | 7 | 1 | 18521 | 50 |
LIFR |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA3 |
1.875e-02 | -3.98 | Aquaporin_transptr | interpro domains | IPR034294 | 7 | 1 | 18521 | 50 |
AQP4 |
1.884e-02 | -3.97 | extracellular region | cellular component | GO:0005576 | 4350 | 18 | 19108 | 49 |
TNIK,CST3,GRIA1,NRG3,NTM,LSAMP,LAMA2,PTPRZ1,SPON1,SPARCL1,LIFR,GRIA4,AQP4,CPE,CLU,GPM6A,ATP1A2,SMOC1 |
1.885e-02 | -3.97 | heparan sulfate biosynthesis (late stages) | BIOCYC pathways | META_PWY-6558 | 17 | 1 | 902 | 1 |
HS6ST3 |
1.886e-02 | -3.97 | GINM1 (glycosylated integral membrane protein 1) | protein interactions | 116254 | 82 | 2 | 19454 | 50 |
SMOC1,CLU |
1.891e-02 | -3.97 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 2 |
ATP1A2 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.905e-02 | -3.96 | kidney-Wilms_tumour | COSMIC cancer mutations | kidney-Wilms_tumour | 545 | 5 | 16828 | 48 |
DCLK1,MYO16,PRKG1,NTRK2,TNIK |
1.918e-02 | -3.95 | leg | COSMIC cancer mutations | leg | 969 | 7 | 16828 | 48 |
NRG3,NTM,PTPRT,PTPRZ1,ZBTB20,LAMA2,PRKG1 |
1.919e-02 | -3.95 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 50 |
ATP1A2 |
1.919e-02 | -3.95 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 50 |
ATP1A2 |
1.919e-02 | -3.95 | mitogen-activated protein kinase p38 binding | molecular function | GO:0048273 | 7 | 1 | 18094 | 50 |
PRKG1 |
1.919e-02 | -3.95 | LBD domain binding | molecular function | GO:0050693 | 7 | 1 | 18094 | 50 |
SPON1 |
1.919e-02 | -3.95 | Wilms_tumour | COSMIC cancer mutations | Wilms_tumour | 546 | 5 | 16828 | 48 |
DCLK1,PRKG1,MYO16,NTRK2,TNIK |
1.933e-02 | -3.95 | Single helix bin | gene3d domains | 1.20.5.490 | 6 | 1 | 14470 | 47 |
PRKG1 |
1.933e-02 | -3.95 | Dipeptidylpeptidase IV, N-terminal domain | gene3d domains | 2.140.10.30 | 6 | 1 | 14470 | 47 |
DPP6 |
1.939e-02 | -3.94 | PSEN1 (presenilin 1) | protein interactions | 5663 | 222 | 3 | 19454 | 50 |
GFAP,DTNA,CTNND2 |
1.950e-02 | -3.94 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 3 | 18204 | 48 |
NTRK2,GRID2,GPM6B |
1.966e-02 | -3.93 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 4 | 16828 | 48 |
GRIA1,PCDH9,CPE,CTNND2 |
1.974e-02 | -3.93 | DCX (doublecortin) | protein interactions | 1641 | 84 | 2 | 19454 | 50 |
GPM6A,DCLK1 |
1.974e-02 | -3.93 | PSEN2 (presenilin 2) | protein interactions | 5664 | 84 | 2 | 19454 | 50 |
GFAP,CTNND2 |
1.983e-02 | -3.92 | signaling receptor binding | molecular function | GO:0005102 | 1493 | 9 | 18094 | 50 |
CLU,GFAP,CPE,NRG3,LIFR,GABRB1,GRIA1,PTPRZ1,LAMA2 |
2.015e-02 | -3.90 | skin-upper_arm-malignant_melanoma | COSMIC cancer mutations | skin-upper_arm-malignant_melanoma | 553 | 5 | 16828 | 48 |
CTNNA3,PTPRT,GRIA4,GRIK1,GRIA1 |
2.018e-02 | -3.90 | CCND3 (cyclin D3) | protein interactions | 896 | 85 | 2 | 19454 | 50 |
CLU,QKI |
2.021e-02 | -3.90 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 48 |
ATP1A2,SLC1A3,DMD |
2.023e-02 | -3.90 | regulation of amine transport | biological process | GO:0051952 | 83 | 2 | 18204 | 48 |
ATP1A2,PRKG1 |
2.023e-02 | -3.90 | cardiac muscle contraction | biological process | GO:0060048 | 83 | 2 | 18204 | 48 |
ATP1A2,DMD |
2.034e-02 | -3.90 | spherical high-density lipoprotein particle | cellular component | GO:0034366 | 8 | 1 | 19108 | 49 |
CLU |
2.038e-02 | -3.89 | GRIK4 (glutamate ionotropic receptor kainate type subunit 4) | protein interactions | 2900 | 8 | 1 | 19454 | 50 |
GRIK1 |
2.038e-02 | -3.89 | DEPP1 (DEPP autophagy regulator 1) | protein interactions | 11067 | 8 | 1 | 19454 | 50 |
QKI |
2.038e-02 | -3.89 | ZNF662 (zinc finger protein 662) | protein interactions | 389114 | 8 | 1 | 19454 | 50 |
CTNNA3 |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | UBALD2 (UBA like domain containing 2) | protein interactions | 283991 | 8 | 1 | 19454 | 50 |
GFAP |
2.038e-02 | -3.89 | NKAIN3 (sodium/potassium transporting ATPase interacting 3) | protein interactions | 286183 | 8 | 1 | 19454 | 50 |
GFAP |
2.038e-02 | -3.89 | CNIH2 (cornichon family AMPA receptor auxiliary protein 2) | protein interactions | 254263 | 8 | 1 | 19454 | 50 |
GRIA1 |
2.038e-02 | -3.89 | Chmp2a (charged multivesicular body protein 2A) | protein interactions | 68953 | 8 | 1 | 19454 | 50 |
CLU |
2.056e-02 | -3.88 | organic anion transport | biological process | GO:0015711 | 398 | 4 | 18204 | 48 |
NTRK2,SLC1A3,GFAP,SLC1A2 |
2.058e-02 | -3.88 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 5 | 16828 | 48 |
PRKG1,CTNND2,LIFR,SOX6,NTRK2 |
2.062e-02 | -3.88 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 2 | 18094 | 50 |
SLC1A2,SLC1A3 |
2.069e-02 | -3.88 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
2.069e-02 | -3.88 | peripheral nervous system development | biological process | GO:0007422 | 84 | 2 | 18204 | 48 |
NTRK2,LAMA2 |
2.069e-02 | -3.88 | regulation of release of sequestered calcium ion into cytosol | biological process | GO:0051279 | 84 | 2 | 18204 | 48 |
DMD,ATP1A2 |
2.069e-02 | -3.88 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 48 |
ATP1A2,DMD |
2.079e-02 | -3.87 | Transferase(Phosphotransferase) domain 1 | gene3d domains | 1.10.510.10 | 490 | 5 | 14470 | 47 |
NTRK2,DCLK1,PRKG1,MAPK10,TNIK |
2.087e-02 | -3.87 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 5 | 16828 | 48 |
PRKG1,CTNND2,SOX6,LIFR,NTRK2 |
2.090e-02 | -3.87 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 48 |
SLC1A3 |
2.090e-02 | -3.87 | peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity | biological process | GO:1990264 | 8 | 1 | 18204 | 48 |
PTPRT |
2.090e-02 | -3.87 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 1 | 18204 | 48 |
NRG3 |
2.090e-02 | -3.87 | protein import | biological process | GO:0017038 | 8 | 1 | 18204 | 48 |
CLU |
2.090e-02 | -3.87 | regulation of chaperone-mediated autophagy | biological process | GO:1904714 | 8 | 1 | 18204 | 48 |
GFAP |
2.090e-02 | -3.87 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 48 |
CPE |
2.090e-02 | -3.87 | regulation of synaptic transmission, cholinergic | biological process | GO:0032222 | 8 | 1 | 18204 | 48 |
LAMA2 |
2.090e-02 | -3.87 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 48 |
ATP1A2 |
2.090e-02 | -3.87 | negative regulation of peptidyl-cysteine S-nitrosylation | biological process | GO:1902083 | 8 | 1 | 18204 | 48 |
DMD |
2.100e-02 | -3.86 | cellular process | biological process | GO:0009987 | 14996 | 45 | 18204 | 48 |
DGKG,LAMA2,LIFR,GRIA4,GABRB1,PPP2R2B,NTM,PTPRZ1,GRID2,LSAMP,CTNND2,QKI,PCDH9,PTPRT,GRIK1,TNIK,MAPK10,GFAP,ZBTB20,HS6ST3,DPP6,AQP4,CLU,GLIS3,SLC1A2,NRG3,GPM6A,CST3,GRIA1,CTNNA3,SPON1,SMOC1,MYO16,GPM6B,DMD,SLC1A3,NTRK2,DCLK1,GABBR2,SPARCL1,PRKG1,DTNA,ATP1A2,SOX6,CPE |
2.106e-02 | -3.86 | heparan sulfate biosynthesis (late stages) | BIOCYC pathways | HUMAN_PWY-6558 | 19 | 1 | 902 | 1 |
HS6ST3 |
2.108e-02 | -3.86 | PROTEIN_KINASE_ST | prosite domains | PS00108 | 308 | 4 | 12186 | 42 |
DCLK1,PRKG1,TNIK,MAPK10 |
2.110e-02 | -3.86 | protein kinase activity | molecular function | GO:0004672 | 577 | 5 | 18094 | 50 |
NTRK2,DCLK1,MAPK10,TNIK,PRKG1 |
2.127e-02 | -3.85 | DST (dystonin) | protein interactions | 667 | 230 | 3 | 19454 | 50 |
ATP1A2,TNIK,NTRK2 |
2.130e-02 | -3.85 | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | 561 | 5 | 16828 | 48 |
DCLK1,MYO16,NTRK2,TNIK,LIFR |
2.133e-02 | -3.85 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 46 | 16828 | 48 |
NRG3,GRIK1,TNIK,GLIS3,GRIA1,CPE,LAMA2,GRIA4,NPAS3,SPON1,LIFR,GRID2,PTPRZ1,DGKG,PCDH9,ZBTB20,SLC1A2,SOX6,GABRB1,DTNA,DCLK1,PRKG1,CLU,DPP6,NTM,GFAP,PTPRT,PPP2R2B,CTNNA3,QKI,GPM6A,GABBR2,DMD,LSAMP,SMOC1,MYO16,NTRK2,ATP1A2,SASH1,SPARCL1,PDZRN4,CTNND2,AQP4,SLC1A3,PHYHIPL,HS6ST3 |
2.138e-02 | -3.85 | DCX | pfam domains | PF03607 | 8 | 1 | 17795 | 48 |
DCLK1 |
2.138e-02 | -3.85 | Laminin_B | pfam domains | PF00052 | 8 | 1 | 17795 | 48 |
LAMA2 |
2.140e-02 | -3.84 | Laminin_IV | interpro domains | IPR000034 | 8 | 1 | 18521 | 50 |
LAMA2 |
2.157e-02 | -3.84 | FYN (FYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 2534 | 414 | 4 | 19454 | 50 |
CTNNA3,CTNND2,PTPRZ1,NTRK2 |
2.186e-02 | -3.82 | EF_HAND_1 | prosite domains | PS00018 | 174 | 3 | 12186 | 42 |
SPARCL1,DGKG,SMOC1 |
2.190e-02 | -3.82 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 50 |
SLC1A3 |
2.190e-02 | -3.82 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 50 |
ATP1A2 |
2.190e-02 | -3.82 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 50 |
ATP1A2 |
2.190e-02 | -3.82 | cyclic nucleotide-dependent protein kinase activity | molecular function | GO:0004690 | 8 | 1 | 18094 | 50 |
PRKG1 |
2.199e-02 | -3.82 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 48 |
ATP1A2,PRKG1,TNIK,MYO16,DMD,MAPK10 |
2.199e-02 | -3.82 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 50 |
DTNA,DMD |
2.209e-02 | -3.81 | associative learning | biological process | GO:0008306 | 87 | 2 | 18204 | 48 |
ATP1A2,CSMD1 |
2.244e-02 | -3.80 | stomach | COSMIC cancer mutations | stomach | 15550 | 48 | 16828 | 48 |
HS6ST3,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,GABBR2,SMOC1,NTM,PTPRT,SLC1A2,SPON1,GRID2,PTPRZ1,GRIA1,GRIA4,LAMA2,SLC1A3,PHYHIPL,SASH1,PDZRN4,DMD,LSAMP,CST3,MYO16,DPP6,CLU,GFAP,CTNNA3,QKI,PPP2R2B,GPM6A,GPM6B,GABRB1,SOX6,DTNA,DCLK1,PRKG1,DGKG,PCDH9,ZBTB20,NPAS3,LIFR,NRG3,TNIK,GRIK1,GLIS3,CPE |
2.246e-02 | -3.80 | SEMG1 (semenogelin 1) | protein interactions | 6406 | 90 | 2 | 19454 | 50 |
PPP2R2B,CLU |
2.249e-02 | -3.79 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 3 | 19454 | 50 |
DTNA,PPP2R2B,NTRK2 |
2.251e-02 | -3.79 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 6 | 16828 | 48 |
NTRK2,TNIK,DCLK1,GRIA4,PRKG1,CTNND2 |
2.251e-02 | -3.79 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 6 | 16828 | 48 |
GRIA4,PRKG1,DCLK1,CTNND2,TNIK,NTRK2 |
2.260e-02 | -3.79 | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | 8 | 1 | 16828 | 48 |
QKI |
2.260e-02 | -3.79 | Tyr_Pase_dom | interpro domains | IPR000387 | 86 | 2 | 18521 | 50 |
PTPRZ1,PTPRT |
2.263e-02 | -3.79 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 24 |
SLC1A3,ATP1A2 |
2.272e-02 | -3.78 | human chr6q26 | chromosome location | human chr6q26 | 12 | 1 | 26134 | 50 |
QKI |
2.272e-02 | -3.78 | human chr6q22.33 | chromosome location | human chr6q22.33 | 12 | 1 | 26134 | 50 |
LAMA2 |
2.285e-02 | -3.78 | fascia adherens | cellular component | GO:0005916 | 9 | 1 | 19108 | 49 |
CTNNA3 |
2.290e-02 | -3.78 | PI3 (peptidase inhibitor 3) | protein interactions | 5266 | 9 | 1 | 19454 | 50 |
PPP2R2B |
2.290e-02 | -3.78 | IER5 (immediate early response 5) | protein interactions | 51278 | 9 | 1 | 19454 | 50 |
PPP2R2B |
2.290e-02 | -3.78 | SOBP (sine oculis binding protein homolog) | protein interactions | 55084 | 9 | 1 | 19454 | 50 |
SOX6 |
2.290e-02 | -3.78 | LSB3 (Lsb3p) | protein interactions | 850580 | 9 | 1 | 19454 | 50 |
GFAP |
2.290e-02 | -3.78 | Ywhag (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide) | protein interactions | 22628 | 9 | 1 | 19454 | 50 |
QKI |
2.290e-02 | -3.78 | LOC102724023 (glutamine amidotransferase class 1 domain containing 3B) | protein interactions | 102724023 | 9 | 1 | 19454 | 50 |
PHYHIPL |
2.292e-02 | -3.78 | NEIL3 (nei like DNA glycosylase 3) | protein interactions | 55247 | 91 | 2 | 19454 | 50 |
QKI,GFAP |
2.294e-02 | -3.77 | regulation of cellular component organization | biological process | GO:0051128 | 2455 | 12 | 18204 | 48 |
GPM6B,LAMA2,GFAP,PTPRT,GRID2,CST3,GPM6A,TNIK,DGKG,NRG3,NTRK2,CLU |
2.296e-02 | -3.77 | response to external stimulus | biological process | GO:0009605 | 1882 | 10 | 18204 | 48 |
NRG3,ATP1A2,DCLK1,AQP4,SLC1A3,CLU,CSMD1,DMD,GRID2,GPM6A |
2.299e-02 | -3.77 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 50 |
GFAP,GRIA1,GPM6A |
2.305e-02 | -3.77 | cellular response to amino acid stimulus | biological process | GO:0071230 | 89 | 2 | 18204 | 48 |
NTRK2,GRIA1 |
2.308e-02 | -3.77 | FN3 | smart domains | SM00060 | 149 | 3 | 9717 | 40 |
PTPRZ1,LIFR,PTPRT |
2.329e-02 | -3.76 | basement membrane | cellular component | GO:0005604 | 92 | 2 | 19108 | 49 |
LAMA2,SMOC1 |
2.339e-02 | -3.76 | ADGRG5 (adhesion G protein-coupled receptor G5) | protein interactions | 221188 | 92 | 2 | 19454 | 50 |
GPM6B,GPM6A |
2.341e-02 | -3.75 | upper_aerodigestive_tract-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-carcinoma | 383 | 4 | 16828 | 48 |
DCLK1,NTRK2,TNIK,LIFR |
2.341e-02 | -3.75 | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 48 |
DCLK1,LIFR,TNIK,NTRK2 |
2.341e-02 | -3.75 | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 48 |
DCLK1,LIFR,NTRK2,TNIK |
2.341e-02 | -3.75 | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 48 |
DCLK1,NTRK2,TNIK,LIFR |
2.341e-02 | -3.75 | salivary_gland-carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma | 383 | 4 | 16828 | 48 |
DCLK1,NTRK2,TNIK,LIFR |
2.348e-02 | -3.75 | RANBP9 (RAN binding protein 9) | protein interactions | 10048 | 425 | 4 | 19454 | 50 |
SPON1,NTRK2,TNIK,GRIK1 |
2.349e-02 | -3.75 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 48 |
CLU |
2.349e-02 | -3.75 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 48 |
ATP1A2 |
2.349e-02 | -3.75 | negative regulation of neurotransmitter transport | biological process | GO:0051589 | 9 | 1 | 18204 | 48 |
GPM6B |
2.349e-02 | -3.75 | cerebellar granular layer morphogenesis | biological process | GO:0021683 | 9 | 1 | 18204 | 48 |
GRID2 |
2.349e-02 | -3.75 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 48 |
CLU |
2.380e-02 | -3.74 | PROTEIN_KINASE_DOM | prosite domains | PS50011 | 480 | 5 | 12186 | 42 |
NTRK2,DCLK1,PRKG1,TNIK,MAPK10 |
2.387e-02 | -3.74 | parotid | COSMIC cancer mutations | parotid | 578 | 5 | 16828 | 48 |
MYO16,DCLK1,TNIK,NTRK2,LIFR |
2.388e-02 | -3.73 | HEMATOPO_REC_L_F2 | prosite domains | PS01353 | 7 | 1 | 12186 | 42 |
LIFR |
2.400e-02 | -3.73 | spindle | COSMIC cancer mutations | spindle | 386 | 4 | 16828 | 48 |
GRIA1,CPE,PCDH9,CTNND2 |
2.402e-02 | -3.73 | Peptidase_S9 | pfam domains | PF00326 | 9 | 1 | 17795 | 48 |
DPP6 |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Peptidase_S9 | interpro domains | IPR001375 | 9 | 1 | 18521 | 50 |
DPP6 |
2.404e-02 | -3.73 | Doublecortin_dom | interpro domains | IPR003533 | 9 | 1 | 18521 | 50 |
DCLK1 |
2.425e-02 | -3.72 | Terminal pathway of complement | REACTOME pathways | R-HSA-166665 | 9 | 1 | 10285 | 28 |
CLU |
2.435e-02 | -3.72 | TTR (transthyretin) | protein interactions | 7276 | 94 | 2 | 19454 | 50 |
CLU,CTNND2 |
2.450e-02 | -3.71 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 5 | 16828 | 48 |
GRIK1,GRIA1,PTPRT,CTNNA3,GRIA4 |
2.459e-02 | -3.71 | human chr13q33.3 | chromosome location | human chr13q33.3 | 13 | 1 | 26134 | 50 |
MYO16 |
2.460e-02 | -3.70 | delta-catenin binding | molecular function | GO:0070097 | 9 | 1 | 18094 | 50 |
PTPRT |
2.469e-02 | -3.70 | Ion Channels and Their Functional Role in Vascular Endothelium | SMPDB pathways | SMP0063778 | 17 | 1 | 1369 | 2 |
PRKG1 |
2.479e-02 | -3.70 | DDX31 (DEAD-box helicase 31) | protein interactions | 64794 | 244 | 3 | 19454 | 50 |
CLU,CST3,PRKG1 |
2.479e-02 | -3.70 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 48 |
DTNA,DMD,ATP1A2 |
2.485e-02 | -3.70 | response to radiation | biological process | GO:0009314 | 422 | 4 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2,MAPK10 |
2.486e-02 | -3.69 | enzyme binding | molecular function | GO:0019899 | 2086 | 11 | 18094 | 50 |
GFAP,CLU,NRG3,MYO16,PRKG1,NTRK2,DMD,PTPRT,SASH1,GRIA1,CST3 |
2.494e-02 | -3.69 | Epithelial cell signaling in Helicobacter pylori infection | KEGG pathways | hsa05120 | 68 | 2 | 7161 | 26 |
PTPRZ1,MAPK10 |
2.494e-02 | -3.69 | Epithelial cell signaling in Helicobacter pylori infection | KEGG pathways | ko05120 | 68 | 2 | 7161 | 26 |
MAPK10,PTPRZ1 |
2.494e-02 | -3.69 | Amphetamine addiction | KEGG pathways | hsa05031 | 68 | 2 | 7161 | 26 |
GRIA4,GRIA1 |
2.494e-02 | -3.69 | Amphetamine addiction | KEGG pathways | ko05031 | 68 | 2 | 7161 | 26 |
GRIA4,GRIA1 |
2.518e-02 | -3.68 | oesophagus | COSMIC cancer mutations | oesophagus | 14970 | 47 | 16828 | 48 |
SOX6,GABRB1,PRKG1,DCLK1,PCDH9,DGKG,ZBTB20,LIFR,NPAS3,CPE,GLIS3,TNIK,GRIK1,NRG3,PHYHIPL,SLC1A3,SASH1,PDZRN4,DMD,MYO16,LSAMP,CST3,DPP6,CLU,GPM6B,GPM6A,CTNNA3,PPP2R2B,QKI,GFAP,SLC1A2,SPON1,PTPRZ1,GRID2,GRIA1,LAMA2,GRIA4,HS6ST3,SPARCL1,ATP1A2,NTRK2,AQP4,CTNND2,GABBR2,SMOC1,NTM,PTPRT |
2.532e-02 | -3.68 | E7 (E7 protein) | protein interactions | 1489369 | 96 | 2 | 19454 | 50 |
QKI,SASH1 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.541e-02 | -3.67 | Hsp90aa1 (heat shock protein 90, alpha (cytosolic), class A member 1) | protein interactions | 15519 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.541e-02 | -3.67 | PGM5 (phosphoglucomutase 5) | protein interactions | 5239 | 10 | 1 | 19454 | 50 |
DMD |
2.541e-02 | -3.67 | DEFA1B (defensin alpha 1B) | protein interactions | 728358 | 10 | 1 | 19454 | 50 |
PPP2R2B |
2.541e-02 | -3.67 | CDH4 (cadherin 4) | protein interactions | 1002 | 10 | 1 | 19454 | 50 |
CTNNA3 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Mrpl13 (mitochondrial ribosomal protein L13) | protein interactions | 68537 | 10 | 1 | 19454 | 50 |
QKI |
2.546e-02 | -3.67 | TYR_PHOSPHATASE_1 | prosite domains | PS00383 | 72 | 2 | 12186 | 42 |
PTPRT,PTPRZ1 |
2.550e-02 | -3.67 | heparan sulfate biosynthesis | BIOCYC pathways | META_PWY-6564 | 23 | 1 | 902 | 1 |
HS6ST3 |
2.573e-02 | -3.66 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 28 |
LSAMP,NTM |
2.581e-02 | -3.66 | PLCB3 (phospholipase C beta 3) | protein interactions | 5331 | 97 | 2 | 19454 | 50 |
PRKG1,CTNNA3 |
2.581e-02 | -3.66 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 2 | 19454 | 50 |
CLU,SPARCL1 |
2.581e-02 | -3.66 | SNTA1 (syntrophin alpha 1) | protein interactions | 6640 | 97 | 2 | 19454 | 50 |
DMD,DTNA |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
DGKG,TNIK,SOX6 |
2.595e-02 | -3.65 | pancreas-other-adenoma | COSMIC cancer mutations | pancreas-other-adenoma | 224 | 3 | 16828 | 48 |
PCDH9,CTNND2,PTPRT |
2.595e-02 | -3.65 | PTPc_motif | smart domains | SM00404 | 61 | 2 | 9717 | 40 |
PTPRT,PTPRZ1 |
2.595e-02 | -3.65 | response to organic substance | biological process | GO:0010033 | 2498 | 12 | 18204 | 48 |
ATP1A2,ZBTB20,GRIA1,TNIK,GABRB1,SLC1A2,NTRK2,SLC1A3,CLU,AQP4,LIFR,PTPRT |
2.606e-02 | -3.65 | Brain-Derived Neurotrophic Factor (BDNF) signaling pathway | WikiPathways | WP2380 | 144 | 3 | 5310 | 24 |
GRIA1,MAPK10,NTRK2 |
2.606e-02 | -3.65 | trans-synaptic signaling, modulating synaptic transmission | biological process | GO:0099550 | 10 | 1 | 18204 | 48 |
NTRK2 |
2.606e-02 | -3.65 | retinal rod cell development | biological process | GO:0046548 | 10 | 1 | 18204 | 48 |
NTRK2 |
2.606e-02 | -3.65 | response to histamine | biological process | GO:0034776 | 10 | 1 | 18204 | 48 |
GABRB1 |
2.606e-02 | -3.65 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 48 |
SOX6 |
2.606e-02 | -3.65 | substrate-independent telencephalic tangential migration | biological process | GO:0021826 | 10 | 1 | 18204 | 48 |
NRG3 |
2.606e-02 | -3.65 | positive regulation of lipopolysaccharide-mediated signaling pathway | biological process | GO:0031666 | 10 | 1 | 18204 | 48 |
SASH1 |
2.606e-02 | -3.65 | substrate-independent telencephalic tangential interneuron migration | biological process | GO:0021843 | 10 | 1 | 18204 | 48 |
NRG3 |
2.606e-02 | -3.65 | regulation of postsynaptic cytosolic calcium ion concentration | biological process | GO:0099566 | 10 | 1 | 18204 | 48 |
GRIA1 |
2.616e-02 | -3.64 | negative regulation of biological process | biological process | GO:0048519 | 5737 | 22 | 18204 | 48 |
ATP1A2,QKI,ZBTB20,MYO16,SOX6,PRKG1,GFAP,SPON1,GRIA1,CST3,GRID2,PTPRZ1,DCLK1,NTRK2,GLIS3,CLU,NRG3,GRIA4,DGKG,DMD,GPM6B,PTPRT |
2.622e-02 | -3.64 | nervous system process | biological process | GO:0050877 | 1376 | 8 | 18204 | 48 |
GRIA1,PTPRZ1,GRID2,SLC1A3,CSMD1,AQP4,NTRK2,ATP1A2 |
2.631e-02 | -3.64 | DMD (dystrophin) | protein interactions | 1756 | 98 | 2 | 19454 | 50 |
DTNA,DMD |
2.647e-02 | -3.63 | soft_tissue-striated_muscle-rhabdomyosarcoma | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma | 594 | 5 | 16828 | 48 |
SPON1,SOX6,PDZRN4,CTNND2,CTNNA3 |
2.666e-02 | -3.62 | DAGK_acc | pfam domains | PF00609 | 10 | 1 | 17795 | 48 |
DGKG |
2.666e-02 | -3.62 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 48 |
NPAS3 |
2.666e-02 | -3.62 | Laminin_G_1 | pfam domains | PF00054 | 10 | 1 | 17795 | 48 |
LAMA2 |
2.666e-02 | -3.62 | Ig_sub2 | interpro domains | IPR003598 | 239 | 3 | 18521 | 50 |
NTM,LSAMP,NTRK2 |
2.668e-02 | -3.62 | Diacylglycerol_kin_accessory | interpro domains | IPR000756 | 10 | 1 | 18521 | 50 |
DGKG |
2.668e-02 | -3.62 | Doublecortin_dom_sf | interpro domains | IPR036572 | 10 | 1 | 18521 | 50 |
DCLK1 |
2.668e-02 | -3.62 | DGK | interpro domains | IPR037607 | 10 | 1 | 18521 | 50 |
DGKG |
2.668e-02 | -3.62 | MIP_CS | interpro domains | IPR022357 | 10 | 1 | 18521 | 50 |
AQP4 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.680e-02 | -3.62 | DEFA1 (defensin alpha 1) | protein interactions | 1667 | 99 | 2 | 19454 | 50 |
SMOC1,LIFR |
2.680e-02 | -3.62 | TNKS (tankyrase) | protein interactions | 8658 | 99 | 2 | 19454 | 50 |
PCDH9,TNIK |
2.690e-02 | -3.62 | Activation of the AP-1 family of transcription factors | REACTOME pathways | R-HSA-450341 | 10 | 1 | 10285 | 28 |
MAPK10 |
2.690e-02 | -3.62 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 1 | 10285 | 28 |
NRG3 |
2.701e-02 | -3.61 | anchoring junction | cellular component | GO:0070161 | 902 | 6 | 19108 | 49 |
DMD,CTNNA3,CTNND2,GRIA1,PCDH9,ATP1A2 |
2.702e-02 | -3.61 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 26 |
ATP1A2,AQP4 |
2.702e-02 | -3.61 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 26 |
AQP4,ATP1A2 |
2.725e-02 | -3.60 | LAMININ_IVA | prosite domains | PS51115 | 8 | 1 | 12186 | 42 |
LAMA2 |
2.730e-02 | -3.60 | alpha-catenin binding | molecular function | GO:0045294 | 10 | 1 | 18094 | 50 |
PTPRT |
2.730e-02 | -3.60 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 50 |
NTRK2 |
2.731e-02 | -3.60 | PLG (plasminogen) | protein interactions | 5340 | 100 | 2 | 19454 | 50 |
DPP6,PPP2R2B |
2.731e-02 | -3.60 | DTNB (dystrobrevin beta) | protein interactions | 1838 | 100 | 2 | 19454 | 50 |
DMD,DTNA |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
GPM6A,ATP1A2 |
2.756e-02 | -3.59 | cellular response to acid chemical | biological process | GO:0071229 | 98 | 2 | 18204 | 48 |
NTRK2,GRIA1 |
2.769e-02 | -3.59 | potassium channel complex | cellular component | GO:0034705 | 101 | 2 | 19108 | 49 |
DPP6,GRIK1 |
2.772e-02 | -3.59 | heparan sulfate biosynthesis | BIOCYC pathways | HUMAN_PWY-6564 | 25 | 1 | 902 | 1 |
HS6ST3 |
2.777e-02 | -3.58 | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-aldosterone_producing | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-aldosterone_producing | 91 | 2 | 16828 | 48 |
GRIA1,SOX6 |
2.781e-02 | -3.58 | FAM110A (family with sequence similarity 110 member A) | protein interactions | 83541 | 101 | 2 | 19454 | 50 |
DCLK1,CTNNA3 |
2.781e-02 | -3.58 | PRKCG (protein kinase C gamma) | protein interactions | 5582 | 101 | 2 | 19454 | 50 |
GFAP,GRIA4 |
2.786e-02 | -3.58 | G protein-coupled receptor complex | cellular component | GO:0097648 | 11 | 1 | 19108 | 49 |
GABBR2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.792e-02 | -3.58 | C17orf50 (chromosome 17 open reading frame 50) | protein interactions | 146853 | 11 | 1 | 19454 | 50 |
CTNNA3 |
2.792e-02 | -3.58 | SPATS1 (spermatogenesis associated serine rich 1) | protein interactions | 221409 | 11 | 1 | 19454 | 50 |
CTNNA3 |
2.792e-02 | -3.58 | DAZ1 (deleted in azoospermia 1) | protein interactions | 1617 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 50 |
PRKG1 |
2.792e-02 | -3.58 | CACNG8 (calcium voltage-gated channel auxiliary subunit gamma 8) | protein interactions | 59283 | 11 | 1 | 19454 | 50 |
GRIA1 |
2.792e-02 | -3.58 | MSRB1 (methionine sulfoxide reductase B1) | protein interactions | 51734 | 11 | 1 | 19454 | 50 |
CLU |
2.792e-02 | -3.58 | NEUROD4 (neuronal differentiation 4) | protein interactions | 58158 | 11 | 1 | 19454 | 50 |
GABRB1 |
2.792e-02 | -3.58 | IL7 (interleukin 7) | protein interactions | 3574 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | KCTD16 (potassium channel tetramerization domain containing 16) | protein interactions | 57528 | 11 | 1 | 19454 | 50 |
GABBR2 |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | ZG16 (zymogen granule protein 16) | protein interactions | 653808 | 11 | 1 | 19454 | 50 |
CTNNA3 |
2.808e-02 | -3.57 | spinal cord development | biological process | GO:0021510 | 99 | 2 | 18204 | 48 |
SOX6,GRIA1 |
2.808e-02 | -3.57 | heart contraction | biological process | GO:0060047 | 99 | 2 | 18204 | 48 |
ATP1A2,DMD |
2.814e-02 | -3.57 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 2 | 12186 | 42 |
GLIS3,CPE |
2.817e-02 | -3.57 | chiasm | COSMIC cancer mutations | chiasm | 10 | 1 | 16828 | 48 |
QKI |
2.822e-02 | -3.57 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 7 | 18204 | 48 |
GRIA1,SOX6,GABRB1,SLC1A2,SLC1A3,NTRK2,ATP1A2 |
2.832e-02 | -3.56 | HP (haptoglobin) | protein interactions | 3240 | 102 | 2 | 19454 | 50 |
CLU,PPP2R2B |
2.832e-02 | -3.56 | TMPRSS13 (transmembrane serine protease 13) | protein interactions | 84000 | 102 | 2 | 19454 | 50 |
SPON1,CPE |
2.861e-02 | -3.55 | regulation of dendrite development | biological process | GO:0050773 | 100 | 2 | 18204 | 48 |
TNIK,DGKG |
2.863e-02 | -3.55 | negative regulation of neuron migration | biological process | GO:2001223 | 11 | 1 | 18204 | 48 |
NRG3 |
2.863e-02 | -3.55 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 48 |
NTRK2 |
2.863e-02 | -3.55 | ectodermal placode formation | biological process | GO:0060788 | 11 | 1 | 18204 | 48 |
NRG3 |
2.863e-02 | -3.55 | regulation of peptidyl-cysteine S-nitrosylation | biological process | GO:2000169 | 11 | 1 | 18204 | 48 |
DMD |
2.863e-02 | -3.55 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 48 |
ATP1A2 |
2.863e-02 | -3.55 | negative regulation of platelet aggregation | biological process | GO:0090331 | 11 | 1 | 18204 | 48 |
PRKG1 |
2.863e-02 | -3.55 | lipid phosphorylation | biological process | GO:0046834 | 11 | 1 | 18204 | 48 |
DGKG |
2.863e-02 | -3.55 | intracellular mRNA localization | biological process | GO:0008298 | 11 | 1 | 18204 | 48 |
QKI |
2.863e-02 | -3.55 | negative regulation of cardiac muscle cell differentiation | biological process | GO:2000726 | 11 | 1 | 18204 | 48 |
SOX6 |
2.863e-02 | -3.55 | physiological muscle hypertrophy | biological process | GO:0003298 | 11 | 1 | 18204 | 48 |
PRKG1 |
2.863e-02 | -3.55 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 48 |
ATP1A2 |
2.863e-02 | -3.55 | ectodermal placode morphogenesis | biological process | GO:0071697 | 11 | 1 | 18204 | 48 |
NRG3 |
2.863e-02 | -3.55 | cell growth involved in cardiac muscle cell development | biological process | GO:0061049 | 11 | 1 | 18204 | 48 |
PRKG1 |
2.863e-02 | -3.55 | Bergmann glial cell differentiation | biological process | GO:0060020 | 11 | 1 | 18204 | 48 |
GFAP |
2.863e-02 | -3.55 | regulation of basement membrane organization | biological process | GO:0110011 | 11 | 1 | 18204 | 48 |
LAMA2 |
2.863e-02 | -3.55 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 48 |
ATP1A2 |
2.863e-02 | -3.55 | regulation of Schwann cell proliferation | biological process | GO:0010624 | 11 | 1 | 18204 | 48 |
GFAP |
2.863e-02 | -3.55 | physiological cardiac muscle hypertrophy | biological process | GO:0003301 | 11 | 1 | 18204 | 48 |
PRKG1 |
2.886e-02 | -3.55 | Doublecortin domain | gene3d domains | 3.10.20.230 | 9 | 1 | 14470 | 47 |
DCLK1 |
2.889e-02 | -3.54 | MARK2 (microtubule affinity regulating kinase 2) | protein interactions | 2011 | 259 | 3 | 19454 | 50 |
DTNA,PPP2R2B,DMD |
2.891e-02 | -3.54 | aldosterone_producing | COSMIC cancer mutations | aldosterone_producing | 93 | 2 | 16828 | 48 |
SOX6,GRIA1 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
LSAMP,PTPRT,NTRK2,NTM |
2.931e-02 | -3.53 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 1 | 18521 | 50 |
NTRK2 |
2.936e-02 | -3.53 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 2 | 19454 | 50 |
SPARCL1,CLU |
2.958e-02 | -3.52 | breast-carcinoma | COSMIC cancer mutations | breast-carcinoma | 15030 | 47 | 16828 | 48 |
DCLK1,PRKG1,SOX6,GABRB1,ZBTB20,PCDH9,DGKG,LIFR,NPAS3,GLIS3,CPE,NRG3,GRIK1,TNIK,SLC1A3,PHYHIPL,PDZRN4,SASH1,MYO16,LSAMP,CST3,DMD,GPM6A,GPM6B,GFAP,CTNNA3,QKI,PPP2R2B,CLU,DPP6,SLC1A2,GRID2,PTPRZ1,SPON1,LAMA2,GRIA4,GRIA1,HS6ST3,AQP4,CTNND2,SPARCL1,NTRK2,ATP1A2,SMOC1,GABBR2,PTPRT,NTM |
2.969e-02 | -3.52 | phosphate-containing compound metabolic process | biological process | GO:0006796 | 1681 | 9 | 18204 | 48 |
ATP1A2,DCLK1,NTRK2,PTPRZ1,PTPRT,MAPK10,DGKG,PRKG1,TNIK |
2.970e-02 | -3.52 | cellular macromolecule localization | biological process | GO:0070727 | 1962 | 10 | 18204 | 48 |
DMD,GPM6B,GFAP,GRID2,TNIK,DPP6,CPE,DCLK1,QKI,CLU |
2.979e-02 | -3.51 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | 413 | 4 | 16828 | 48 |
GRIK1,DGKG,PTPRT,MYO16 |
2.979e-02 | -3.51 | myelofibrosis | COSMIC cancer mutations | myelofibrosis | 413 | 4 | 16828 | 48 |
PTPRT,MYO16,DGKG,GRIK1 |
2.999e-02 | -3.51 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 50 |
SLC1A2 |
2.999e-02 | -3.51 | nitric-oxide synthase binding | molecular function | GO:0050998 | 11 | 1 | 18094 | 50 |
DMD |
2.999e-02 | -3.51 | ATP-dependent diacylglycerol kinase activity | molecular function | GO:0004143 | 11 | 1 | 18094 | 50 |
DGKG |
2.999e-02 | -3.51 | structural constituent of myelin sheath | molecular function | GO:0019911 | 11 | 1 | 18094 | 50 |
GPM6B |
2.999e-02 | -3.51 | STAT family protein binding | molecular function | GO:0097677 | 11 | 1 | 18094 | 50 |
PTPRT |
2.999e-02 | -3.51 | dystroglycan binding | molecular function | GO:0002162 | 11 | 1 | 18094 | 50 |
DMD |
3.021e-02 | -3.50 | regulation of heart rate | biological process | GO:0002027 | 103 | 2 | 18204 | 48 |
CTNNA3,DMD |
3.025e-02 | -3.50 | protein serine/threonine kinase activity | molecular function | GO:0004674 | 428 | 4 | 18094 | 50 |
DCLK1,MAPK10,TNIK,PRKG1 |
3.027e-02 | -3.50 | filopodium | cellular component | GO:0030175 | 106 | 2 | 19108 | 49 |
GPM6A,DMD |
3.033e-02 | -3.50 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 48 |
NTM,ATP1A2,NPAS3,GRIA4,ZBTB20,PTPRT,GRID2,PDZRN4 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.042e-02 | -3.49 | CTF1 (cardiotrophin 1) | protein interactions | 1489 | 12 | 1 | 19454 | 50 |
LIFR |
3.042e-02 | -3.49 | INTS4P2 (integrator complex subunit 4 pseudogene 2) | protein interactions | 644619 | 12 | 1 | 19454 | 50 |
GFAP |
3.042e-02 | -3.49 | KIF26A (kinesin family member 26A) | protein interactions | 26153 | 12 | 1 | 19454 | 50 |
MAPK10 |
3.042e-02 | -3.49 | NTF4 (neurotrophin 4) | protein interactions | 4909 | 12 | 1 | 19454 | 50 |
NTRK2 |
3.042e-02 | -3.49 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | MMP25 (matrix metallopeptidase 25) | protein interactions | 64386 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | MYBPHL (myosin binding protein H like) | protein interactions | 343263 | 12 | 1 | 19454 | 50 |
GFAP |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.044e-02 | -3.49 | Prot-tyrosine_phosphatase-like | interpro domains | IPR029021 | 101 | 2 | 18521 | 50 |
PTPRT,PTPRZ1 |
3.053e-02 | -3.49 | regulation of phosphate metabolic process | biological process | GO:0019220 | 1154 | 7 | 18204 | 48 |
PTPRT,DMD,SASH1,TNIK,PRKG1,ZBTB20,NTRK2 |
3.060e-02 | -3.49 | DC | prosite domains | PS50309 | 9 | 1 | 12186 | 42 |
DCLK1 |
3.060e-02 | -3.49 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 42 |
CST3 |
3.066e-02 | -3.48 | regulation of phosphorus metabolic process | biological process | GO:0051174 | 1155 | 7 | 18204 | 48 |
NTRK2,ZBTB20,SASH1,DMD,PTPRT,TNIK,PRKG1 |
3.072e-02 | -3.48 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 25 | 16828 | 48 |
DMD,CTNNA3,PTPRT,NTM,CLU,PHYHIPL,CTNND2,SASH1,ATP1A2,NTRK2,PTPRZ1,GRID2,LIFR,SPON1,GRIA4,LAMA2,CPE,GRIA1,TNIK,NRG3,PRKG1,DCLK1,GABRB1,ZBTB20,DGKG |
3.072e-02 | -3.48 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 25 | 16828 | 48 |
PHYHIPL,CTNND2,NTRK2,ATP1A2,SASH1,DMD,PTPRT,CTNNA3,CLU,NTM,DCLK1,PRKG1,GABRB1,ZBTB20,DGKG,GRID2,PTPRZ1,SPON1,LIFR,GRIA4,LAMA2,NRG3,TNIK,GRIA1,CPE |
3.091e-02 | -3.48 | positive regulation of cell differentiation | biological process | GO:0045597 | 906 | 6 | 18204 | 48 |
NTRK2,QKI,GFAP,SOX6,LAMA2,PTPRZ1 |
3.093e-02 | -3.48 | ERRFI1 (ERBB receptor feedback inhibitor 1) | protein interactions | 54206 | 107 | 2 | 19454 | 50 |
GFAP,PHYHIPL |
3.119e-02 | -3.47 | protein tyrosine phosphatase activity | molecular function | GO:0004725 | 100 | 2 | 18094 | 50 |
PTPRZ1,PTPRT |
3.120e-02 | -3.47 | heparan sulfate proteoglycan biosynthetic process, enzymatic modification | biological process | GO:0015015 | 12 | 1 | 18204 | 48 |
HS6ST3 |
3.120e-02 | -3.47 | microglia differentiation | biological process | GO:0014004 | 12 | 1 | 18204 | 48 |
QKI |
3.120e-02 | -3.47 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 48 |
CST3 |
3.120e-02 | -3.47 | negative regulation of smooth muscle contraction | biological process | GO:0045986 | 12 | 1 | 18204 | 48 |
PRKG1 |
3.120e-02 | -3.47 | negative regulation of protein localization to cell surface | biological process | GO:2000009 | 12 | 1 | 18204 | 48 |
GPM6B |
3.120e-02 | -3.47 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 48 |
SLC1A2 |
3.120e-02 | -3.47 | regulation of ventricular cardiac muscle cell action potential | biological process | GO:0098911 | 12 | 1 | 18204 | 48 |
CTNNA3 |
3.120e-02 | -3.47 | auditory behavior | biological process | GO:0031223 | 12 | 1 | 18204 | 48 |
SLC1A3 |
3.120e-02 | -3.47 | positive regulation of membrane potential | biological process | GO:0045838 | 12 | 1 | 18204 | 48 |
GRIA1 |
3.120e-02 | -3.47 | positive regulation of integrin-mediated signaling pathway | biological process | GO:2001046 | 12 | 1 | 18204 | 48 |
LAMA2 |
3.120e-02 | -3.47 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 48 |
CST3 |
3.129e-02 | -3.46 | gland morphogenesis | biological process | GO:0022612 | 105 | 2 | 18204 | 48 |
NRG3,CSMD1 |
3.139e-02 | -3.46 | regulation of blood circulation | biological process | GO:1903522 | 261 | 3 | 18204 | 48 |
CTNNA3,DMD,ATP1A2 |
3.147e-02 | -3.46 | HSP90AA4P (heat shock protein 90 alpha family class A member 4, pseudogene) | protein interactions | 3323 | 108 | 2 | 19454 | 50 |
SMOC1,DTNA |
3.147e-02 | -3.46 | BIN1 (bridging integrator 1) | protein interactions | 274 | 108 | 2 | 19454 | 50 |
GPM6A,CLU |
3.190e-02 | -3.45 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 48 |
CPE |
3.190e-02 | -3.45 | Sulfotransfer_2 | pfam domains | PF03567 | 12 | 1 | 17795 | 48 |
HS6ST3 |
3.193e-02 | -3.44 | MAP_kinase_CS | interpro domains | IPR003527 | 12 | 1 | 18521 | 50 |
MAPK10 |
3.193e-02 | -3.44 | Sulfotransferase | interpro domains | IPR005331 | 12 | 1 | 18521 | 50 |
HS6ST3 |
3.200e-02 | -3.44 | SIPA1L3 (signal induced proliferation associated 1 like 3) | protein interactions | 23094 | 109 | 2 | 19454 | 50 |
GFAP,GRIK1 |
3.204e-02 | -3.44 | human chr9q21.33 | chromosome location | human chr9q21.33 | 17 | 1 | 26134 | 50 |
NTRK2 |
3.204e-02 | -3.44 | human chr5q33.2 | chromosome location | human chr5q33.2 | 17 | 1 | 26134 | 50 |
GRIA1 |
3.207e-02 | -3.44 | chemical homeostasis | biological process | GO:0048878 | 914 | 6 | 18204 | 48 |
SLC1A3,CSMD1,AQP4,ZBTB20,ATP1A2,GRIA1 |
3.220e-02 | -3.44 | Ionotropic activity of Kainate Receptors | REACTOME pathways | R-HSA-451306 | 12 | 1 | 10285 | 28 |
GRIK1 |
3.220e-02 | -3.44 | Activation of Ca-permeable Kainate Receptor | REACTOME pathways | R-HSA-451308 | 12 | 1 | 10285 | 28 |
GRIK1 |
3.222e-02 | -3.44 | cGMP signaling | KEGG pathways | M00694 | 9 | 1 | 7161 | 26 |
PRKG1 |
3.222e-02 | -3.44 | cGMP signaling | KEGG pathways | hsa_M00694 | 9 | 1 | 7161 | 26 |
PRKG1 |
3.223e-02 | -3.43 | positive regulation of cell development | biological process | GO:0010720 | 458 | 4 | 18204 | 48 |
QKI,NTRK2,PTPRZ1,GFAP |
3.237e-02 | -3.43 | phosphorus metabolic process | biological process | GO:0006793 | 1707 | 9 | 18204 | 48 |
DCLK1,NTRK2,ATP1A2,TNIK,PRKG1,DGKG,MAPK10,PTPRT,PTPRZ1 |
3.243e-02 | -3.43 | large_intestine-rectum-adenoma | COSMIC cancer mutations | large_intestine-rectum-adenoma | 99 | 2 | 16828 | 48 |
NTRK2,LIFR |
3.247e-02 | -3.43 | LamB | smart domains | SM00281 | 8 | 1 | 9717 | 40 |
LAMA2 |
3.267e-02 | -3.42 | gamma-catenin binding | molecular function | GO:0045295 | 12 | 1 | 18094 | 50 |
PTPRT |
3.267e-02 | -3.42 | G protein-coupled neurotransmitter receptor activity | molecular function | GO:0099528 | 12 | 1 | 18094 | 50 |
GABRB1 |
3.267e-02 | -3.42 | vinculin binding | molecular function | GO:0017166 | 12 | 1 | 18094 | 50 |
DMD |
3.267e-02 | -3.42 | adenylate cyclase binding | molecular function | GO:0008179 | 12 | 1 | 18094 | 50 |
GRIA1 |
3.267e-02 | -3.42 | dipeptidyl-peptidase activity | molecular function | GO:0008239 | 12 | 1 | 18094 | 50 |
DPP6 |
3.281e-02 | -3.42 | distal axon | cellular component | GO:0150034 | 273 | 3 | 19108 | 49 |
NTRK2,GPM6A,PCDH9 |
3.284e-02 | -3.42 | cytoplasmic side of lysosomal membrane | cellular component | GO:0098574 | 13 | 1 | 19108 | 49 |
GFAP |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | KCNQ2 (potassium voltage-gated channel subfamily Q member 2) | protein interactions | 3785 | 13 | 1 | 19454 | 50 |
GRIK1 |
3.291e-02 | -3.41 | EID2B (EP300 interacting inhibitor of differentiation 2B) | protein interactions | 126272 | 13 | 1 | 19454 | 50 |
CTNNA3 |
3.291e-02 | -3.41 | Rbm47 (RNA binding motif protein 47) | protein interactions | 245945 | 13 | 1 | 19454 | 50 |
QKI |
3.312e-02 | -3.41 | cell migration | biological process | GO:0016477 | 921 | 6 | 18204 | 48 |
PRKG1,GPM6A,CTNNA3,NTRK2,DCLK1,NRG3 |
3.312e-02 | -3.41 | Protein tyrosine phosphatase superfamily | gene3d domains | 3.90.190.10 | 88 | 2 | 14470 | 47 |
PTPRZ1,PTPRT |
3.319e-02 | -3.41 | arm | COSMIC cancer mutations | arm | 1331 | 8 | 16828 | 48 |
GRID2,NPAS3,ZBTB20,GRIA4,PDZRN4,PTPRT,NTM,ATP1A2 |
3.322e-02 | -3.40 | protein domain specific binding | molecular function | GO:0019904 | 651 | 5 | 18094 | 50 |
QKI,GRID2,DTNA,GRIA1,SPON1 |
3.333e-02 | -3.40 | cellular response to organic substance | biological process | GO:0071310 | 1716 | 9 | 18204 | 48 |
ATP1A2,SLC1A3,AQP4,ZBTB20,GABRB1,SLC1A2,LIFR,GRIA1,PTPRT |
3.349e-02 | -3.40 | endometrium-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-endometrioid_carcinoma | 15680 | 48 | 16828 | 48 |
ZBTB20,PCDH9,DGKG,DCLK1,PRKG1,SOX6,GABRB1,DTNA,GLIS3,CPE,NRG3,TNIK,GRIK1,LIFR,NPAS3,PDZRN4,SASH1,SLC1A3,PHYHIPL,GPM6A,GPM6B,GFAP,QKI,PPP2R2B,CTNNA3,CLU,DPP6,MYO16,CST3,LSAMP,DMD,SLC1A2,LAMA2,GRIA4,GRIA1,GRID2,PTPRZ1,SPON1,AQP4,CTNND2,SPARCL1,NTRK2,ATP1A2,HS6ST3,PTPRT,NTM,SMOC1,GABBR2 |
3.351e-02 | -3.40 | positive regulation of tumor necrosis factor production | biological process | GO:0032760 | 109 | 2 | 18204 | 48 |
ZBTB20,CLU |
3.352e-02 | -3.40 | exopeptidase activity | molecular function | GO:0008238 | 104 | 2 | 18094 | 50 |
CPE,DPP6 |
3.363e-02 | -3.39 | HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1) | protein interactions | 3157 | 112 | 2 | 19454 | 50 |
GPM6A,PPP2R2B |
3.371e-02 | -3.39 | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | 12 | 1 | 16828 | 48 |
QKI |
3.375e-02 | -3.39 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 48 |
ATP1A2 |
3.375e-02 | -3.39 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 1 | 18204 | 48 |
CLU |
3.375e-02 | -3.39 | regulation of postsynaptic density assembly | biological process | GO:0099151 | 13 | 1 | 18204 | 48 |
GRID2 |
3.375e-02 | -3.39 | ectodermal placode development | biological process | GO:0071696 | 13 | 1 | 18204 | 48 |
NRG3 |
3.375e-02 | -3.39 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 48 |
ATP1A2 |
3.375e-02 | -3.39 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 48 |
GRID2 |
3.375e-02 | -3.39 | negative regulation of homotypic cell-cell adhesion | biological process | GO:0034111 | 13 | 1 | 18204 | 48 |
PRKG1 |
3.375e-02 | -3.39 | cerebellar granular layer development | biological process | GO:0021681 | 13 | 1 | 18204 | 48 |
GRID2 |
3.383e-02 | -3.39 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 48 |
PRKG1,DCLK1,TNIK,NTRK2 |
3.383e-02 | -3.39 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 48 |
PRKG1,DCLK1,TNIK,NTRK2 |
3.383e-02 | -3.39 | TYR_PHOSPHATASE_2 | prosite domains | PS50056 | 84 | 2 | 12186 | 42 |
PTPRT,PTPRZ1 |
3.386e-02 | -3.39 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 5 | 10285 | 28 |
ATP1A2,SLC1A2,SLC1A3,AQP4,GABRB1 |
3.388e-02 | -3.38 | PICK1 (protein interacting with PRKCA 1) | protein interactions | 9463 | 477 | 4 | 19454 | 50 |
DMD,GRIK1,GRIA4,GRIA1 |
3.389e-02 | -3.38 | human chr4p12 | chromosome location | human chr4p12 | 18 | 1 | 26134 | 50 |
GABRB1 |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.395e-02 | -3.38 | MIP | prosite domains | PS00221 | 10 | 1 | 12186 | 42 |
AQP4 |
3.395e-02 | -3.38 | MAM_1 | prosite domains | PS00740 | 10 | 1 | 12186 | 42 |
PTPRT |
3.397e-02 | -3.38 | import into cell | biological process | GO:0098657 | 687 | 5 | 18204 | 48 |
GFAP,SLC1A2,GRIA1,ATP1A2,SLC1A3 |
3.400e-02 | -3.38 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 2 | 10285 | 28 |
SLC1A2,SLC1A3 |
3.408e-02 | -3.38 | chloride transmembrane transport | biological process | GO:1902476 | 110 | 2 | 18204 | 48 |
GABRB1,SLC1A3 |
3.408e-02 | -3.38 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 2 | 18204 | 48 |
NTRK2,GRID2 |
3.418e-02 | -3.38 | UBR2 (ubiquitin protein ligase E3 component n-recognin 2) | protein interactions | 23304 | 113 | 2 | 19454 | 50 |
GFAP,SMOC1 |
3.420e-02 | -3.38 | rhythmic process | biological process | GO:0048511 | 270 | 3 | 18204 | 48 |
GABRB1,MAPK10,NTRK2 |
3.453e-02 | -3.37 | endometrioid_carcinoma | COSMIC cancer mutations | endometrioid_carcinoma | 15690 | 48 | 16828 | 48 |
NTM,PTPRT,GABBR2,SMOC1,ATP1A2,NTRK2,SPARCL1,CTNND2,AQP4,HS6ST3,GRIA1,GRIA4,LAMA2,SPON1,PTPRZ1,GRID2,SLC1A2,CLU,DPP6,QKI,PPP2R2B,CTNNA3,GFAP,GPM6B,GPM6A,DMD,LSAMP,CST3,MYO16,SASH1,PDZRN4,PHYHIPL,SLC1A3,GRIK1,TNIK,NRG3,CPE,GLIS3,NPAS3,LIFR,DGKG,PCDH9,ZBTB20,DTNA,GABRB1,SOX6,PRKG1,DCLK1 |
3.474e-02 | -3.36 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 50 |
PCDH9,ZBTB20 |
3.474e-02 | -3.36 | endometrium | COSMIC cancer mutations | endometrium | 15692 | 48 | 16828 | 48 |
NTM,PTPRT,GABBR2,SMOC1,SPARCL1,ATP1A2,NTRK2,AQP4,CTNND2,HS6ST3,GRIA1,LAMA2,GRIA4,SPON1,PTPRZ1,GRID2,SLC1A2,CLU,DPP6,GPM6B,GPM6A,QKI,CTNNA3,PPP2R2B,GFAP,DMD,MYO16,CST3,LSAMP,SASH1,PDZRN4,PHYHIPL,SLC1A3,CPE,GLIS3,GRIK1,TNIK,NRG3,LIFR,NPAS3,PCDH9,DGKG,ZBTB20,DTNA,SOX6,GABRB1,PRKG1,DCLK1 |
3.484e-02 | -3.36 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 1 | 10285 | 28 |
NRG3 |
3.484e-02 | -3.36 | GABA A receptor activation | REACTOME pathways | R-HSA-977441 | 13 | 1 | 10285 | 28 |
GABRB1 |
3.484e-02 | -3.36 | Passive transport by Aquaporins | REACTOME pathways | R-HSA-432047 | 13 | 1 | 10285 | 28 |
AQP4 |
3.514e-02 | -3.35 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 47 | 16828 | 48 |
NPAS3,LIFR,NRG3,GRIK1,TNIK,GLIS3,CPE,DCLK1,PRKG1,GABRB1,SOX6,DTNA,ZBTB20,DGKG,PCDH9,LSAMP,CST3,MYO16,DMD,GFAP,QKI,PPP2R2B,CTNNA3,GPM6A,GPM6B,DPP6,CLU,SLC1A3,PHYHIPL,PDZRN4,SASH1,GRID2,PTPRZ1,LAMA2,GRIA4,GRIA1,SLC1A2,SMOC1,GABBR2,PTPRT,NTM,HS6ST3,CTNND2,AQP4,NTRK2,ATP1A2,SPARCL1 |
3.514e-02 | -3.35 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 47 | 16828 | 48 |
SLC1A3,PHYHIPL,SASH1,PDZRN4,DMD,LSAMP,CST3,MYO16,DPP6,CLU,GFAP,QKI,PPP2R2B,CTNNA3,GPM6A,GPM6B,GABRB1,SOX6,DTNA,DCLK1,PRKG1,DGKG,PCDH9,ZBTB20,NPAS3,LIFR,NRG3,GRIK1,TNIK,GLIS3,CPE,HS6ST3,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,GABBR2,SMOC1,NTM,PTPRT,SLC1A2,GRID2,PTPRZ1,GRIA1,GRIA4,LAMA2 |
3.517e-02 | -3.35 | homeostatic process | biological process | GO:0042592 | 1456 | 8 | 18204 | 48 |
ATP1A2,ZBTB20,AQP4,CSMD1,SLC1A3,LAMA2,DMD,GRIA1 |
3.517e-02 | -3.35 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 47 |
CPE |
3.527e-02 | -3.34 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 3 | 5310 | 24 |
NTRK2,AQP4,SLC1A3 |
3.528e-02 | -3.34 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 12 | 16828 | 48 |
GRIA1,CLU,PPP2R2B,LAMA2,GABBR2,SPON1,NPAS3,GRID2,SASH1,SPARCL1,SLC1A3,DCLK1 |
3.528e-02 | -3.34 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 12 | 16828 | 48 |
GRID2,SPON1,GABBR2,NPAS3,LAMA2,PPP2R2B,GRIA1,CLU,DCLK1,SLC1A3,SASH1,SPARCL1 |
3.530e-02 | -3.34 | DTNA (dystrobrevin alpha) | protein interactions | 1837 | 115 | 2 | 19454 | 50 |
DMD,NTRK2 |
3.530e-02 | -3.34 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 2 | 19454 | 50 |
CTNND2,CTNNA3 |
3.532e-02 | -3.34 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 49 |
CLU |
3.535e-02 | -3.34 | GABA-gated chloride ion channel activity | molecular function | GO:0022851 | 13 | 1 | 18094 | 50 |
GABRB1 |
3.535e-02 | -3.34 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 50 |
ATP1A2 |
3.540e-02 | -3.34 | GRID2 (glutamate ionotropic receptor delta type subunit 2) | protein interactions | 2895 | 14 | 1 | 19454 | 50 |
GRIA1 |
3.540e-02 | -3.34 | C9 (complement C9) | protein interactions | 735 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 50 |
CST3 |
3.540e-02 | -3.34 | Stag2 (STAG2 cohesin complex component) | protein interactions | 20843 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | JMJD7-PLA2G4B (JMJD7-PLA2G4B readthrough) | protein interactions | 8681 | 14 | 1 | 19454 | 50 |
PPP2R2B |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | FCGBP (Fc gamma binding protein) | protein interactions | 8857 | 14 | 1 | 19454 | 50 |
PPP2R2B |
3.540e-02 | -3.34 | SH3YL1 (SH3 and SYLF domain containing 1) | protein interactions | 26751 | 14 | 1 | 19454 | 50 |
GFAP |
3.540e-02 | -3.34 | GAGE1 (G antigen 1) | protein interactions | 2543 | 14 | 1 | 19454 | 50 |
PRKG1 |
3.540e-02 | -3.34 | SPRR2D (small proline rich protein 2D) | protein interactions | 6703 | 14 | 1 | 19454 | 50 |
PPP2R2B |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
ZBTB20 |
3.540e-02 | -3.34 | Aifm1 (apoptosis-inducing factor, mitochondrion-associated 1) | protein interactions | 26926 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | CABS1 (calcium binding protein, spermatid associated 1) | protein interactions | 85438 | 14 | 1 | 19454 | 50 |
GFAP |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.549e-02 | -3.34 | extracellular matrix organization | biological process | GO:0030198 | 274 | 3 | 18204 | 48 |
SMOC1,GFAP,GPM6B |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.579e-02 | -3.33 | heart process | biological process | GO:0003015 | 113 | 2 | 18204 | 48 |
DMD,ATP1A2 |
3.579e-02 | -3.33 | positive regulation of tumor necrosis factor superfamily cytokine production | biological process | GO:1903557 | 113 | 2 | 18204 | 48 |
CLU,ZBTB20 |
3.579e-02 | -3.33 | developmental cell growth | biological process | GO:0048588 | 113 | 2 | 18204 | 48 |
PRKG1,DCLK1 |
3.582e-02 | -3.33 | extracellular structure organization | biological process | GO:0043062 | 275 | 3 | 18204 | 48 |
SMOC1,GPM6B,GFAP |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
SASH1,SPARCL1 |
3.592e-02 | -3.33 | PRKACA (protein kinase cAMP-activated catalytic subunit alpha) | protein interactions | 5566 | 486 | 4 | 19454 | 50 |
TNIK,GFAP,GRIA1,GRIA4 |
3.604e-02 | -3.32 | Hypertrophic cardiomyopathy (HCM) | KEGG pathways | ko05410 | 83 | 2 | 7161 | 26 |
DMD,LAMA2 |
3.604e-02 | -3.32 | Hypertrophic cardiomyopathy (HCM) | KEGG pathways | hsa05410 | 83 | 2 | 7161 | 26 |
LAMA2,DMD |
3.609e-02 | -3.32 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 4 | 16828 | 48 |
DCLK1,PRKG1,NTRK2,TNIK |
3.615e-02 | -3.32 | external encapsulating structure organization | biological process | GO:0045229 | 276 | 3 | 18204 | 48 |
SMOC1,GFAP,GPM6B |
3.630e-02 | -3.32 | mechanosensory behavior | biological process | GO:0007638 | 14 | 1 | 18204 | 48 |
SLC1A3 |
3.630e-02 | -3.32 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 48 |
ATP1A2 |
3.630e-02 | -3.32 | regulation of protein K63-linked ubiquitination | biological process | GO:1900044 | 14 | 1 | 18204 | 48 |
SASH1 |
3.630e-02 | -3.32 | positive regulation of sodium ion transmembrane transporter activity | biological process | GO:2000651 | 14 | 1 | 18204 | 48 |
DMD |
3.630e-02 | -3.32 | negative regulation of adenylate cyclase activity | biological process | GO:0007194 | 14 | 1 | 18204 | 48 |
GABBR2 |
3.630e-02 | -3.32 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 1 | 18204 | 48 |
ATP1A2 |
3.630e-02 | -3.32 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 48 |
SLC1A2 |
3.630e-02 | -3.32 | regulation of long-term synaptic depression | biological process | GO:1900452 | 14 | 1 | 18204 | 48 |
GRID2 |
3.630e-02 | -3.32 | negative regulation of cardiocyte differentiation | biological process | GO:1905208 | 14 | 1 | 18204 | 48 |
SOX6 |
3.630e-02 | -3.32 | bundle of His cell to Purkinje myocyte communication | biological process | GO:0086069 | 14 | 1 | 18204 | 48 |
CTNNA3 |
3.630e-02 | -3.32 | cerebrospinal fluid circulation | biological process | GO:0090660 | 14 | 1 | 18204 | 48 |
AQP4 |
3.630e-02 | -3.32 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 48 |
ATP1A2 |
3.637e-02 | -3.31 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 2 | 18204 | 48 |
PRKG1,MAPK10 |
3.642e-02 | -3.31 | ZMYND19 (zinc finger MYND-type containing 19) | protein interactions | 116225 | 117 | 2 | 19454 | 50 |
CTNND2,SPON1 |
3.646e-02 | -3.31 | DCX | smart domains | SM00537 | 9 | 1 | 9717 | 40 |
DCLK1 |
3.646e-02 | -3.31 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 40 |
SPARCL1 |
3.647e-02 | -3.31 | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | 13 | 1 | 16828 | 48 |
QKI |
3.656e-02 | -3.31 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 48 |
DCLK1,PRKG1,LAMA2,NTRK2,TNIK |
3.695e-02 | -3.30 | cell growth | biological process | GO:0016049 | 115 | 2 | 18204 | 48 |
PRKG1,DCLK1 |
3.699e-02 | -3.30 | CEACAM8 (CEA cell adhesion molecule 8) | protein interactions | 1088 | 118 | 2 | 19454 | 50 |
CLU,CPE |
3.712e-02 | -3.29 | MIP | pfam domains | PF00230 | 14 | 1 | 17795 | 48 |
AQP4 |
3.713e-02 | -3.29 | structural constituent of cytoskeleton | molecular function | GO:0005200 | 110 | 2 | 18094 | 50 |
DMD,GFAP |
3.715e-02 | -3.29 | GPCR_3 | interpro domains | IPR000337 | 14 | 1 | 18521 | 50 |
GABBR2 |
3.715e-02 | -3.29 | GPCR_3_CS | interpro domains | IPR017979 | 14 | 1 | 18521 | 50 |
GABBR2 |
3.715e-02 | -3.29 | Aquaporin-like | interpro domains | IPR023271 | 14 | 1 | 18521 | 50 |
AQP4 |
3.715e-02 | -3.29 | MIP | interpro domains | IPR000425 | 14 | 1 | 18521 | 50 |
AQP4 |
3.726e-02 | -3.29 | transferase activity, transferring phosphorus-containing groups | molecular function | GO:0016772 | 903 | 6 | 18094 | 50 |
TNIK,DCLK1,NTRK2,MAPK10,PRKG1,DGKG |
3.728e-02 | -3.29 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 1 | 12186 | 42 |
NTRK2 |
3.728e-02 | -3.29 | G_PROTEIN_RECEP_F3_3 | prosite domains | PS00981 | 11 | 1 | 12186 | 42 |
GABBR2 |
3.747e-02 | -3.28 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 1 | 10285 | 28 |
NRG3 |
3.756e-02 | -3.28 | RBM7 (RNA binding motif protein 7) | protein interactions | 10179 | 119 | 2 | 19454 | 50 |
PPP2R2B,QKI |
3.756e-02 | -3.28 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 2 | 19454 | 50 |
CLU,PCDH9 |
3.759e-02 | -3.28 | human chr10q21.1 | chromosome location | human chr10q21.1 | 20 | 1 | 26134 | 50 |
PHYHIPL |
3.759e-02 | -3.28 | human chr8p21.1 | chromosome location | human chr8p21.1 | 20 | 1 | 26134 | 50 |
CLU |
3.764e-02 | -3.28 | Sufentanil Action Pathway | SMPDB pathways | SMP0000417 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Remifentanil Action Pathway | SMPDB pathways | SMP0000416 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Escitalopram Action Pathway | SMPDB pathways | SMP0000425 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levobupivacaine Action Pathway | SMPDB pathways | SMP0000397 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levorphanol Action Pathway | SMPDB pathways | SMP0000673 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Hydrocodone Action Pathway | SMPDB pathways | SMP0000411 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxycodone Action Pathway | SMPDB pathways | SMP0000409 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Anileridine Action Pathway | SMPDB pathways | SMP0000674 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dibucaine Action Pathway | SMPDB pathways | SMP0000396 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Pentazocine Action Pathway | SMPDB pathways | SMP0000686 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Naltrexone Action Pathway | SMPDB pathways | SMP0000687 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ropivacaine Action Pathway | SMPDB pathways | SMP0000404 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Proparacaine Action Pathway | SMPDB pathways | SMP0000403 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ethylmorphine Action Pathway | SMPDB pathways | SMP0000681 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | 3-Methylthiofentanyl Action Pathway | SMPDB pathways | SMP0000679 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Propoxyphene Action Pathway | SMPDB pathways | SMP0000672 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Naloxone Action Pathway | SMPDB pathways | SMP0000688 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dimethylthiambutene Action Pathway | SMPDB pathways | SMP0000680 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Alvimopan Action Pathway | SMPDB pathways | SMP0000685 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Cocaine Action Pathway | SMPDB pathways | SMP0000395 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Procaine Action Pathway | SMPDB pathways | SMP0000402 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Fentanyl Action Pathway | SMPDB pathways | SMP0000415 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Hydromorphone Action Pathway | SMPDB pathways | SMP0000410 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levomethadyl Acetate Action Action Pathway | SMPDB pathways | SMP0000677 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Bupivacaine Action Pathway | SMPDB pathways | SMP0000393 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Chloroprocaine Action Pathway | SMPDB pathways | SMP0000394 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dezocine Action Pathway | SMPDB pathways | SMP0000676 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ketobemidone Action Pathway | SMPDB pathways | SMP0000690 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dihydromorphine Action Pathway | SMPDB pathways | SMP0000689 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Alfentanil Action Pathway | SMPDB pathways | SMP0000413 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Tramadol Action Action Pathway | SMPDB pathways | SMP0000671 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Carfentanil Action Pathway | SMPDB pathways | SMP0000414 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Mepivacaine Action Pathway | SMPDB pathways | SMP0000399 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Buprenorphine Action Pathway | SMPDB pathways | SMP0000684 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Prilocaine Action Pathway | SMPDB pathways | SMP0000401 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levallorphan Action Pathway | SMPDB pathways | SMP0000683 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxymorphone Action Pathway | SMPDB pathways | SMP0000412 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxybuprocaine Action Pathway | SMPDB pathways | SMP0000400 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Benzocaine Action Pathway | SMPDB pathways | SMP0000392 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Methadyl Acetate Action Pathway | SMPDB pathways | SMP0000678 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Diphenoxylate Action Pathway | SMPDB pathways | SMP0000675 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | ErbB signaling pathway | KEGG pathways | ko04012 | 85 | 2 | 7161 | 26 |
MAPK10,NRG3 |
3.764e-02 | -3.28 | ErbB signaling pathway | KEGG pathways | hsa04012 | 85 | 2 | 7161 | 26 |
NRG3,MAPK10 |
3.779e-02 | -3.28 | NEDD4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 4734 | 494 | 4 | 19454 | 50 |
GLIS3,GRIA1,DMD,TNIK |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.780e-02 | -3.28 | dendritic spine membrane | cellular component | GO:0032591 | 15 | 1 | 19108 | 49 |
GRIA1 |
3.788e-02 | -3.27 | NPR1 (natriuretic peptide receptor 1) | protein interactions | 4881 | 15 | 1 | 19454 | 50 |
PRKG1 |
3.788e-02 | -3.27 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 50 |
TNIK |
3.788e-02 | -3.27 | FERD3L (Fer3 like bHLH transcription factor) | protein interactions | 222894 | 15 | 1 | 19454 | 50 |
CTNNA3 |
3.813e-02 | -3.27 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 2 | 18204 | 48 |
GRID2,NTRK2 |
3.814e-02 | -3.27 | ZDHHC15 (zinc finger DHHC-type palmitoyltransferase 15) | protein interactions | 158866 | 120 | 2 | 19454 | 50 |
DMD,LAMA2 |
3.830e-02 | -3.26 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 47 |
CTNNA3 |
3.849e-02 | -3.26 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 3 | 18204 | 48 |
TNIK,CTNND2,CPE |
3.854e-02 | -3.26 | regulation of transmembrane transport | biological process | GO:0034762 | 485 | 4 | 18204 | 48 |
ATP1A2,DPP6,DMD,SLC1A2 |
3.884e-02 | -3.25 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 47 | 16828 | 48 |
SPARCL1,NTRK2,ATP1A2,AQP4,CTNND2,HS6ST3,NTM,PTPRT,GABBR2,SMOC1,SLC1A2,GRIA1,LAMA2,GRIA4,SPON1,GRID2,PTPRZ1,SASH1,PDZRN4,SLC1A3,PHYHIPL,DPP6,CLU,GPM6A,GPM6B,GFAP,PPP2R2B,CTNNA3,QKI,DMD,MYO16,LSAMP,PCDH9,DGKG,ZBTB20,SOX6,GABRB1,DTNA,DCLK1,PRKG1,GLIS3,CPE,NRG3,GRIK1,TNIK,LIFR,NPAS3 |
3.884e-02 | -3.25 | peripheral nervous system neuron differentiation | biological process | GO:0048934 | 15 | 1 | 18204 | 48 |
NTRK2 |
3.884e-02 | -3.25 | negative regulation of cyclase activity | biological process | GO:0031280 | 15 | 1 | 18204 | 48 |
GABBR2 |
3.884e-02 | -3.25 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 48 |
ATP1A2 |
3.884e-02 | -3.25 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 48 |
ATP1A2 |
3.884e-02 | -3.25 | peripheral nervous system neuron development | biological process | GO:0048935 | 15 | 1 | 18204 | 48 |
NTRK2 |
3.884e-02 | -3.25 | collateral sprouting | biological process | GO:0048668 | 15 | 1 | 18204 | 48 |
PRKG1 |
3.884e-02 | -3.25 | negative regulation of amino acid transport | biological process | GO:0051956 | 15 | 1 | 18204 | 48 |
PRKG1 |
3.884e-02 | -3.25 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 48 |
SLC1A2 |
3.884e-02 | -3.25 | regulation of inositol phosphate biosynthetic process | biological process | GO:0010919 | 15 | 1 | 18204 | 48 |
PRKG1 |
3.894e-02 | -3.25 | NAKATPASE | prints domains | PR00121 | 9 | 1 | 5227 | 23 |
ATP1A2 |
3.907e-02 | -3.24 | Nalbuphine Action Pathway | SMPDB pathways | SMP0000691 | 27 | 1 | 1369 | 2 |
ATP1A2 |
3.907e-02 | -3.24 | Desipramine Action Pathway | SMPDB pathways | SMP0000423 | 27 | 1 | 1369 | 2 |
ATP1A2 |
3.923e-02 | -3.24 | DNA-binding transcription repressor activity | molecular function | GO:0001217 | 272 | 3 | 18094 | 50 |
SOX6,ZBTB20,GLIS3 |
3.923e-02 | -3.24 | phosphatase activity | molecular function | GO:0016791 | 272 | 3 | 18094 | 50 |
ATP1A2,PTPRT,PTPRZ1 |
3.925e-02 | -3.24 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 9 | 16828 | 48 |
SASH1,GRIK1,ZBTB20,GABBR2,NPAS3,PRKG1,MYO16,PTPRZ1,GRID2 |
3.930e-02 | -3.24 | MED31 (mediator complex subunit 31) | protein interactions | 51003 | 122 | 2 | 19454 | 50 |
CPE,QKI |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.943e-02 | -3.23 | human chr13q32.1 | chromosome location | human chr13q32.1 | 21 | 1 | 26134 | 50 |
HS6ST3 |
3.943e-02 | -3.23 | human chr10q23.1 | chromosome location | human chr10q23.1 | 21 | 1 | 26134 | 50 |
NRG3 |
3.972e-02 | -3.23 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 48 |
ATP1A2 |
3.972e-02 | -3.23 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 48 |
TNIK |
3.972e-02 | -3.23 | DAGK_cat | pfam domains | PF00781 | 15 | 1 | 17795 | 48 |
DGKG |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | Diacylglycerol_kinase_cat_dom | interpro domains | IPR001206 | 15 | 1 | 18521 | 50 |
DGKG |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.992e-02 | -3.22 | regulation of peptidyl-serine phosphorylation | biological process | GO:0033135 | 120 | 2 | 18204 | 48 |
DMD,NTRK2 |
3.995e-02 | -3.22 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 3 | 18094 | 50 |
ATP1A2,SLC1A2,SLC1A3 |
4.008e-02 | -3.22 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 4 | 12186 | 42 |
TNIK,DCLK1,PRKG1,NTRK2 |
4.009e-02 | -3.22 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 1 | 10285 | 28 |
NRG3 |
4.009e-02 | -3.22 | GABAergic synapse | KEGG pathways | ko04727 | 88 | 2 | 7161 | 26 |
GABRB1,GABBR2 |
4.009e-02 | -3.22 | GABAergic synapse | KEGG pathways | hsa04727 | 88 | 2 | 7161 | 26 |
GABBR2,GABRB1 |
4.022e-02 | -3.21 | ErbB receptor signaling network | Pathway Interaction DB | erbb_network_pathway | 13 | 1 | 2226 | 7 |
NRG3 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | KCNJ4 (potassium inwardly rectifying channel subfamily J member 4) | protein interactions | 3761 | 16 | 1 | 19454 | 50 |
DMD |
4.035e-02 | -3.21 | ORM2 (orosomucoid 2) | protein interactions | 5005 | 16 | 1 | 19454 | 50 |
PPP2R2B |
4.035e-02 | -3.21 | IFFO2 (intermediate filament family orphan 2) | protein interactions | 126917 | 16 | 1 | 19454 | 50 |
GFAP |
4.035e-02 | -3.21 | RETNLB (resistin like beta) | protein interactions | 84666 | 16 | 1 | 19454 | 50 |
SMOC1 |
4.035e-02 | -3.21 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 50 |
CPE |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA3 |
4.035e-02 | -3.21 | CNTFR (ciliary neurotrophic factor receptor) | protein interactions | 1271 | 16 | 1 | 19454 | 50 |
LIFR |
4.035e-02 | -3.21 | TAMALIN (trafficking regulator and scaffold protein tamalin) | protein interactions | 160622 | 16 | 1 | 19454 | 50 |
GABBR2 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | TMCO6 (transmembrane and coiled-coil domains 6) | protein interactions | 55374 | 16 | 1 | 19454 | 50 |
PHYHIPL |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | GABRR1 (gamma-aminobutyric acid type A receptor subunit rho1) | protein interactions | 2569 | 16 | 1 | 19454 | 50 |
PRKG1 |
4.036e-02 | -3.21 | skin-malignant_melanoma | COSMIC cancer mutations | skin-malignant_melanoma | 15741 | 48 | 16828 | 48 |
SLC1A3,PHYHIPL,SASH1,PDZRN4,DMD,CST3,LSAMP,MYO16,CLU,DPP6,GFAP,QKI,PPP2R2B,CTNNA3,GPM6A,GPM6B,SOX6,GABRB1,DTNA,DCLK1,PRKG1,DGKG,PCDH9,ZBTB20,NPAS3,LIFR,NRG3,TNIK,GRIK1,GLIS3,CPE,HS6ST3,NTRK2,ATP1A2,SPARCL1,CTNND2,AQP4,GABBR2,SMOC1,NTM,PTPRT,SLC1A2,SPON1,GRID2,PTPRZ1,GRIA1,LAMA2,GRIA4 |
4.043e-02 | -3.21 | DAGKa | smart domains | SM00045 | 10 | 1 | 9717 | 40 |
DGKG |
4.047e-02 | -3.21 | TNK2 (tyrosine kinase non receptor 2) | protein interactions | 10188 | 124 | 2 | 19454 | 50 |
DCLK1,NTRK2 |
4.050e-02 | -3.21 | Lidocaine (Local Anaesthetic) Action Pathway | SMPDB pathways | SMP0000398 | 28 | 1 | 1369 | 2 |
ATP1A2 |
4.052e-02 | -3.21 | chloride transport | biological process | GO:0006821 | 121 | 2 | 18204 | 48 |
GABRB1,SLC1A3 |
4.055e-02 | -3.21 | muscle cell differentiation | biological process | GO:0042692 | 289 | 3 | 18204 | 48 |
QKI,PRKG1,DMD |
4.059e-02 | -3.20 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 4 | 16828 | 48 |
PRKG1,DCLK1,TNIK,NTRK2 |
4.060e-02 | -3.20 | MAPK | prosite domains | PS01351 | 12 | 1 | 12186 | 42 |
MAPK10 |
4.060e-02 | -3.20 | CNMP_BINDING_2 | prosite domains | PS00889 | 12 | 1 | 12186 | 42 |
PRKG1 |
4.067e-02 | -3.20 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 50 |
CPE |
4.067e-02 | -3.20 | heparan sulfate sulfotransferase activity | molecular function | GO:0034483 | 15 | 1 | 18094 | 50 |
HS6ST3 |
4.076e-02 | -3.20 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 23 | 18204 | 48 |
SPON1,GRIA1,PTPRZ1,GRID2,GPM6A,QKI,LIFR,LAMA2,SLC1A2,GLIS3,CLU,SASH1,GFAP,TNIK,PRKG1,SOX6,ATP1A2,ZBTB20,DMD,GPM6B,NTRK2,SLC1A3,NPAS3 |
4.093e-02 | -3.20 | Dilated cardiomyopathy | KEGG pathways | hsa05414 | 89 | 2 | 7161 | 26 |
LAMA2,DMD |
4.093e-02 | -3.20 | Dilated cardiomyopathy | KEGG pathways | ko05414 | 89 | 2 | 7161 | 26 |
LAMA2,DMD |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
LSAMP,NTRK2,PTPRT,NTM |
4.106e-02 | -3.19 | SLAMF1 (signaling lymphocytic activation molecule family member 1) | protein interactions | 6504 | 125 | 2 | 19454 | 50 |
LIFR,CPE |
4.106e-02 | -3.19 | SCGB1D1 (secretoglobin family 1D member 1) | protein interactions | 10648 | 125 | 2 | 19454 | 50 |
LIFR,CPE |
4.114e-02 | -3.19 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 4 | 16828 | 48 |
PRKG1,DCLK1,TNIK,NTRK2 |
4.118e-02 | -3.19 | lung-carcinoma | COSMIC cancer mutations | lung-carcinoma | 4255 | 18 | 16828 | 48 |
PTPRZ1,LIFR,DMD,GRIA4,GPM6B,CTNNA3,QKI,PPP2R2B,PTPRT,CLU,TNIK,PRKG1,DCLK1,HS6ST3,CTNND2,PDZRN4,NTRK2,DGKG |
4.138e-02 | -3.18 | glutamatergic neuron differentiation | biological process | GO:1905962 | 16 | 1 | 18204 | 48 |
GRID2 |
4.138e-02 | -3.18 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 48 |
SLC1A2 |
4.138e-02 | -3.18 | heparan sulfate proteoglycan metabolic process | biological process | GO:0030201 | 16 | 1 | 18204 | 48 |
HS6ST3 |
4.138e-02 | -3.18 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 48 |
CPE |
4.138e-02 | -3.18 | response to lithium ion | biological process | GO:0010226 | 16 | 1 | 18204 | 48 |
GRIA1 |
4.138e-02 | -3.18 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 48 |
CPE |
4.138e-02 | -3.18 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | regulation of postsynaptic specialization assembly | biological process | GO:0099150 | 16 | 1 | 18204 | 48 |
GRID2 |
4.138e-02 | -3.18 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 48 |
SLC1A3 |
4.152e-02 | -3.18 | calcium channel activity | molecular function | GO:0005262 | 117 | 2 | 18094 | 50 |
GRIA1,GPM6A |
4.152e-02 | -3.18 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 2 | 18094 | 50 |
SLC1A2,SLC1A3 |
4.166e-02 | -3.18 | SERPINA3 (serpin family A member 3) | protein interactions | 12 | 126 | 2 | 19454 | 50 |
CLU,PPP2R2B |
4.166e-02 | -3.18 | DAG1 (dystroglycan 1) | protein interactions | 1605 | 126 | 2 | 19454 | 50 |
DMD,LAMA2 |
4.185e-02 | -3.17 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 8 | 18204 | 48 |
SLC1A2,CPE,NTRK2,QKI,CLU,SLC1A3,GPM6B,GFAP |
4.193e-02 | -3.17 | Codeine Action Pathway | SMPDB pathways | SMP0000405 | 29 | 1 | 1369 | 2 |
ATP1A2 |
4.196e-02 | -3.17 | hypothalamus | COSMIC cancer mutations | hypothalamus | 15 | 1 | 16828 | 48 |
QKI |
4.226e-02 | -3.16 | DES (desmin) | protein interactions | 1674 | 127 | 2 | 19454 | 50 |
GFAP,DTNA |
4.231e-02 | -3.16 | Laminin_N | pfam domains | PF00055 | 16 | 1 | 17795 | 48 |
LAMA2 |
4.235e-02 | -3.16 | cNMP-bd_CS | interpro domains | IPR018488 | 16 | 1 | 18521 | 50 |
PRKG1 |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.235e-02 | -3.16 | Laminin_N | interpro domains | IPR008211 | 16 | 1 | 18521 | 50 |
LAMA2 |
4.261e-02 | -3.16 | Morphine addiction | KEGG pathways | hsa05032 | 91 | 2 | 7161 | 26 |
GABBR2,GABRB1 |
4.261e-02 | -3.16 | Morphine addiction | KEGG pathways | ko05032 | 91 | 2 | 7161 | 26 |
GABBR2,GABRB1 |
4.271e-02 | -3.15 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 1 | 10285 | 28 |
NRG3 |
4.271e-02 | -3.15 | Rap1 signalling | REACTOME pathways | R-HSA-392517 | 16 | 1 | 10285 | 28 |
PRKG1 |
4.271e-02 | -3.15 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 1 | 10285 | 28 |
NRG3 |
4.273e-02 | -3.15 | apical dendrite | cellular component | GO:0097440 | 17 | 1 | 19108 | 49 |
CLU |
4.273e-02 | -3.15 | protein complex involved in cell-matrix adhesion | cellular component | GO:0098637 | 17 | 1 | 19108 | 49 |
LAMA2 |
4.282e-02 | -3.15 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 4 | 16828 | 48 |
NTRK2,TNIK,DCLK1,PRKG1 |
4.282e-02 | -3.15 | UNC45B (unc-45 myosin chaperone B) | protein interactions | 146862 | 17 | 1 | 19454 | 50 |
GRIA1 |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | Pef1 (penta-EF hand domain containing 1) | protein interactions | 67898 | 17 | 1 | 19454 | 50 |
QKI |
4.282e-02 | -3.15 | GRID1 (glutamate ionotropic receptor delta type subunit 1) | protein interactions | 2894 | 17 | 1 | 19454 | 50 |
GRIA1 |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | CLEC4M (C-type lectin domain family 4 member M) | protein interactions | 10332 | 17 | 1 | 19454 | 50 |
GFAP |
4.297e-02 | -3.15 | cerebral cortex development | biological process | GO:0021987 | 125 | 2 | 18204 | 48 |
NTRK2,GRIA1 |
4.297e-02 | -3.15 | memory | biological process | GO:0007613 | 125 | 2 | 18204 | 48 |
GRIA1,CSMD1 |
4.297e-02 | -3.15 | mammary gland development | biological process | GO:0030879 | 125 | 2 | 18204 | 48 |
CSMD1,NRG3 |
4.318e-02 | -3.14 | MAMDOMAIN | prints domains | PR00020 | 10 | 1 | 5227 | 23 |
PTPRT |
4.333e-02 | -3.14 | misfolded protein binding | molecular function | GO:0051787 | 16 | 1 | 18094 | 50 |
CLU |
4.333e-02 | -3.14 | MAP kinase kinase activity | molecular function | GO:0004708 | 16 | 1 | 18094 | 50 |
MAPK10 |
4.333e-02 | -3.14 | mitogen-activated protein kinase kinase kinase binding | molecular function | GO:0031435 | 16 | 1 | 18094 | 50 |
SASH1 |
4.333e-02 | -3.14 | cGMP binding | molecular function | GO:0030553 | 16 | 1 | 18094 | 50 |
PRKG1 |
4.333e-02 | -3.14 | MAP kinase activity | molecular function | GO:0004707 | 16 | 1 | 18094 | 50 |
MAPK10 |
4.333e-02 | -3.14 | water channel activity | molecular function | GO:0015250 | 16 | 1 | 18094 | 50 |
AQP4 |
4.336e-02 | -3.14 | Imipramine Action Pathway | SMPDB pathways | SMP0000422 | 30 | 1 | 1369 | 2 |
ATP1A2 |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
ZBTB20,SOX6 |
4.364e-02 | -3.13 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 48 |
SLC1A3,GABRB1,SLC1A2,GRIA1 |
4.389e-02 | -3.13 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 46 | 16828 | 48 |
GRID2,PTPRZ1,SPON1,GRIA4,LAMA2,GRIA1,SLC1A2,SMOC1,GABBR2,PTPRT,NTM,HS6ST3,CTNND2,AQP4,NTRK2,ATP1A2,SPARCL1,NPAS3,LIFR,NRG3,TNIK,GRIK1,GLIS3,CPE,DCLK1,PRKG1,SOX6,GABRB1,DTNA,ZBTB20,DGKG,PCDH9,LSAMP,MYO16,DMD,GFAP,PPP2R2B,QKI,CTNNA3,GPM6A,DPP6,CLU,SLC1A3,PHYHIPL,PDZRN4,SASH1 |
4.391e-02 | -3.13 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 1 | 18204 | 48 |
CLU |
4.391e-02 | -3.13 | regulation of postsynaptic density organization | biological process | GO:1905874 | 17 | 1 | 18204 | 48 |
GRID2 |
4.391e-02 | -3.13 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 48 |
TNIK |
4.391e-02 | -3.13 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 1 | 18204 | 48 |
CLU |
4.391e-02 | -3.13 | negative regulation of smooth muscle cell apoptotic process | biological process | GO:0034392 | 17 | 1 | 18204 | 48 |
GRIA4 |
4.391e-02 | -3.13 | regulation of excitatory synapse assembly | biological process | GO:1904889 | 17 | 1 | 18204 | 48 |
GRID2 |
4.391e-02 | -3.13 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 48 |
ATP1A2 |
4.391e-02 | -3.13 | regulation of inclusion body assembly | biological process | GO:0090083 | 17 | 1 | 18204 | 48 |
CLU |
4.391e-02 | -3.13 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 48 |
SLC1A2 |
4.391e-02 | -3.13 | retinal rod cell differentiation | biological process | GO:0060221 | 17 | 1 | 18204 | 48 |
NTRK2 |
4.391e-02 | -3.13 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 48 |
ATP1A2 |
4.391e-02 | -3.13 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 42 |
CPE |
4.391e-02 | -3.13 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 42 |
CPE |
4.415e-02 | -3.12 | negative regulation of cellular process | biological process | GO:0048523 | 5320 | 20 | 18204 | 48 |
ATP1A2,QKI,ZBTB20,MYO16,SOX6,PRKG1,GFAP,GRIA1,PTPRZ1,CST3,NTRK2,DCLK1,CLU,GLIS3,NRG3,GRIA4,DGKG,DMD,GPM6B,PTPRT |
4.455e-02 | -3.11 | - | gene3d domains | 2.60.200.40 | 14 | 1 | 14470 | 47 |
DGKG |
4.455e-02 | -3.11 | Glycerol uptake facilitator protein | gene3d domains | 1.20.1080.10 | 14 | 1 | 14470 | 47 |
AQP4 |
4.479e-02 | -3.11 | Fluoxetine Action Pathway | SMPDB pathways | SMP0000426 | 31 | 1 | 1369 | 2 |
ATP1A2 |
4.490e-02 | -3.10 | Thyroglobulin_1 | pfam domains | PF00086 | 17 | 1 | 17795 | 48 |
SMOC1 |
4.490e-02 | -3.10 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 48 |
CST3 |
4.490e-02 | -3.10 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 48 |
PTPRZ1 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | ATP-NAD_kinase_N | interpro domains | IPR017438 | 17 | 1 | 18521 | 50 |
DGKG |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | Thyroglobulin_1_sf | interpro domains | IPR036857 | 17 | 1 | 18521 | 50 |
SMOC1 |
4.493e-02 | -3.10 | NAD/diacylglycerol_kinase_sf | interpro domains | IPR016064 | 17 | 1 | 18521 | 50 |
DGKG |
4.493e-02 | -3.10 | Thyroglobulin_1 | interpro domains | IPR000716 | 17 | 1 | 18521 | 50 |
SMOC1 |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.512e-02 | -3.10 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 10 | 16828 | 48 |
NPAS3,GRID2,DPP6,PCDH9,TNIK,GPM6A,ZBTB20,LAMA2,GRIA4,PDZRN4 |
4.519e-02 | -3.10 | filopodium membrane | cellular component | GO:0031527 | 18 | 1 | 19108 | 49 |
DMD |
4.519e-02 | -3.10 | protein phosphatase type 2A complex | cellular component | GO:0000159 | 18 | 1 | 19108 | 49 |
PPP2R2B |
4.519e-02 | -3.10 | costamere | cellular component | GO:0043034 | 18 | 1 | 19108 | 49 |
DMD |
4.519e-02 | -3.10 | dystrophin-associated glycoprotein complex | cellular component | GO:0016010 | 18 | 1 | 19108 | 49 |
DMD |
4.529e-02 | -3.09 | CMC2 (C-X9-C motif containing 2) | protein interactions | 56942 | 18 | 1 | 19454 | 50 |
CTNNA3 |
4.529e-02 | -3.09 | CYP2E1 (cytochrome P450 family 2 subfamily E member 1) | protein interactions | 1571 | 18 | 1 | 19454 | 50 |
CLU |
4.529e-02 | -3.09 | RAI2 (retinoic acid induced 2) | protein interactions | 10742 | 18 | 1 | 19454 | 50 |
SOX6 |
4.529e-02 | -3.09 | SELL (selectin L) | protein interactions | 6402 | 18 | 1 | 19454 | 50 |
PRKG1 |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | SERTAD4 (SERTA domain containing 4) | protein interactions | 56256 | 18 | 1 | 19454 | 50 |
PPP2R2B |
4.539e-02 | -3.09 | larynx | COSMIC cancer mutations | larynx | 1948 | 10 | 16828 | 48 |
PCDH9,DPP6,TNIK,LAMA2,GRIA4,ZBTB20,GPM6A,PDZRN4,NPAS3,GRID2 |
4.553e-02 | -3.09 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 48 |
TNIK,ATP1A2,PTPRT |
4.575e-02 | -3.08 | Oxidative Stress Induced Senescence | REACTOME pathways | R-HSA-2559580 | 126 | 2 | 10285 | 28 |
TNIK,MAPK10 |
4.597e-02 | -3.08 | myosin V binding | molecular function | GO:0031489 | 17 | 1 | 18094 | 50 |
GRIA1 |
4.597e-02 | -3.08 | ligand-gated sodium channel activity | molecular function | GO:0015280 | 17 | 1 | 18094 | 50 |
GRIK1 |
4.598e-02 | -3.08 | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 120 | 2 | 16828 | 48 |
PTPRT,CTNND2 |
4.622e-02 | -3.07 | Nicotine Action Pathway | SMPDB pathways | SMP0000431 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.622e-02 | -3.07 | Methadone Action Pathway | SMPDB pathways | SMP0000408 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.622e-02 | -3.07 | Citalopram Action Pathway | SMPDB pathways | SMP0000424 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.629e-02 | -3.07 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 4 | 16828 | 48 |
GPM6A,PRKG1,GRIA4,SOX6 |
4.633e-02 | -3.07 | positive regulation of cellular component biogenesis | biological process | GO:0044089 | 515 | 4 | 18204 | 48 |
GPM6A,NTRK2,CLU,GRID2 |
4.643e-02 | -3.07 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 48 |
PRKG1 |
4.643e-02 | -3.07 | negative regulation of anoikis | biological process | GO:2000811 | 18 | 1 | 18204 | 48 |
NTRK2 |
4.643e-02 | -3.07 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 48 |
CST3 |
4.643e-02 | -3.07 | negative regulation of lyase activity | biological process | GO:0051350 | 18 | 1 | 18204 | 48 |
GABBR2 |
4.643e-02 | -3.07 | response to misfolded protein | biological process | GO:0051788 | 18 | 1 | 18204 | 48 |
CLU |
4.643e-02 | -3.07 | regulation of protein kinase C signaling | biological process | GO:0090036 | 18 | 1 | 18204 | 48 |
DGKG |
4.643e-02 | -3.07 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 48 |
PRKG1 |
4.643e-02 | -3.07 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 48 |
ATP1A2 |
4.643e-02 | -3.07 | myelin maintenance | biological process | GO:0043217 | 18 | 1 | 18204 | 48 |
CLU |
4.643e-02 | -3.07 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 48 |
CTNND2 |
4.643e-02 | -3.07 | positive regulation of sodium ion transmembrane transport | biological process | GO:1902307 | 18 | 1 | 18204 | 48 |
DMD |
4.643e-02 | -3.07 | regulation of skeletal muscle contraction | biological process | GO:0014819 | 18 | 1 | 18204 | 48 |
DMD |
4.653e-02 | -3.07 | H3-7 (H3.7 histone (putative)) | protein interactions | 440686 | 134 | 2 | 19454 | 50 |
PPP2R2B,LAMA2 |
4.655e-02 | -3.07 | ATP binding | molecular function | GO:0005524 | 1467 | 8 | 18094 | 50 |
TNIK,MYO16,NTRK2,DCLK1,PRKG1,MAPK10,DGKG,ATP1A2 |
4.677e-02 | -3.06 | human chr10q21.3 | chromosome location | human chr10q21.3 | 25 | 1 | 26134 | 50 |
CTNNA3 |
4.715e-02 | -3.05 | thalamus | COSMIC cancer mutations | thalamus | 284 | 3 | 16828 | 48 |
DTNA,QKI,GRIA4 |
4.716e-02 | -3.05 | FAM83H (family with sequence similarity 83 member H) | protein interactions | 286077 | 135 | 2 | 19454 | 50 |
GFAP,PPP2R2B |
4.716e-02 | -3.05 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 2 | 19454 | 50 |
NTRK2,DTNA |
4.716e-02 | -3.05 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 50 |
SOX6,SASH1 |
4.739e-02 | -3.05 | inorganic anion transmembrane transport | biological process | GO:0098661 | 132 | 2 | 18204 | 48 |
GABRB1,SLC1A3 |
4.742e-02 | -3.05 | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | 17 | 1 | 16828 | 48 |
QKI |
4.742e-02 | -3.05 | optic_nerve | COSMIC cancer mutations | optic_nerve | 17 | 1 | 16828 | 48 |
QKI |
4.748e-02 | -3.05 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 1 | 17795 | 48 |
ATP1A2 |
4.748e-02 | -3.05 | MAM | pfam domains | PF00629 | 18 | 1 | 17795 | 48 |
PTPRT |
4.752e-02 | -3.05 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 1 | 18521 | 50 |
ATP1A2 |
4.752e-02 | -3.05 | MAM_dom | interpro domains | IPR000998 | 18 | 1 | 18521 | 50 |
PTPRT |
4.764e-02 | -3.04 | GABA-A receptor complex | cellular component | GO:1902711 | 19 | 1 | 19108 | 49 |
GABRB1 |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.774e-02 | -3.04 | PDP2 (pyruvate dehydrogenase phosphatase catalytic subunit 2) | protein interactions | 57546 | 19 | 1 | 19454 | 50 |
GFAP |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | PLA2G4E (phospholipase A2 group IVE) | protein interactions | 123745 | 19 | 1 | 19454 | 50 |
PPP2R2B |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.774e-02 | -3.04 | CDH3 (cadherin 3) | protein interactions | 1001 | 19 | 1 | 19454 | 50 |
CTNNA3 |
4.774e-02 | -3.04 | FBXO27 (F-box protein 27) | protein interactions | 126433 | 19 | 1 | 19454 | 50 |
CLU |
4.774e-02 | -3.04 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 50 |
LIFR |
4.774e-02 | -3.04 | Trp53 (transformation related protein 53) | protein interactions | 22059 | 19 | 1 | 19454 | 50 |
MAPK10 |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | KCNF1 (potassium voltage-gated channel modifier subfamily F member 1) | protein interactions | 3754 | 19 | 1 | 19454 | 50 |
GFAP |
4.774e-02 | -3.04 | LONRF3 (LON peptidase N-terminal domain and ring finger 3) | protein interactions | 79836 | 19 | 1 | 19454 | 50 |
DMD |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.784e-02 | -3.04 | regulation of monoatomic cation transmembrane transport | biological process | GO:1904062 | 309 | 3 | 18204 | 48 |
DPP6,DMD,ATP1A2 |
4.792e-02 | -3.04 | cGMP effects | REACTOME pathways | R-HSA-418457 | 18 | 1 | 10285 | 28 |
PRKG1 |
4.802e-02 | -3.04 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 48 | 16828 | 48 |
LAMA2,GRIA4,GRIA1,GRID2,PTPRZ1,SPON1,SLC1A2,PTPRT,NTM,SMOC1,GABBR2,AQP4,CTNND2,SPARCL1,NTRK2,ATP1A2,HS6ST3,GLIS3,CPE,NRG3,TNIK,GRIK1,LIFR,NPAS3,ZBTB20,PCDH9,DGKG,DCLK1,PRKG1,SOX6,GABRB1,DTNA,GPM6A,GPM6B,GFAP,QKI,CTNNA3,PPP2R2B,DPP6,CLU,MYO16,LSAMP,CST3,DMD,PDZRN4,SASH1,SLC1A3,PHYHIPL |
4.804e-02 | -3.04 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 2 | 18204 | 48 |
DMD,ATP1A2 |
4.826e-02 | -3.03 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 6 | 16828 | 48 |
DCLK1,PRKG1,PPP2R2B,NTRK2,ATP1A2,TNIK |
4.828e-02 | -3.03 | seminoma | COSMIC cancer mutations | seminoma | 700 | 5 | 16828 | 48 |
TNIK,NTRK2,PRKG1,LAMA2,DCLK1 |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
SOX6,DGKG |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.859e-02 | -3.02 | human chr14q24.2 | chromosome location | human chr14q24.2 | 26 | 1 | 26134 | 50 |
SMOC1 |
4.861e-02 | -3.02 | adrenergic receptor binding | molecular function | GO:0031690 | 18 | 1 | 18094 | 50 |
GRIA1 |
4.861e-02 | -3.02 | transmembrane receptor protein tyrosine kinase activator activity | molecular function | GO:0030297 | 18 | 1 | 18094 | 50 |
NRG3 |
4.861e-02 | -3.02 | GABA receptor binding | molecular function | GO:0050811 | 18 | 1 | 18094 | 50 |
GABRB1 |
4.895e-02 | -3.02 | microvillus organization | biological process | GO:0032528 | 19 | 1 | 18204 | 48 |
TNIK |
4.895e-02 | -3.02 | vascular associated smooth muscle cell differentiation | biological process | GO:0035886 | 19 | 1 | 18204 | 48 |
QKI |
4.895e-02 | -3.02 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 1 | 18204 | 48 |
GRID2 |
4.895e-02 | -3.02 | regulation of glutamate secretion | biological process | GO:0014048 | 19 | 1 | 18204 | 48 |
PRKG1 |
4.895e-02 | -3.02 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 48 |
PRKG1 |
4.895e-02 | -3.02 | response to potassium ion | biological process | GO:0035864 | 19 | 1 | 18204 | 48 |
ATP1A2 |
4.895e-02 | -3.02 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 1 | 18204 | 48 |
CLU |
4.895e-02 | -3.02 | cartilage condensation | biological process | GO:0001502 | 19 | 1 | 18204 | 48 |
SOX6 |
4.895e-02 | -3.02 | long-term synaptic depression | biological process | GO:0060292 | 19 | 1 | 18204 | 48 |
GRIA1 |
4.907e-02 | -3.01 | Indapamide Action Pathway | SMPDB pathways | SMP0000110 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Trichlormethiazide Action Pathway | SMPDB pathways | SMP0000121 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Furosemide Action Pathway | SMPDB pathways | SMP0000115 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Eplerenone Action Pathway | SMPDB pathways | SMP0000135 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Torsemide Action Pathway | SMPDB pathways | SMP0000118 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Quinethazone Action Pathway | SMPDB pathways | SMP0000091 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Chlorothiazide Action Pathway | SMPDB pathways | SMP0000078 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Ethacrynic Acid Action Pathway | SMPDB pathways | SMP0000097 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Iminoglycinuria | SMPDB pathways | SMP0000193 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Blue Diaper Syndrome | SMPDB pathways | SMP0000583 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Bendroflumethiazide Action Pathway | SMPDB pathways | SMP0000090 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Cyclothiazide Action Pathway | SMPDB pathways | SMP0000103 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Polythiazide Action Pathway | SMPDB pathways | SMP0000080 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Glucose Transporter Defect (SGLT2) | SMPDB pathways | SMP0000184 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Bumetanide Action Pathway | SMPDB pathways | SMP0000088 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Metolazone Action Pathway | SMPDB pathways | SMP0000105 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hydrochlorothiazide Action Pathway | SMPDB pathways | SMP0000100 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hartnup Disorder | SMPDB pathways | SMP0000189 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Lysinuric Protein Intolerance (LPI) | SMPDB pathways | SMP0000585 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Triamterene Action Pathway | SMPDB pathways | SMP0000132 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hydroflumethiazide Action Pathway | SMPDB pathways | SMP0000108 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Chlorthalidone Action Pathway | SMPDB pathways | SMP0000122 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Cystinuria | SMPDB pathways | SMP0000723 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Lysinuric Protein Intolerance | SMPDB pathways | SMP0000197 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Methyclothiazide Action Pathway | SMPDB pathways | SMP0000081 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Kidney Function | SMPDB pathways | SMP0000483 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Spironolactone Action Pathway | SMPDB pathways | SMP0000134 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Amiloride Action Pathway | SMPDB pathways | SMP0000133 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.958e-02 | -3.00 | regulation of cellular component biogenesis | biological process | GO:0044087 | 1016 | 6 | 18204 | 48 |
GPM6A,GPM6B,GFAP,GRID2,NTRK2,CLU |
4.959e-02 | -3.00 | Choline metabolism in cancer | KEGG pathways | hsa05231 | 99 | 2 | 7161 | 26 |
MAPK10,DGKG |
4.959e-02 | -3.00 | Choline metabolism in cancer | KEGG pathways | ko05231 | 99 | 2 | 7161 | 26 |
DGKG,MAPK10 |
4.961e-02 | -3.00 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 4 | 16828 | 48 |
PRKG1,DCLK1,TNIK,NTRK2 |
4.968e-02 | -3.00 | HOMEZ (homeobox and leucine zipper encoding) | protein interactions | 57594 | 139 | 2 | 19454 | 50 |
CTNNA3,GFAP |
4.968e-02 | -3.00 | NEFM (neurofilament medium chain) | protein interactions | 4741 | 139 | 2 | 19454 | 50 |
GFAP,TNIK |
4.999e-02 | -3.00 | protein dephosphorylation | biological process | GO:0006470 | 136 | 2 | 18204 | 48 |
PTPRT,PTPRZ1 |